

DEPARTMENT OF ONCOLOGY-PATHOLOGY
Karolinska Institutet, Stockholm, Sweden

MOLECULAR CHARACTERIZATION OF PHENOTHIAZINES IN EXPERIMENTAL CANCER THERAPY - NEW TRICKS OF AN OLD DRUG REVEALED

Dali Zong

宗大力



**Karolinska
Institutet**

Stockholm 2012

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet.

Printed by Larseries Digital Print AB.

Cover graphics by Darawalee Wangsa Zong

© Dali Zong, 2012

ISBN 978-91-7457-712-9

"chance favors the prepared mind"

Louis Pasteur (1854)

To my beloved family who always supported and believed in me

ABSTRACT

Cancer is characterized by uncontrolled malignant proliferation of cells that eventually interfere with tissue/organ functions. Traditionally, cancer is treated with chemo- and/or radiotherapy when surgery is not an option. Unfortunately, the efficacy of conventional anti-cancer chemotherapy is severely limited by therapy resistance. A conceptually appealing strategy to combat tumor resistance is to use chemosensitizers, compounds that selectively sensitize tumor cells to chemotherapy without affecting normal tissue. Phenothiazines belong to a class of “old” drugs that are used clinically to treat psychiatric disorders. In this thesis, we characterized the chemosensitizing potential of phenothiazines in combination with DNA damaging chemotherapeutic drugs. Our primary aims are to elucidate the molecular mechanisms by which phenothiazines impart sensitization and to delineate molecular determinants that predict responsiveness of tumors to phenothiazine-based intervention. In **Paper I**, we confirmed that the phenothiazine compound trifluoperazine (TFP) was a potent sensitizer of bleomycin in human non-small cell lung carcinoma (NSCLC) cells; the likely mechanism being inhibition of repair of DNA single strand breaks (SSB) as well as DNA double strand breaks (DSB). In **Paper II**, we found that TFP delayed the resolution of bleomycin- or cisplatin-induced γ H2AX, a marker of unrepaired DNA DSB, prolonged the cell cycle arrest and increased oxidative stress in NSCLC cells. TFP co-treated cells eventually resumed cycling without fully repairing the DNA damage, which led to mitotic defects, secondary checkpoint arrest, exacerbated oxidative stress, organelle dysfunction, caspase activation and ultimately apoptosis. In **Paper III**, we uncovered a possible link between phenothiazines and chromatin remodeling by *in silico* gene expression analysis. We found that TFP and structurally related phenothiazines significantly enhanced the activity DNA-PK/ATM in tumor but not normal fibroblasts in response to DNA DSB-inducing agents, resulting in increased selective phosphorylation of a subset of ATM substrates with chromatin regulatory functions. Notably, this represents an adaptive response which could be targeted by DNA-PK/ATM inhibitors to further enhance TFP-mediated chemosensitization in NSCLC cells. Moreover, we found that wild-type p53 is a potential predictor of unresponsiveness to phenothiazine-based chemosensitization. We further demonstrated that TFP preferentially increased the cytotoxicity of direct-acting DNA damaging agents, but not indirect-acting DNA damaging or non-DNA damaging agents, in p53-deficient tumor cells (NSCLC, breast cancer). In **Paper IV**, we compared the gene expression profile of NSCLC residual clones that survived cisplatin treatment with counterparts that survived cisplatin/TFP co-treatment. We found that survival after cisplatin was associated with enrichment of pathways involved in DNA metabolism/repair, cell cycle and RNA post-translational modification. Pathway analysis showed that several DNA repair genes were concurrently up-regulated in residual clones that survived cisplatin treatment, but not in residual clones that survived cisplatin/TFP co-treatment did not shown such enrichment of DNA repair genes. In summary, our data showed for the first time that inhibition of DNA DSB repair by TFP is related to alterations in DNA-PK/ATM signaling, which led to increased apoptosis in the short term and gene expression changes as well as loss of clonogenicity in the long term. Further, our identification of molecular contexts that predict responsiveness to phenothiazines will aid in the design of future clinical trials.

LIST OF PUBLICATIONS

- I. Polischouk AG, Holgersson A, **Zong D**, Stenerlöw B, Karlsson HL, Möller L, Viktorsson K, Lewensohn R. The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death. *Mol Cancer Ther.* 2007; 6(8):2303-9.
- II. **Zong D***, Hååg P, Yakymovych I, Lewensohn R, Viktorsson K*. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γ H2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. *Cell Death Dis.* 2011; 2:e181.
- III. **Zong D***, Hååg P, Zielinska-Chomej K, Yakymovych I, Lewensohn R, Viktorsson K*. Identification of phenothiazines as putative regulators of the chromatin response to DNA damage provides a rationale for context-dependent chemosensitization. (*manuscript*)
- IV. Salim H[#], **Zong D[#]**, Lundholm L[#], Hååg P, Mörk B, Lewensohn R, Viktorsson K. Gene expression analysis reveals DNA repair pathway modulation as a potential mechanism for phenothiazine-mediated long term cisplatin sensitization in NSCLC. (*manuscript*)

* Corresponding author

[#] These authors contributed equally

CONTENTS

1	INTRODUCTION	1
1.1	DNA damaging chemotherapy in cancer treatment	1
1.2	The DNA damage response (DDR)	1
1.2.1	Detection of DNA DSBs.....	2
1.2.2	Cell cycle checkpoints	4
1.3	DNA DSB repair	8
1.3.1	Non-homologous end joining	9
1.3.2	Homologous recombination repair	10
1.3.3	Fanconi anemia pathway	12
1.4	DNA DSB and the fate of cells with damage.....	13
1.4.1	Cell survival	14
1.4.2	Cell death.....	14
1.5	DDR signaling in cancer	20
1.5.1	DDR as a barrier against tumorigenesis	20
1.5.2	DNA DSB repair deficiency and cancer predisposition	21
1.5.3	De-regulation of DNA DSB repair in cancer	22
1.5.4	DNA DSB repair and tumor chemosensitivity.....	22
1.6	Resistance to DNA damaging chemotherapy.....	22
1.6.1	Mechanisms of resistance	22
1.7	DDR signaling as a target for chemotherapy sensitization	26
1.7.1	Abrogation of cell cycle checkpoints	26
1.7.2	Inhibition of DNA DSB repair	27
1.8	Phenothiazines – What are they and what can they do?	28
1.8.1	Molecular targets of phenothiazines.....	29
1.8.2	Cellular processes that are affected by phenothiazines.....	30
1.8.3	Phenothiazines as potential anti-cancer therapeutics	34
2	AIMS	39
3	MATERIALS AND METHODS	40
3.1	Cell lines	40
3.2	DNA damaging agents	40
3.3	Assessment of cytotoxicity	41
3.3.1	Short-term assay.....	41
3.3.2	Long-term assay	41
3.4	Analysis of DNA damage induction AND DNA repair	42
3.4.1	Electrophoresis-based assays.....	42
3.4.2	Antibody-based assays.....	43
3.4.3	<i>In vitro</i> kinase assays	43
3.5	Assessment of chromatin accessibility	44
3.6	Analysis of cell cycle progression	44
3.7	Assessment of apoptosis and mitotic fidelity	44
3.8	Analysis of pro-apoptotic signaling.....	45
3.8.1	Oxidative stress	45
3.8.2	Caspase activation and caspase activity	45
3.8.3	Organelle dysfunction	46
3.9	Assessment of gene expression.....	47

3.9.1	DNA microarray.....	47
3.9.2	Real time quantitative PCR.....	47
3.9.3	Data mining and bioinformatics analysis	48
3.9.4	Hierarchical clustering and principal component analysis..	48
3.9.5	Ingenuity pathway analysis.....	49
3.9.6	Gene ontology terms	49
3.9.7	Gene set enrichment analysis.....	49
4	RESULTS AND DISCUSSION.....	51
4.1	Paper I	51
4.2	Paper II.....	52
4.3	Paper III:	54
4.4	Paper IV	57
5	CONCLUSIONS & FUTURE PERSPECTIVE	60
5.1	Our main conclusions	60
5.2	Unresolved questions and future perspectives.....	61
5.2.1	Intracellular localization of phenothiazines.....	61
5.2.2	Analysis of TFP-interacting partners.....	61
5.2.3	TFP in combination chemotherapy.....	62
5.3	A unified view of phenothiazine-mediated chemosensitization	66
5.4	Concluding remarks.....	67
6	ACKNOWLEDGEMENTS.....	68
7	REFERENCES.....	72

LIST OF ABBREVIATIONS

AML	Acute myeloid leukemia
A-NHEJ	Alternative NHEJ
ATM	Ataxia telangiectasia mutated
BIR	Break-induced replication
BLM	Bleomycin
B-NHEJ	Backup NHEJ
CaM	Calmodulin
CDDP	Cisplatin
C-NHEJ	Classic NHEJ
CNS	Central nervous system
Cmap	Connectivity Map
CPZ	Chlorpromazine
DDR	DNA damage response
DNA-PK	DNA-dependent protein kinase
DNA-PKcs	DNA-PK catalytic subunit
DSB	Double strand break
DSBR	DSB repair
FA	Fanconi anemia
FANC	Fanconi anemia complementation group
FPZ	Fluphenazine
GO	Gene Ontology
GSEA	Gene set enrichment analysis
HDAC	Histone deacetylase
HDR	Homology-directed repair
HRR	Homologous recombination repair
ICL	Interstrand crosslink
IPA	Ingenuity pathway analysis
IR	Ionizing radiation
LMP	Lysosomal membrane permeabilization
MDR	Multidrug resistance
MMEJ	Microhomology-mediated end joining
MMR	Mismatch repair
MOMP	Mitochondrial outer membrane permeabilization
NER	Nucleotide excision repair
NHEJ	Non-homologous end joining
NSCLC	Non-small cell lung carcinoma
OIS	Oncogene-induced senescence
PARP-1	Poly(ADP-ribose) polymerase-1
PCA	Principal component analysis
PFGE	Pulsed-field gel electrophoresis
PIKK	Phosphatidylinositol 3'-kinase-like protein kinase
PRKDC	Protein kinase, DNA-activated, catalytic polypeptide
PTM	Post-translational modification
ROS	Reactive oxygen species

RT-qPCR	Real time quantitative polymerase chain reaction
SAC	Spindle assembly checkpoint
SDSA	Synthesis-dependent strand annealing
SSA	Single strand annealing
SSB	Single strand break
TLS	Translesion synthesis
TFP	Trifluoperazine
TFPZ	Triflupromazine
VP16	Etoposide
VPA	Valproic acid

1 INTRODUCTION

1.1 DNA damaging chemotherapy in cancer treatment

Cancer is the collective name for a large number of pathologic conditions characterized by uncontrolled malignant proliferation of cells. It may originate from almost any type of tissues in the body and is usually rapidly fatal if not promptly treated. The latest estimates for the global incidence of cancer and its associated mortality are 12.7 million and 7.6 million, respectively, in 2008 ¹. Although cancer can affect people of all ages, there is a steep increase in cancer incidence amongst the elderly (>65 years), suggesting that it is an age-related pathology. Whenever possible, surgery is the treatment of choice because it has the highest chance of achieving a complete cure. If surgery is not an option, for instance due to physical inaccessibility of the tumor site or poor health of the patient, chemotherapy and/or radiotherapy may be considered. Ionizing radiation (IR) and most conventional chemotherapeutic agents directly or indirectly cause DNA damage, which is generally more toxic to proliferating cells. However, as neither of these treatment modalities can discriminate tumor cells from rapidly dividing non-cancerous cells (e.g. bone marrow cells, intestinal cells), their anti-tumor efficacy comes at the cost of significant normal tissue toxicity. Therefore, the development of chemosensitizers, compounds that can selectively enhance the cytotoxicity of chemotherapeutic agents without affecting the sensitivity of normal tissues, is urgently needed.

1.2 The DNA damage response (DDR)

DNA molecules are chemically reactive, and as such are susceptible to attack from endogenous (e.g. reactive oxygen intermediates of mitochondrial aerobic respiration) and/or exogenous DNA damaging agents (e.g. ionizing radiation, chemotherapeutic drugs), which produce a wide spectrum of DNA lesions, ranging from oxidative base damages (e.g. 8-oxoguanine) to breakage of DNA strands (e.g. DNA double strand break, DSB) ². The cytotoxic potential of any DNA lesion is influenced by a variety of cell-intrinsic factors, such as lineage, position within the cell cycle, availability of dedicated or redundant DNA repair factors, etc. It is generally accepted that DNA DSB has the highest cytotoxic potential ³. Different types of DNA lesions can also occur within close proximity of each other (i.e. clustered damage), making them more difficult to repair ^{4, 5}. Incursion of DNA damage in eukaryotic cells triggers the DNA damage response (DDR), which elicits temporally concerted activation of multiple signaling networks that together bring about cell cycle arrest, cessation of RNA polymerase II-mediated transcription, localized chromatin remodeling and DNA repair ⁶⁻¹¹ (Figure 1). If the DNA damage is successfully repaired by the afflicted cells, DDR signaling is shut off allowing cell cycle to recommence. However, if the lesions can not be adequately repaired or if DDR signaling cannot be turned off following completion of repair, persistent DDR signaling can drive cells into senescence or apoptosis ^{12, 13}. The ultimate goal of DDR is to maintain genomic integrity at the organism level.




Figure 1. The DNA damage response.

1.2.1 Detection of DNA DSBs

DNA DSB sensors

DNA DSBs are particularly dangerous because they can lead to loss of genetic information and genomic rearrangements¹⁴. To ensure rapid detection of these potentially deleterious lesions, eukaryotic cells are equipped with a set of damage sensors that can recognize DNA DSBs, including the Ku70/Ku80 (Ku) complex, the Mre11/Rad50/Nbs1 (MRN) complex, poly(ADP-ribose) polymerase 1 (PARP-1), and Rad52¹⁵⁻¹⁸. These factors bind to similar double stranded DNA substrates *in vitro* and can under certain circumstances functionally compensate for each other *in vivo*. As of yet, the molecular parameters that determine which of these DNA DSB sensors will be recruited to a given DNA DSB are not well understood. Cell-intrinsic factors such as protein expression level, cell cycle position, chemical milieu in the vicinity of the break and genomic localization of the break may all influence which sensors are preferentially engaged. Regardless, it is clear that the choice of DNA DSB sensor governs repair pathway utilization. In line with this, direct competition between different sensors for binding dsDNA ends has been demonstrated¹⁹⁻²¹.

DNA damage-associated chromatin remodeling

The DNA of eukaryotes exists in close association with a large number of proteins that together comprise the chromatin, whose primary functions are to enable efficient packaging of DNA into nucleosomes, to protect DNA from damage and to allow molecular fine-tuning of essential DNA-centered processes such as gene expression and DNA replication²². The chief protein components of the chromatin are histones, which contain numerous amino acids in their N-terminus that are amenable to post-translational modifications (PTMs), including phosphorylation, acetylation, methylation, ubiquitination, sumoylation and ADP-ribosylation²³. Histone PTMs determine the level of chromatin compaction/relaxation as well as the recruitment of non-histone proteins by creating specific docking sites²⁴. While some PTMs can occur

independently, others are induced in a synergistic or antagonistic manner. In addition, the structure of chromatin can also be regulated by processes that do not involve histone PTMs, such as CpG island DNA methylation or nucleosome shuffling/eviction by ATP-dependent chromatin remodeling complexes^{25,26}.

The compact organization of eukaryotic chromosomes poses a big challenge to the cellular DNA repair machinery due to its limited accessibility²⁷. To ensure rapid detection and repair of genomic lesions, damage-proximal DDR signaling triggers the concerted activation of many proteins with chromatin remodeling functions leading to changes in both local and global chromatin landscape^{28, 29} (Figure 2). Localized chromatin relaxation can occur by several parallel mechanisms. Activation of the apical kinase Ataxia Telangiectasia Mutated (ATM) represents one of the earliest events in DDR signaling³⁰. Active ATM relocates to sites of DNA DSB where it phosphorylates histone H2AX on serine-139 (aka γ H2AX) in the immediate vicinity of the break³¹. The initial ATM-dependent γ H2AX formation is facilitated by localized chromatin relaxation following casein kinase 2-mediated release of HP1 β from histone H3 trimethylated on lysine 9 (H3K9Me3, a marker of compact chromatin)³². This generates a binding site for the Tip60 histone acetyltransferase, which acetylates ATM on lysine-3016 resulting in enhanced ATM kinase activity³³. Efficient activation of ATM also requires HMGN1-dependent histone acetylation^{30,34}. In turn, γ H2AX serve as molecular platforms to help concentrate various checkpoint mediators (e.g. ATM, MDC1, MRN, BRIT1/MCPH1) and ATP-dependent chromatin remodeling complexes (e.g. NuA4, SWI/SNF) at the sites of DNA DSB^{24, 35-38}. This creates a self-sustained cycle whereby ATM promotes further spreading of γ H2AX along the chromosome^{31, 39, 40}. Recruitment of NuA4 and SWI/SNF complexes to γ H2AX domains surrounding DSBs leads to local destabilization/disruption of nucleosomes and promotes histone ubiquitination by RNF8/RNF168, which facilitates the subsequent ubiquitination-dependent recruitment of BRCA1 to amplify checkpoint signaling^{38, 41-45}. 53BP1 is an important checkpoint mediator whose retention on chromatin in response to DNA damage requires *de novo* histone methylation as well as unmasking of pre-existing ones. Localized methylation of histone H4 on lysine-20 (H4K20Me) and histone H3 on lysine-79 (H3K79Me) are catalyzed by MMSET and Dot1L, respectively⁴⁶⁻⁴⁹. Unmasking of pre-existing H4K20Me requires RNF8/RNF168-mediated displacement of JMJD2A and L3MBTL1^{50, 51}. In turn, 53BP1 interacts with the chromatin architectural protein EXPAND/MUM1 to bring about chromosomal decondensation⁵². Moreover, phosphorylation of KAP-1 (S824) by ATM causes chromatin relaxation by disrupting the SUMO-dependent interaction between KAP-1 and CHD3, a component of the Mi-2/NuRD ATP-dependent chromatin remodeling complex^{53, 54}. The precise role of ATM-dependent phosphorylation of cohesin components SMC1 (S957, S966) and SMC3 is less clear, but appears to be required for the activation of intra-S checkpoint and reinforcement of chromosome cohesion⁵⁵⁻⁵⁸. The latter function may be important for maintaining the positional stability of DNA DSBs^{29, 59-61}.

In addition to its role in checkpoint regulation, chromatin remodeling is also intimately linked to DNA DSB repair. Localized mono-ubiquitination of histone H2B by RNF20/RNF40 is required for chromatin relaxation and the timely recruitment of several DSB repair factors that participate in non-homologous end joining (NHEJ) as well as homologous recombination repair (HRR)⁶²⁻⁶⁴. Binding of Ku to damaged DNA is facilitated by acetylation of histones H3 and H4 by the CBP/p300 complex⁶⁵. On the other hand, HDAC1/2-mediated deacetylation of histone H3 on lysine-56 (H3K56Ac) is required for efficient Ku-dependent NHEJ⁶⁶. Direct polyADP-ribosylation (PARylation) of histones by PARP-1 enhances chromatin accessibility⁶⁷. PARP-1 and




Figure 3. A schematic view of the cell cycle and the main checkpoint regulators. DNA damage activates checkpoint mechanisms in G₁, intra-S, G₂ and M phases to stop cell cycle progression. The existence of the antepause checkpoint (orange) is controversial.

G₁ checkpoint

The G₁ checkpoint is activated during late G₁ to prevent cells with DNA damage from transiting into S phase and initiate DNA replication⁸⁰. The best characterized mechanism by which DNA damage triggers G₁ arrest is mediated by the tumor suppressor protein p53⁸⁰. Stabilization of p53 and up-regulation of its transcriptional activity can be achieved by multiple PTMs, such as phosphorylation and acetylation. Depending on the precise pattern of PTMs, p53 may selectively transactivate genes that contain high affinity p53-binding sites (e.g., CDKN1A) or broadly transactivate genes containing p53-binding sites of varying affinity, many of which are pro-apoptotic (e.g., PUMA, BAX)^{81, 82}. The main effectors of p53-mediated G₁ arrest are p21^{Cip1/Waf1} (encoded by CDKN1A), a universal inhibitor of cyclin-dependent kinases (cdks), and to a lesser degree p16^{INK4a}, a predominantly G₁-restricted cdk inhibitor⁸⁰. Suppression of the kinase activities of G₁ cyclin-cdk complexes by p21^{Cip1/Waf1} (cyclin D-cdk4/6, cyclin E-cdk2) and p16^{INK4a} (cyclin D-cdk4/6) prevents the phosphorylation-dependent release of E2F family transcription factors from the Pocket proteins (pRb, p107, p130) and inhibits the E2F-mediated transactivation of genes required for S phase entry. Transient G₁ checkpoint arrest is usually reversible while prolonged activation of p21^{Cip1/Waf1}/p16^{INK4a} can drive cells into premature senescence⁸³. Given that the p53 pathway is functionally inactivated in a majority of human tumors⁸⁴, the G₁ checkpoint (and hence the ability to senesce) is compromised or lacking in most cancer cells.

Intra-S checkpoint

The intra-S checkpoint (aka replication checkpoint) is activated primarily by disturbances in DNA replication, such as replication stress caused by oncogene-induced

hyper-proliferation and stalling of replication forks on DNA strands damaged by anti-cancer drugs^{74, 85, 86}. Regardless of the cause, collapse of replication forks may follow their initial stalling leading to the exposure of single stranded DNA (ssDNA), a potent signal for the activation of ATR⁸⁷. ATRIP recruits ATR to RPA-coated ssDNA where Rad9-Rad1-Hus1 (9-1-1 complex), claspin and TopBP1 collaborate to promote ATR activation and phosphorylation of the downstream checkpoint effector kinase Chk1. In turn, Chk1 phosphorylates Cdc25A leading to the latter's proteasomal degradation and/or cytoplasmic sequestration by 14-3-3 proteins⁸⁸⁻⁹². The loss of Cdc25A phosphatase activity prevents the activation of cyclin A-cdk1/2, which is required for completion of S phase and entry into G₂.

G₂ checkpoint

The G₂ checkpoint (aka G₂-M checkpoint) functions to prevent cells from entering mitosis. DNA damage detected in G₂ activates both ATM-Chk2 and ATR-Chk1 arms of the DDR, with the net result being the inactivation of Cdc25 family of protein phosphatases (Cdc25A/B/C) and inhibition of cyclin B-cdk1 whose activity is required for mitotic entry^{74, 93, 94}. The p53-p21^{Cip1/Waf1} pathway in p53 wild-type tumors and the p38MAPK-MK2 pathway in p53-deficient tumors have also been implicated in the enforcement of G₂ checkpoint arrest⁹⁵⁻⁹⁷. It is worth pointing out that in human tumors, the ATM/R-Chk1/2-Cdc25 pathway may be incapacitated by over-expression of Akt or polo-like kinases (e.g. Plk-1), while both the p53-p21^{Cip1/Waf1} and the p38MAPK-MK2 pathways may also be attenuated^{84, 98-103}. Therefore, the G₂ checkpoint may be compromised or sub-optimal in a large proportion of tumor cells, rendering them more susceptible to pharmacologically-induced checkpoint abrogation^{78, 79}.

Antephase checkpoint

The term "antephase" refers the relatively short window of time from late G₂, when chromosome condensation first becomes visible, until commitment to mitosis. Based on this definition, the antephase checkpoint is a putative checkpoint that blocks cell cycle progression somewhere between late G₂ and early prophase¹⁰⁴. Signals that activate the antephase checkpoint appear to be topologic disturbances in the DNA molecule rather than *bona fide* DNA damage^{104, 105}. In this respect, it is similar to another putative checkpoint that operates at the G₂-M border, the decatenation checkpoint, which is activated in response to chromosome entanglement (e.g. topoisomerase II inhibition)^{106, 107}. It is not clear whether the antephase checkpoint represents an extension of the "conventional" DNA damage-induced G₂ checkpoint or is in fact a separate entity with its own distinct molecular control mechanisms. It is however possible that there is a temporal constraint on the activation of the conventional G₂ checkpoint and that the antephase checkpoint represents a last attempt by the cell to arrest before progressing into mitosis. So far, p38MAPK and CHFR are the only proteins that have been implicated in the antephase checkpoint^{105, 108}.

Spindle assembly checkpoint

During late G₂ and early prophase, the nuclear membrane breaks down and the chromatin undergoes marked condensation accompanied by phosphorylation of histone H3 on serine-10¹⁰⁹. From late prophase through metaphase, sister chromatids become attached to the mitotic spindle at their kinetochores, which are specialized protein structures that form at centromeres. Sister chromatids align at the metaphase plate but

are prevented from separating by the spindle assembly checkpoint (SAC, aka mitotic checkpoint). The SAC is an active signal generated by mitotic spindle microtubules that lack tension at unattached or improperly attached kinetochores^{110, 111}. A host of proteins have been implicated in the execution of SAC, including MAD1, MAD2, MAD3, BUB1, BUB3, BUBR1 and MPS1. SAC blocks anaphase by negatively regulating CDC20, a component of the anaphase promoting complex/cyclosome (APC/C)¹¹². Once correct bi-orientation of sister chromatids has been achieved, SAC is turned off and its inhibition on APC/C is lifted. The E3 ubiquitin-ligase activity of APC/C is required to target securin and cyclin B for proteasomal degradation. This in turn frees a protease called separase to cleave the cohesin ring that holds sister chromatids together. Loss of cohesion then allows the sister chromatids to segregate towards opposite spindle poles to complete anaphase. This is followed by telophase and cytokinesis in which the nuclear membrane reforms around the newly-separated chromosomes and the cytoplasm is cleaved along the mitotic furrow to produce two daughter cells. A functional SAC is therefore vital for the maintenance of genome integrity by ensuring faithful division of genetic material between two daughter cells. Mutation of SAC components is quite common in human cancers and compromised SAC function is thought to be a major cause of aneuploidy^{113, 114}. However, even a fully functional SAC cannot arrest cells in mitosis indefinitely and mitotic slippage can occur, especially in cancer cells, as a result of checkpoint adaptation¹¹⁵⁻¹¹⁷. Since prolonged mitotic arrest promotes apoptosis, blocking mitotic exit may be a promising strategy to selectively sensitize tumor cells to anti-mitotic drugs such as taxanes^{75, 116, 118-120}.

Checkpoint recovery

Checkpoint recovery refers to the resumption of cell cycle progression after dissipation of signals that maintain cell cycle arrest. Recovery from DNA damage-induced checkpoint arrest occurs when genomic lesions have been repaired with sufficient fidelity that they no longer engage the DDR machinery. As human tumors show a high propensity to harbor mutations that inactivate the G₁ checkpoint, considerable efforts have been devoted to the elucidation of regulatory mechanisms that control recovery from G₂ arrest¹²¹⁻¹²⁵. These mechanisms can be broadly divided into three categories: (1) epigenetic modifications, (2) inactivation of checkpoint signaling and (3) transcriptional responses. The best characterized epigenetic modifications that accompany checkpoint recovery are γ H2AX dephosphorylation by protein serine/threonine phosphatases (e.g., PP2A, PP4, PP6, Wip1) and re-acetylation of H3K56 by histone chaperones/histone acetylases¹²⁶⁻¹³¹. Meanwhile, checkpoint signaling can be shut off by several mitotic kinases (e.g., Plk1, Aurora A) that block the activation of checkpoint kinases while promoting Cdk1 activation¹³²⁻¹³⁴. Finally, a number of transcription factors (e.g., B-Myb, FoxM1) have been shown to facilitate checkpoint recovery by transcriptionally up-regulating genes that are essential for mitotic entry while repressing genes that are involved in checkpoint control^{135, 136}. It is conceivable that these mechanisms act in a non-mutually exclusive manner and may promote and/or cooperate with each other. The complex network of molecular interactions that regulates checkpoint recovery is only partially understood.

Checkpoint adaptation

Cells that cannot adequately repair its damaged DNA can still resume cell cycle progression by undergoing a process called checkpoint adaptation, which involves

active shutdown of checkpoint signaling in the face of residual DNA damage^{121, 122, 137}. Checkpoint adaptation was originally observed in yeast and was thought to be limited to unicellular organisms, since it carries a high risk for mutations¹³⁸. Nevertheless, checkpoint adaptation has since been found in human cancer cells after exposure to chemo- and/or radiotherapy¹³⁹. The molecular pathways involved in G₂ checkpoint adaptation appear to overlap with those that control checkpoint recovery^{121, 122, 137}. In particular, Plk1 has been implicated in the adaptation to the G₂ checkpoint. Given the fact that human tumors frequently over-express Plk1, checkpoint adaptation may be expected to play a critical role in promoting tumor survival and genomic instability, making it a promising target for anti-cancer intervention¹⁴⁰.

1.3 DNA DSB repair

Since the DNA molecule can incur a broad spectrum of lesions, eukaryotes have evolved an elaborate set of DNA repair mechanisms (Figure 4). Two principal modes of DNA DSB repair, namely NHEJ and HRR, are utilized by eukaryotic cells. In NHEJ, the two ends of a DNA DSB are directly rejoined with little or no requirement for terminal homology¹⁴¹. In HRR, homologous sequences on another chromosome (usually sister chromatids) is used as a template to restore the lost genomic information across the DNA DSB¹⁴². Notably, DNA DSB repair is frequently intersected by other DNA repair pathways because genomic lesions tend to be structurally and chemically heterogeneous, requiring additional factors to process the damaged DNA into substrates that can be used by NHEJ or HRR. This scenario is neatly illustrated the cooperation between Fanconi anemia (FA) pathway and HRR (see below). There is evidence that NHEJ and HRR can function cooperatively, independently/sequentially or antagonistically¹⁴³⁻¹⁴⁶. Moreover, both NHEJ and HRR contain several competing sub-modules that differ in repair efficiency as well as fidelity. In general, low fidelity sub-modules are mostly employed as backups that are negatively regulated by high fidelity ones^{147, 148}.




Figure 4. An overview of DNA repair pathways in eukaryotes.

1.3.1 Non-homologous end joining

Classic NHEJ

Classic NHEJ is initiated by Ku, which binds DNA DSB with high avidity in a sequence- and homology-independent manner by forming a ring shaped structure that encloses the DNA double helix ¹⁴⁹ (Figure 5). Ku in turn recruits the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) to form the DNA-PK holoenzyme ¹⁷. The physical interaction between two DNA-PK molecules on either side of a DNA DSB helps align the ends in a synapse that facilitates end joining ^{150, 151}. Binding to Ku and DNA greatly stimulates its serine/threonine kinase activity, resulting in substrate phosphorylation (including autophosphorylation) which is required for efficient NHEJ ^{152, 153}. DNA-PKcs also causes Ku to slide inwards away from the DNA termini allowing chromatin access to several end-processing enzymes (e.g. Artemis, DNA polymerase μ , DNA polymerase λ , polynucleotide kinase/phosphatase) which together with Ku convert DNA ends into chemical configurations suitable for ligation ^{141, 154-158}. The final resealing of the broken DNA ends is carried out by a ternary complex consisting of XRCC4, XLF and DNA Ligase IV ¹⁵⁴. Although the above description gives the impression that NHEJ follows a highly ordered sequence of events, substantial amount of mechanistic flexibility are observed during NHEJ *in vivo* whereby the order of recruitment of different factors may be more varied and the two broken strands can be rejoined independent of each other ^{154, 159}. Moreover, several NHEJ proteins, including Ku and DNA-PKcs, are mobile and dynamically exchange between chromatin-bound and soluble forms ^{160, 161}. It is not yet clear at what stage of NHEJ DSB repair proteins are released from the chromatin. The available data suggest that DNA-PKcs dissociates from the DNA DSB in an autophosphorylation-dependent manner and that the Ku complex is removed from DNA following RNF8-dependent K48-linked poly-ubiquitination and subsequently degraded ¹⁶²⁻¹⁶⁴. In the budding yeast, release of Ku from DNA requires the nuclease activity of Mre11, but it is not known whether Mre11 has a similar function in mammalian cells ¹⁶⁵.

Backup NHEJ

Backup NHEJ (B-NHEJ) refers to cellular processes that promote rejoining of DNA DSBs when classic NHEJ (C-NHEJ) is absent or functionally inactivated ¹⁶⁶. The molecular composition of B-NHEJ is largely undefined and might possibly encompass several sub-pathways with overlapping activities. For instance, it is not known whether alternative NHEJ (A-NHEJ), microhomology-mediated end joining (MMEJ) and B-NHEJ are simply different terms used to describe the same pathway or in fact represent distinct sub-pathways that operate (at least partially) independent of each other ¹⁶⁷⁻¹⁶⁹. For the purpose of this thesis, however, all end joining events supported by non-canonical NHEJ will be collectively called B-NHEJ. There is substantial experimental evidence demonstrating that B-NHEJ is normally suppressed by DNA-PK and that B-NHEJ utilizes a separate set of DNA repair proteins such as PARP-1, Mre11, CtIP and XRCC1/DNA Ligase III ^{20, 147, 167, 170-177} (Figure 5). In comparison to C-NHEJ, which is usually rapid and relatively accurate, DSB repair via B-NHEJ is both slower and generally more error-prone, which increases the likelihood of chromosomal translocations especially involving the immunoglobulin heavy chain (IgH) locus in developing lymphocytes ^{14, 166, 175, 177-180}. Moreover, increased activity of B-NHEJ has been observed in human cancers, such as bladder, breast and acute/chronic myeloid leukemia, concomitant with a reduced ability to perform C-NHEJ ^{14, 174, 179, 180}. These

data suggest that de-regulation of NHEJ may favor mutation-driven tumor evolution and adversely affect clinical treatment responses.




Figure 5. A schematic view of the classic (canonical) and backup (alternative) pathways of NHEJ.

1.3.2 Homologous recombination repair

Homologous recombination repair (HRR), aka homology-directed repair (HDR), is actually a collective term for a number of functionally overlapping DSB repair sub-modules that all use a homologous template to restore lost genetic information¹⁴² (Figure 6). Unlike MMEJ, which is facilitated by short terminal homologies (2-3 nucleotide), all HRR sub-pathways require significant longer (>100 nucleotides) homology tracts on the template, which is usually but not always provided by the sister chromatid^{142, 169, 181}. HRR begins with DNA DSB end resection, whereby stretches of the 5'-strand is removed by the concerted actions of Mre11, CtIP and BLM-Exo1 to form long single stranded 3'-DNA (ssDNA) tails which becomes coated with RPA¹⁸²⁻¹⁸⁴. DNA DSB end resection is most efficient during S and G₂, when it is stimulated by CDK2-mediated phosphorylation, but is significantly suppressed by Ku during G₁¹⁸⁵⁻¹⁸⁷. Next, Rad51 is recruited to the RPA-coated ssDNA where it forms Rad51 nucleofilament by displacing RPA¹⁸⁸. Loading of Rad51 is facilitated by Rad52, BRCA2, PALB2 and the Rad51 paralogs but the molecular details of Rad51 nucleofilament formation are not fully defined^{142, 189-192}. Regardless, Rad51 then catalyzes a homology-dependent strand exchange (or invasion) reaction in which the 3'-overhang of a resected ssDNA end becomes annealed to the 5'-strand of an intact template DNA molecule, resulting in the formation of a displacement loop (D-loop) connected by a Holliday junction (HJ)^{142, 188}. This is followed by end extension through polymerase-mediated DNA synthesis and D-loop expansion. After this stage, the HRR sub-modules become distinct. In the DSB repair (DSBR, aka gene conversion) pathway, Rad52 promotes the annealing of a second resected ssDNA end to the displaced strand of the template molecule in a reaction known as second-end

capture to form a stabilized joint molecule with double HJs¹⁹³. Rad54 has the ability to promote ATP-dependent branch migration of HJs along the joint molecule in a bi-directional manner, which determines the extent of heteroduplex formation and hence the amount of genetic information that is transferred during recombination¹⁹⁴. Upon completion of repair-associated DNA synthesis and ligation of the broken strands, the double HJs are resolved by specialized endonucleases such as GEN1 and SLX1-SLX4^{195, 196}. Depending on which strands of the HJ the enzymatic nicks occur, crossover or non-crossover recombinants will be produced. DSBR is thought to be the predominant HRR pathway during meiosis due to its propensity to generate crossover recombinants. Conversely, the synthesis-dependent strand annealing (SDSA) and break-induced replication (BIR) pathways are primarily used to repair DSBs in proliferating somatic cells. In SDSA, where only a single HJ is formed, end extension is coupled to branch migration followed by D-loop dissociation such that the newly synthesized 3'-end of the invading strand is annealed to the 3'-overhang of the second resected end. Any gaps or flaps that may arise are subsequently filled in/resealed and excised by polymerases and nucleases, respectively. The SDSA pathway generates only non-crossover products¹⁴². DSBR and SDSA are generally perceived as conservative HRR pathways because recombination occurs preferentially between sister chromatids¹⁹⁰. However, mitotic HRR can also occur between allelic loci located on homologous chromosomes, which may lead to loss of heterozygosity (LOH) if the homologues are polymorphic. Moreover, on relatively rare occasions (<2% compared to gene conversion) when the other end of the DSB is either missing or is heterologous, DNA synthesis on the invading strand primes the assembly of replication forks, leading to extensive DNA




Figure 6. A schematic view of the different sub-modules of homologous recombination repair (HRR). DSBR and SDSA are considered to be error-free as long as the sister chromatid is used as the template for repair. BIR and SSA are considered to be mutagenic.

replication to the end of the template chromosome. This process, termed break-induced replication (BIR), always leads to non-reciprocal crossover and as such may lead to LOH or even chromosomal translocation¹⁹⁷. Unlike DSB, SDSA and BIR, which involve inter-chromosomal recombination events, repetitive sequences within the vicinity of the break on the same chromosome can also be used for DSB repair. This pathway, termed single strand annealing (SSA), is initiated by Rad52-mediated homologous pairing of two complementary repeat sequences exposed by DNA end resection¹⁴². This annealing reaction produces non-homologous 3'-overhangs that are cut by nucleases such as ERCC1-XPF and SLX1-SLX4. DNA synthesis then fills in any gaps and ligation re-seals the broken strands. Since one of the two repeats along with the intervening sequences in-between are lost during the process, SSA should always be considered as mutagenic.

1.3.3 Fanconi anemia pathway

The Fanconi anemia (FA) pathway is involved in the repair of DNA DSBs and interstrand crosslinks (ICLs)¹⁹⁸ (Figure 7). ICLs, which can be induced by platinum- and nitrogen mustard-based chemotherapeutic drugs, covalently connects two guanines located on opposite strands of the DNA molecule and thereby block any DNA transaction that require strand separation, such as DNA replication and transcription^{199, 200}. ICLs are therefore exceedingly toxic in proliferating cells. Thirteen FANC proteins have been identified to date, namely FANCA, FANCB, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCIJ/BRIP1, FANCL, FANCM, FANCN/PALB2²⁰¹. ICLs physically block the progress of replication forks during S phase, causing the fork to stall. This in turn leads to activation of ATR signaling, which engages the intra-S checkpoint, stabilizes the fork and coordinates the recruitment of repair proteins to the site of DNA damage²⁰². Incision on either side of the lesion on one DNA strand by ERCC1-XPF helps unhook the ICL. The gap generated by unhooking is filled in by translesion synthesis (TLS) utilizing error-prone DNA polymerases that can bypass the lesion, and the unhooked adduct is subsequently removed by nucleotide excision repair (NER)^{199, 200, 203}. This process creates a DNA DSB at the same time, which undergoes end resection and is then channeled into HRR. It is thought that the primary function of FA in ICL repair is to couple DSB generation to HRR, although the precise mechanisms are still being investigated^{203, 204}. Eight of the identified FA proteins, FANCA, B, C, E, F, G, L and M, form a nuclear complex (the FA core complex) and together with two other non-FA proteins FAAP24 and FAAP100 promotes the mono-ubiquitination of FANCD2 and FANCI, which is critical for mediating cellular resistance of ICL-inducing agents, such as cisplatin or mitomycin C^{198, 203-205}. FANCD2 and FANCI can also be phosphorylated by ATM/ATR in response to replication and/or oxidative stress although its significance to activation of the FA pathway is not yet clear. Identified interaction partners of FA proteins are implicated in a number of cellular processes including DNA repair, chromatin remodeling and anti-oxidant defense, suggesting that the FA pathway may broadly influence several aspects of the DDR^{206, 207}. Consistent with this notion, loss-of-function mutation in any of the known components of FA causes Fanconi anemia, a pediatric cancer disposition syndrome characterized by bone marrow failure, developmental defects and a high incidence of hematologic malignancies²⁰¹.




Figure 7. A schematic view of the Fanconi anemia pathway and its intersection with HRR. The different sub-units of the FA core complex (except FANCM) are depicted by single letters to indicate the complementation groups they belong to.

1.4 DNA DSB and the fate of cells with damage

The fate of cells that incur DNA DSBs is determined by a complex interplay between many factors²⁰⁸. First, the intrinsic ability of cells to maintain cell cycle arrest, which provides time for DNA repair, has a major impact on cell survival. For instance, acute myeloid leukemia (AML) cell lines that exhibit stringent G₂ checkpoint responses are more resistant to chemotherapy than counterparts that show transient G₂ arrest⁷⁷. Likewise, glioma progenitor cells have a more robust G₂ checkpoint response than non-progenitor cells and are consequently more radioresistant^{76, 209}. However, prolonged checkpoint activation can also be detrimental to cells in certain settings due to depletion of anti-apoptotic factors with short half-lives (e.g. Mcl-1) and in the extreme case, cause permanent loss of proliferative capacity^{12, 13, 119}. Second, the ability of cells to accurately repair DNA DSBs influences whether cells can survive DNA damaging treatment. This point is particularly well illustrated by the extreme radio- and chemosensitivity of mammalian cells that are genetically deficient in DNA DSB repair²¹⁰. Moreover, the developmental identities of cells are important determinants of fate by impinging on the proficiency of DSB repair. Thus for a given lineage, DNA repair is generally more precise in stem/progenitor cells than in more differentiated progenies²¹¹⁻²¹³. In addition, mesenchymal cells tend to be more resistant than epithelial or hematopoietic cells due to inherent differences in growth rate and/or apoptotic threshold. Fourth, microenvironmental factors including autocrine/paracrine growth factor signaling, oxygenation/hypoxia and pH can greatly influence the susceptibility/resistance to DNA damage^{214, 215}. Finally, mutations and/or de-regulated expression of certain proteins can sever (e.g. p53) or strengthen (e.g. E2F1) the signaling link between the DDR and cell death pathways, leading to either decreased or increased sensitivity to DNA damage^{216, 217}.

1.4.1 Cell survival

In order for a cell to survive DNA damage, several conditions must be satisfied. First, the amount of DNA damage incurred must not be large enough to trigger cell death outright²¹⁸⁻²²¹. Second, checkpoint mechanisms need to kick in promptly and provide time for DNA repair⁷⁹. Third, genomic lesions need to be repaired with sufficient fidelity such that residual damage, if any, no longer sustains checkpoint signaling (recovery)^{121, 122, 222, 223}. Alternatively, checkpoint signaling must be actively shut off by pro-survival signaling (adaptation) if efficient repair of DNA damage cannot be accomplished^{121, 122, 137}. Fourth, cells must maintain low level expression of essential cell cycle regulators during checkpoint arrest allowing them to retain cell cycle competency following checkpoint release¹³⁵. Fifth, any residual DNA damage should not elicit (prolonged) DDR signaling in the next cell cycle phase or overtly interfere with mitotic chromosome segregation¹¹⁹. Finally, the complement of genetic material inherited by each daughter cell after mitosis must be of sufficient quality to support various cellular processes that are essential for long-term viability²²¹. Hence, cell survival following complete and faithful repair of all DNA lesions represents the best case scenario of a continuum of possible scenarios, where variable but relatively low levels of residual DNA damage may exist in viable cycling cells. As such, cells that survive DNA damage carry an increased risk for the development of delayed chromosomal instability.

1.4.2 Cell death

A failure to meet one or more of the above-mentioned conditions for survival significantly increases the likelihood that a cell will succumb to DNA damage-induced cell death, which has been shown to occur by multiple modes^{220, 224-226}. Apoptosis and necrosis are two unequivocal cell death mechanisms. On the other hand, autophagy and mitotic catastrophe are more ambiguous in that they can also promote survival under certain conditions²²⁷⁻²³¹. Senescence is not strictly a cell death mode since senescent cells remain metabolically active albeit being clonogenically dead²³². While apoptosis and necrosis are generally considered to be irreversible, both autophagy and senescence are clearly reversible^{233, 234}. Notably, multiple cell death modes can be triggered by different genotoxic stimuli, the same stimulus at different strengths, the same stimulus at identical strength in different cells or even transition into each other in the same cell²³⁵⁻²⁴⁰.

Apoptosis

Apoptosis is a form of programmed cell death that is evolutionarily conserved from yeast to humans. Morphologically, apoptosis is characterized by cell shrinkage, membrane blebbing, chromatin condensation and DNA fragmentation that culminate in the formation of apoptotic bodies and rapid removal by professional phagocytes or neighboring cells^{241, 242}. The main cellular enforcers of apoptosis are a family of cysteine proteases known as caspases²⁴³. These are synthesized as inactive zymogens containing an N-terminal pro-domain of variable length and a C-terminal protease domain. Depending on the length of their pro-domains, caspases are subdivided into two categories: initiator and effector (executioner). Initiator caspases (e.g. caspases-2, -8, -9) have large pro-domains containing specialized protein-protein interaction motifs (e.g. caspase recruitment domain, CARD; death effector domain, DED) that enable their recruitment into multi-protein complexes (e.g. PIDDosome, death-inducing signaling complex, apoptosome) through homotypic interactions with adaptor

molecules (e.g. RAIDD, FADD, Apaf-1)²⁴⁴. Within these complexes, inactive procaspases undergo conformational changes and/or auto-processing leading to their activation. By contrast, effector caspases (e.g. caspases-3, -6, -7) have short pro-domains. Activation of these caspases requires proteolytic maturation by either initiator caspases or other proteases (e.g. cathepsins)²⁴⁵. Enzymatically active effector caspases cleave protein substrates that function in a wide variety of cellular processes, such as structural maintenance (e.g. lamins), adhesion (e.g. focal adhesion kinase), anti-apoptotic signaling (e.g. Bcl-2) and DNA repair (e.g. DNA-PKcs, PARP-1), to bring about cell demise in an ordered and energy-dependent manner^{246, 247}. There are two main apoptotic pathways operating in mammalian cells which are activated predominantly by extracellular (extrinsic) and intracellular (intrinsic) stimuli, respectively (Figure 8). In the extrinsic pathway, binding of extracellular death ligands (e.g. FasL/CD95L, TRAIL) to cell surface death receptors triggers receptor clustering and the formation of a death-inducing signaling complex (DISC) leading to the recruitment and activation of caspase-8, which in turn activates caspase-3²⁴⁸. In the intrinsic pathway, intracellular stress signal (e.g. DNA damage) trigger multiple pro-apoptotic signaling modules (e.g. JNK, p38) to bring about the conformational activation of pro-apoptotic Bcl-2 family members Bak and Bax, leading to mitochondrial outer membrane permeabilization (MOMP) and the release of cytochrome c^{249, 250} [Roos, 2006 #737]. Once in the cytosol, cytochrome c and Apaf-1 assemble into a complex called the apoptosome that leads to the recruitment and activation of caspase-9, which in turn activates caspase-3. In addition, there is substantial cross-talk between these two pathways. For instance, cleavage of the pro-apoptotic Bcl-2 family member Bid by caspase-8 produces a truncated molecule (tBid) that translocates to the mitochondrial membrane where it contributes to the activation of Bak and Bax²⁵¹. Conversely, caspase-3 activated through the intrinsic pathway can also cleave caspase-8 to further amplify the apoptotic cascade²⁵². Moreover, many noxious stimuli are known to induce oxidative stress, causing damage to intracellular organelles such as lysosomes and endoplasmic reticulum (ER)^{253, 254}. In turn, lysosomal membrane permeabilization (LMP) and ER stress could lead to activation of




Figure 8. A schematic overview of the apoptotic pathways. DNA damage has been shown to activate both the extrinsic death receptor-mediated pathway and the intrinsic mitochondrial pathway. Casp, caspase.

cathepsins and calpains, which in some experimental models have been shown to activate effector caspases^{255, 256}. Unlike caspases-3, -8 and -9, the role of caspase-2 in DNA damage-induced apoptosis is not clearly defined²⁵⁷⁻²⁶¹. Although its structure resembles that of an initiator caspase, the phenotype of caspase-2-deficient cells suggests that it may have a more prominent role in regulating the G₂ checkpoint rather than apoptosis.

Because inappropriate activation of caspases carries potentially deleterious consequences, mammalian cells are equipped with a number of braking mechanisms that inhibit caspase activation and/or activity. Activation of caspase-8 within the DISC can be suppressed by c-FLIP, a DED domain-containing caspase homolog that lacks catalytic activity²⁶². Anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-X_L and Mcl-1 normally hold Bak and Bax in inactive complexes, thereby preventing them from inducing MOMP²⁶³. Furthermore, the pro-apoptotic Bcl-2 family member Bad is phosphorylated by Akt, which leads to its sequestration by 14-3-3 proteins in the cytosol²⁶⁴. Accidental activation of caspases is also prevented by the inhibitor of apoptosis (IAP) family of anti-apoptotic proteins (e.g. XIAP, c-IAP1/2, survivin) which bind to caspases and suppress their activity. In response to DNA damage, p53 becomes stabilized and transcriptionally active, leading to the increased expression of a variety of pro-apoptotic proteins, such as FasL, death receptor-4/TRAIL receptor-1 (DR4/TRAIL-R1), Apaf-1 and the pro-apoptotic Bcl-2 family proteins Puma, Noxa and Bax²⁶⁵. Moreover, cytosolic p53 appears to directly induce MOMP by activating Bak and Bax^{266, 267}, which can release mitochondrial SMAC/Diablo and Htr2a/Omi to inactivate IAPs. Human tumor cells frequently show increased expression of various anti-apoptotic proteins as well as functional inactivation of p53. As expected, the apoptotic propensity of p53 deficient cells in response to DNA damage is markedly reduced²¹⁶. In these cells, however, p53-independent apoptosis can still occur, but the molecular mechanisms are not well understood.

Necrosis

Necrosis is a form of cell death characterized by swelling and rupture of organelles as well as cells that leads to the release of noxious pro-inflammatory mediators and injury to surrounding tissues^{241, 242}. In the context of chemotherapy, it is generally believed that the probability of triggering necrosis increases with increasing doses. Historically, cell death by necrosis is considered to be un-regulated and pathologic, caused by massive irreparable damage to cellular components. However, evidence has emerged over the past decade suggesting that necrosis can also be highly regulated. PARP appears to be an important regulator of necrosis. Over-stimulation of PARP activity by excessive alkylating or oxidative DNA damage causes rapid depletion of intracellular ATP and NAD(+), resulting in the shutdown of metabolism and caspase-independent programmed necrosis (aka necroptosis)²⁶⁸ (Figure 9). As the name indicates, necroptosis share some features with apoptosis, in that its main effector apoptosis-inducing factor (AIF) needs to be released from mitochondria via a process that depends on calpain and Bax. AIF then translocates into the nucleus where it induces chromatinolysis (but not internucleosomal DNA cleavage as in apoptosis) by interacting with H2AX²⁶⁸. Two additional forms of programmed necrosis have been described recently (Figure 9). In one model, necrotic cell death after DNA damage was regulated by p53-dependent up-regulation of lysosomal cathepsin Q and reactive oxygen species (ROS) independently of Bak/Bax-mediated MOMP²⁶⁹. In the other model, necrotic cell death induced by tumor necrosis factor- α (TNF α) was shown to involve RIP1/RIP3-dependent formation of a “necrosome” complex that enhances ROS

production, calcium mobilization and lysosomal dysfunction²⁷⁰. Moreover, apoptotic cells can undergo secondary necrosis, especially in the absence of phagocytes as under most *in vitro* culture conditions²⁷¹. The processes of apoptosis and necrosis are clearly more intertwined than previously thought and both are likely to contribute to chemotherapy-induced cell death *in vivo*²³³.




Figure 9. A schematic overview of the pathways implicated in programmed necrosis. DNA damage has been shown to induce necrotic cell death by at least two mechanisms via p53/cathepsin Q/ROS or PARP-1/Calpain/Bax/ROS/AIF. Depending on the adaptor proteins and cellular context, signaling from death receptors may lead to necrosis, apoptosis or survival.

Mitotic catastrophe

Mitotic catastrophe is a term used to describe highly disorganized and defective mitosis^{225, 242, 272}. It is not clear whether mitotic catastrophe represents a distinct mode of cell death because there are no molecules exclusively linked to the execution of mitotic catastrophe. As such, mitotic catastrophe is more likely a physical manifestation of failed mitosis that is severe enough to trigger cell death by any mode(s)²²⁵ (Figure 10). Mitotic catastrophe appears to be more easily invoked in tumor cells with compromised cell cycle checkpoints due to p53 deficiency or pharmacologically induced checkpoint abrogation^{225, 273, 274}. Hallmarks of apoptosis (e.g., caspase activation) are frequently observed following mitotic catastrophe, suggesting that severe mitotic defects can trigger apoptotic cell death²⁷⁵. However, there is also evidence implicating an adaptive and pro-survival role of mitotic catastrophe²⁷⁶ (Figure 10). Notably, severe DNA damage can drive p53-deficient tumor cells into the endocycle, whereby cells continuously replicate their DNA without undergoing cytokinesis leading to high-level ploidy (endopolyploidy) and formation of giant cells. While the vast majority of endopolyploid tumor cells are not clonogenically viable, a small fraction has been shown to up-regulate genes that control embryonic self-renewal, such as Oct4, Sox2 and Nanog, resulting in transient acquisition of stem cell properties and resistance to apoptosis²⁷⁷. Subsequent depolyploidization and reorganization of the genetic material can produce seemingly diploid daughter cells that are clonogenic. The process of

depolyloidization appears to be regulated by a set of genes normally involved in meiosis, a form of reduction cell division that generates haploid gametes (i.e., spermatogonia and oocytes) ²⁷⁸. Alternatively, before they die non-viable polyploid giant cells produced from mitotic catastrophe may also give rise to mitotically viable daughter cells via nuclear budding and asymmetric cytokinesis in a phenomenon termed neosis ²⁷⁹. Importantly, endopolyloidization-depolyloidization and neosis-like events have been observed during tumorigenesis as well as in response to DNA damaging treatment, suggesting that these processes have the potential to promote tumor heterogeneity and drug resistance ^{229, 230, 276, 278, 280, 281}.




Figure 10. A schematic overview of mitosis. Depending on the severity, unrepaired DNA damage may cause chromosomal segregation defects or mitotic catastrophe. The latter can drive cells into apoptosis or the endocycle leading to high-level polyploidization.

Autophagic cell death

Autophagy involves the sequestration of cellular proteins and organelles into specialized double-membraned vesicles (autophagosomes) which subsequently fuse with lysosomes resulting in proteolytic degradation of the vesicular contents ²⁸² (Figure 11). Autophagy is an essential physiologic process during development and its deregulation has been demonstrated in a variety of human pathologies, including neurodegenerative diseases and cancer ²⁸³⁻²⁸⁵. Autophagy is also elicited by ionizing radiation and many clinically used chemotherapeutic agents, such as temozolomide and etoposide ^{227, 286-288} (Figure 11). However, the consequence of drug-induced autophagy may be either cytoprotective or cytotoxic, depending on the cellular and experimental context under which it was induced ²³³. In general, transient induction of autophagy is beneficial for tumor cells by isolating damaged cell components (e.g., mitochondria) and recycling limiting resources (e.g. nucleotides, amino acids, lipids). On the contrary, persistent autophagy is usually detrimental and leads to cell death. Notably, autophagic cell death often displays certain hallmarks of apoptosis (e.g., caspase activation), suggesting that these cell death modes may share some common features ²⁸⁹. Inhibition of apoptotic effectors can sometimes trigger autophagic cell death ²⁹⁰. Furthermore, apoptosis and autophagy appears to be co-regulated by Bcl-2 family members Bcl-2, Bcl-X_L and Beclin-1 at the level of mitochondria and ER ^{291, 292}. Therefore, autophagic cell death and apoptosis probably exist in a continuum and both of these cell death

modes can be induced in a given tumor. Interestingly, autophagy plays a dual role in tumorigenesis, serving as a barrier against the initiation of incipient tumors while enhancing the survival of established tumors in the face of metabolic crisis or drug treatment^{293, 294}. Consistent with this notion, autophagy inhibition has emerged recently as a promising strategy for combating cancer^{295, 296}.




Figure 11. A schematic overview of autophagy. Autophagy is a normally a homeostatic process by which cells degrade and recycle unused or damaged organelles and macromolecules. Persistent autophagy may lead to autophagic cell death, which shares many features with apoptosis.

Senescence

Senescence refers to a state where cells remain metabolic active but are unable to proliferate. These cells are typically larger, appear flattened and express senescence-associated β -galactosidase²⁹⁷. The replicative life span of mammalian cells is limited by their ability to maintain telomere length²⁹⁸. The telomere is a region of highly repetitive nucleotide sequence at the end of a chromosome which interacts with specialized protein complexes (i.e. shelterin) to form a protective cap that prevent chromosome end-to-end fusion²⁹⁹. During each round of cell cycle, the telomeres become successively shorter because DNA polymerases cannot replicate DNA all the way to the end of the chromosomes. Critically shortened telomeres trigger a p53-dependent DNA damage response leading to permanent cell cycle arrest or replicative senescence that is maintained by p21^{Cip1/Waf1} and p16^{INK4a}¹² (Figure 12). Adult tissue stem cells typically express the enzyme telomerase and are therefore able to delay the onset of replicative senescence³⁰⁰. By contrast, differentiated cells normally do not express telomerase and consequently have a relatively short proliferative life span³⁰¹. Notably, human tumors frequently re-activate telomerase expression giving them the ability to sustain proliferation indefinitely²³². In telomerase-negative tumors, alternative means to maintain telomere length (e.g. BIR) have been described³⁰².

De-regulated oncogenic signaling and chemotherapy have been shown to induce terminal growth arrest in tumor cells by two related processes called oncogene-induced senescence (OIS) and premature senescence (aka accelerated senescence), respectively^{303, 304} (Figure 12). Unlike replicative senescence, OIS and premature senescence are triggered by DNA damage that is not necessarily caused by telomere dysfunction. DDR signaling appears to play a key role in the enforcement of senescence program³⁰⁵, but there is no strict requirement on the p53-p21^{Cip1/Waf1}/p16^{INK4a} pathway^{306, 307}. OIS constitutes an early barrier against tumorigenesis that indolent tumors must overcome to achieve full-blown malignancy³⁰⁸. Drug-induced premature senescence is an important route for tumor clearance *in vivo*^{309, 310} and its evasion may limit the efficacy of cancer treatment³¹¹. However, senescence induction is a double-edged sword because senescent tumor cells and fibroblasts have been shown to secrete pro-inflammatory cytokines, proteases and mitogenic factors that lead to tissue remodeling in the microenvironment and accelerated tumor growth³¹². Hence, novel agents that can prevent the acquisition of senescence-associated secretory phenotype (SASP) have the potential to significantly improve tumor eradication by conventional chemotherapy.




Figure 12. A schematic overview of pro-senescence pathways induced by telomere attrition, oncogene-induced replication stress or chemotherapy. ALT, alternative lengthening of telomeres.

1.5 DDR signaling in cancer

1.5.1 DDR as a barrier against tumorigenesis

There is ample evidence to suggest that the DNA damage response constitutes an early barrier against tumorigenesis^{305, 313}. In pre-neoplastic tissue, oncogene-driven hyperproliferation causes significant replication stress leading to chronic activation of the DDR machinery, orchestrated by ATR-Chk1 and ATM-Chk2^{314, 315}. Persistent DDR signaling induces senescence or death of oncogene-transformed cells resulting in delayed tumor formation. To achieve full-blown malignancy, pre-neoplastic cells must breach this early DDR-imposed barrier, which would explain the propensity of human malignant tumors, including lung cancer, to harbor genetic and/or epigenetic defects that inactivate key components of the DDR network, including ATM, Chk2, H2AX, 53BP1 and p53³¹⁶⁻³¹⁸.

1.5.2 DNA DSB repair deficiency and cancer predisposition

A significant number of (rare) inherited human syndromes are linked to deficient expression of genes encoding proteins that participate in DNA DSB repair and/or checkpoint regulation (Table 1). This list is likely to grow over time as research into the intricacy of the DDR network continues to reveal novel factors not previously known to function in DNA DSB repair. A common characteristic of these familial syndromes is hypersensitivity to endogenous (and exogenous) DNA damage, which in certain instances may predispose afflicted individuals to cancer and/or premature aging. Some inherited DNA DSB repair deficiencies also cause developmental abnormalities, mental retardation and/or immunodeficiency. Complete bi-allelic inactivation of DSB repair genes is relatively uncommon because it is usually not conducive to survival. Instead, most clinically relevant DNA DSB repair deficiencies stem from hypomorphic mutations which allow the mutant proteins to retain some residual activity. Notably, many genes implicated in DNA DSB repair, especially those involved in the ATR network, are haploinsufficient³¹⁹, suggesting that even partially compromised DNA DSB repair may precipitate the development of human pathologies. In addition to these familial cancer predisposition syndromes, somatic mutations and single nucleotide polymorphisms (SNPs) in DSB repair genes have also been implicated in tumorigenesis³²⁰⁻³²⁵. Finally, the DSB repair machinery itself appears to become less efficient and more error-prone during physiological aging, which may account for the age-dependent increases in cancer incidence³²⁶.

Table 1. Human familial syndromes associated with DNA DSB repair deficiency.

Disorder	Gene	Radiation sensitivity	Cancer predisposition	Reference
Ataxia telangiectasia	ATM	yes	yes	327
ATR-Seckel syndrome	ATR	yes	?	328
Nijmegen breakage syndrome	NBN ^a	yes	yes	329
AT-like disorder	MRE11	yes	?	330
Li-Fraumeni syndrome	TP53, CHEK2 ^a	yes	yes	331
Hereditary breast/ovarian cancer syndrome	BRCA1, BARD1, BRCA2, PALB2	yes	yes	332-334
Primary Microcephaly	MCPH1 ^a	yes	?	335
RS-SCID	PRKDC ^a	yes	?	336
LIG4 syndrome	LIG4	yes	?	328
Omenn syndrome (RS-SCID)	DCLRE1C ^a	yes	yes	328
NHEJ1 syndrome (RS-SCID)	NHEJ1 ^a	yes	?	337
RIDDLE syndrome	RNF168	yes	?	338
Bloom syndrome	BLM	yes	yes	339
Werner syndrome	WRN	yes	yes	339
Rothmund-Thomson syndrome	RECQL4	yes	no	339
Fanconi anemia	FANC(A-N)	yes	yes	199

Abbreviations: SCID, severe combined immunodeficiency.

^a *NBN, CHEK2, DCLRE1C, MCPH1, NHEJ1 and PRKDC encode for Nbs1, Chk2, Artemis, microcephalin, XLF and DNA-PKcs, respectively.*

1.5.3 De-regulation of DNA DSB repair in cancer

As partial inactivation of DDR signaling during early stages of tumorigenesis is required for the transition into full-blown malignancy^{314, 315}, DNA DSB repair pathways in established human tumors are likely to be profoundly different from their normal counterparts. For instance, DNA repair in bladder cancer is often characterized by low fidelity NHEJ caused by diminished Ku DNA-binding activity^{340, 341}. In leukemia, expression of oncogenic (fusion) tyrosine kinases (e.g. FLT3-ITD, BCR-ABL, TEL-JAK2, etc.) causes a shift from C-NHEJ to DNA Ligase III-mediated B-NHEJ^{342, 343}. Multiple myelomas also show impaired NHEJ function although these cells seem to become genomically instable due to over-activation of HRR^{344, 345}. Over-expression of Rad51 has been linked to hyper-recombination and/or increased usage of alternative HRR in a variety of cancers, including breast, pancreatic and BCR-ABL⁺ CML^{321, 346-349}. Similarly, loss of BRCA1/2 in breast and ovarian cancer compromises error-free HRR and causes up-regulation of mutagenic SSA¹⁴⁸. Moreover, large tumors with hypoxic regions may resort to error-prone DSB repair due to reduced expression of HRR factors³⁵⁰. Finally, B-NHEJ can promote fusion of dysfunctional telomeres while BIR may facilitate telomerase-independent alternative lengthening of telomeres (ALT)^{302, 351}. De-regulation of DNA repair is thus a double-edged sword; on the one hand promoting genomic instability to fuel the malignant evolution of tumors, while on the other hand imposing over-reliance on inefficient repair and checkpoint mechanisms for survival. As such, many tumors may exist in a primed-for-death state whereby sub-optimal DNA repair just barely manages to hold the mutation load at a survivable level. Consequently, therapeutics that abolish DNA checkpoint and/or repair have the potential to tip this precarious balance and selectively eradicate tumor cells^{352, 353}.

1.5.4 DNA DSB repair and tumor chemosensitivity

The relationship between DNA DSB repair and chemosensitivity is very complex and most likely context-dependent. In terms of relative mRNA and protein expression, different tumors have been found to produce higher, comparable or lower levels of certain DNA DSB repair factors than adjacent normal tissues (Table 2). However, depending on their histological origin and/or stage, such expression changes may or may not be associated with tumor aggressiveness or chemosensitivity. In addition, SNPs in DSB repair genes may also have important bearings on the outcome of treatment^{322, 354}.

1.6 Resistance to DNA damaging chemotherapy

1.6.1 Mechanisms of resistance

The underlying causes of resistance, whether intrinsic or acquired, can be pleiotropic and different for each chemotherapeutic agent. Intrinsic resistance refers to profound drug insensitivity that is apparent already at initial exposure to a particular treatment and is usually linked to processes involved in tumorigenesis itself. By contrast, acquired resistance is by definition induced upon (recurrent) drug treatment, whereby tumors cells that are initially sensitive become progressively more resistant to subsequent treatment. Drug resistance mechanisms can evolve independently or in tandem in a given tumor, and can be transient or long-lasting. Moreover, exposure to a single chemotherapeutic agent may elicit cellular defense mechanisms that render tumor cells cross-resistant to a multitude of other drugs, a condition termed multidrug

resistance (MDR). Because they obvious impact on treatment outcome, resistance mechanisms that human tumors utilize to survive conventional DNA damaging chemotherapy have been the subject of intense research. Known causes of chemoresistance can be broadly divided into four categories: (1) failure of the drug to reach its intended target, the DNA (pre-target resistance), (2) inability of the drug to efficiently induce DNA lesions (on-target resistance), (3) malfunctioning of cell death pathways (post-target resistance) and (4) constitutive activation of pro-survival signaling pathways that are unrelated to the drug treatment *per se* but which can abolish its death-inducing capacity (off-target resistance). A few examples clinically relevant resistance mechanisms are provided below.

Table 2. Alterations in the expression of DNA DSB repair factors and their impact on tumor progression and resistance.

Tumor type	Transcript expression	Protein expression	Resistance ^a	Reference
T-cell lymphomas B-cell lymphomas Multiple myeloma	decreased XRCC6 ^b and MRE11A; increased XRCC4 and Rad50 in MM	n.d.	n.d.	355
Multiple myeloma	increased endo-/ exonucleases, helicases, ERCC1, Rad23, Rad50, Rad51, Rad51B, Rad51C, Rad51D and XRCC3	increased Rad51, Rad51B, Rad51C and Rad51D	n.d.	344
Diffuse large B- cell lymphoma	decreased 53BP1 in a subset of tumors	n.d.	n.d.	356
Chronic myeloid leukemia	n.d.	Increased DNA- PKcs	chlorambucil	357
Breast cancer Bladder cancer	n.d.	increased Ku70/80 only in breast cancer	n.d.	358
Breast cancer	n.d.	increased Rad51 with tumor grade in sporadic cases; increased Rad51 in BRCA1-deficient cases	n.d.	359, 360
Cervical cancer Esophageal cancer	n.d.	increased DNA- PKcs and Ku70/80 in residual tumors	expression correlates with IR resistance	361, 362

Abbreviation: n.d., not determined.

^a Resistance to chemo-/radiotherapy; ^b XRCC6 encodes for Ku70.

Altered drug transport and detoxification as examples of pre-target resistance

Most if not all chemotherapeutics with intracellular targets require some types of transport mechanism en route to their destination. Alterations in drug transport can thus be an important contributor of resistance by preventing chemotherapeutics from reaching their intended targets. For instance, tumor cells may acquire resistance to platinum-based compounds (e.g. cisplatin) as a result of reduced drug uptake, which can occur by drug-induced down-regulation of the copper influx transporter hCtr1 or enhanced expulsion of internalized drug by the copper efflux transporters ATP7A/B³⁶³. Likewise, intracellular accumulation of anthracyclines (e.g. doxorubicin) is hampered

by over-expression of several efflux pumps of the ATP-binding cassette (ABC) transporter superfamily (e.g. p-glycoprotein)³⁶⁴.

Detoxification refers to processes by which cells inactivate xenobiotics either enzymatically or by sequestering them away from their intended targets. Given that many anti-cancer drugs (e.g. bleomycin, cisplatin) trigger the production of ROS through iron-catalyzed redox reactions and/or disruption of mitochondrial respiratory chain, it is perhaps not surprising that increased expression of proteins involved in the cellular antioxidant defense (e.g. glutathione S-transferases, thioredoxin reductase, superoxide dismutase) is frequently observed in chemoresistant tumors³⁶⁵. In addition, increased acidification of intracellular organelles (e.g. lysosomes, endosomes, *trans*-Golgi network) with concomitant cytoplasmic alkalinization is a recurrent feature in many tumors. This would allow the membrane-permeable neutral form of weakly basic drugs (e.g. anthracyclines) to diffuse into acidic organelles where they become protonated and trapped, thereby reducing the intracellular concentration of drugs at their nuclear target sites³⁶⁶.

Enhanced DNA repair as an example of on-target resistance

DNA represents the major intracellular target of many commonly used chemotherapeutic agents. Unrepaired DNA damage is highly cytotoxic, as demonstrated by the extreme radiosensitivity in patients afflicted with rare human syndromes caused by inherited mutations in DNA repair genes, such as ataxia telangiectasia, Fanconi anemia and xeroderma pigmentosum^{367, 368}. It is generally believed that elevated DNA repair capacity correlates with diminished tumor sensitivity to DNA damaging chemotherapy. For instance, high expression of the nucleotide excision repair (NER) and HRR component ERCC1 is associated with platinum resistance in non-small cell lung carcinoma (NSCLC)^{369, 370}. Similarly, high expression of the DNA repair protein MGMT is associated with resistance to alkylating agents, in particular temozolomide, and conversely MGMT promoter methylation correlates with increased drug sensitivity³⁷¹. Enhanced FA/BRCA-mediated ICL repair contributes to melphalan resistance in multiple myeloma and there is evidence suggesting that high expression/activity of DNA-PK is associated with chlorambucil resistance in B-cell chronic lymphocytic leukemia (B-CLL)^{357, 372-374}. The epidermal growth factor receptor (EGFR), which is frequently over-expressed in NSCLC and gliomas, is a positive regulator of DNA-PK activity and this may account for the observed benefit of adding an EGFR inhibitor to standard platinum-based chemotherapy³⁷⁵⁻³⁷⁷. Finally, Rad51 is over-expressed in many human tumors; the available data suggest that Rad51 may confer chemoresistance as well as genomic re-stabilization of previously unstable tumors^{346, 378}.

The cellular DNA repair machinery is subject to complex regulation by growth receptor signaling. For instance, both the EGFR and IGF1R exert cytoprotective effects in lung cancer cells by promoting NHEJ^{376, 379}. Essentially all growth factor receptor studied in connection with DDR have been shown to enhance DNA repair, including c-Met, TrkA, Her2/ErbB2 and the aforementioned EGFR and IGF1R^{376, 379-383}. In addition, growth factor receptor signaling almost invariably leads to activation of the phosphatidylinositol 3'-kinase (PI-3K)/Akt pathway, which is a potent inhibitor of both apoptosis and checkpoint responses^{103, 264}. Since over-expression of growth factor receptors is a fairly common phenomenon in human tumors, paracrine growth factor signaling could have a major influence on chemoresistance by promoting DNA repair, checkpoint override and apoptosis evasion.

Defective apoptotic signaling as an example of post-target resistance

Human tumors can acquire resistance to apoptosis through de-regulation of the extrinsic and intrinsic apoptotic pathways as well as their upstream regulatory networks^{384, 385}. For instance, reduced apoptosis sensitivity of cisplatin-treated NSCLC cells has been shown to result from diminished expression of Fas, pro-caspase-8, pro-caspase-9, XIAP, Bcl-2 and Bcl-X_L³⁸⁶. Similarly, over-expression of c-FLIP in breast cancer cells confers resistance to doxorubicin/interferon- γ co-treatment³⁸⁷. Increased expression of anti-apoptotic Bcl-2 family members (e.g. Mcl-1) is associated with poor prognosis as well as chemoresistance (e.g. etoposide, doxorubicin) in both neuroblastoma and leukemia, while decreased expression/activation of their pro-apoptotic counterparts Bax and Bak in colon cancer and NSCLC resulted in resistance to etoposide and IR, respectively³⁸⁸⁻³⁹¹. Elevated expression of IAPs and heat shock proteins, which negatively regulate caspase activity, has also been implicated in chemoresistance in some tumors^{384, 392}. Furthermore, hyper-activity of Akt, caused by de-regulated upstream signaling from receptor tyrosine kinases (e.g. EGFR), Ras and PI-3K or deletion of its negative regulator PTEN, is observed in a large proportion of tumors and contributes to suppression of chemotherapy-induced apoptosis^{385, 389, 393}. In fact, defective apoptotic signaling is a recurrent feature for most if not all human solid tumors³⁹⁴.

Hypoxia, quiescence and EMT as examples of off-target resistance

Insufficient oxygen delivery is fairly common in solid tumors, especially when a tumor has reached beyond the size of 3 cm. In these cases, the cells located in the center of the tumor experiences hypoxia, which has significant impact on chemosensitivity³⁹⁵. First, the lack of adequate perfusion of blood results in diminished drug delivery to the hypoxic region of the tumor. Second, hypoxia limits the formation of cytotoxic ROS that is induced by many chemotherapeutic drugs. Third, hypoxic cells often enter quiescence and become insensitive towards drugs that selectively target DNA replication-related processes. Finally, hypoxia directly shifts the balance of DNA repair from error-free HRR to error-prone NHEJ^{350, 395}. This decrease in repair accuracy in tandem with increased resistance to cell death can cause genomic instability, rapid tumor evolution and metastasis.

Cancer stem cells (CSCs, aka tumor-initiating cells, TICs) belong to a rare sub-population of cells within the tumor bulk endowed with the capacity to self-renew and sustain tissue ontogeny, a defining property of normal embryonic/adult stem cells^{396, 397}. CSCs typically activate transcriptional modules associated with maintenance of pluripotency (e.g. Oct4, Sox2, Nanog) and express similar surface markers as normal stem cells (e.g. CD133, CD44)³⁹⁸⁻⁴⁰⁰. CSCs generally show increased chemo- and radioresistance as compared to their more differentiated counterparts, which is due partly to their superior capacity in DNA repair and/or checkpoint arrest and partly to their quiescent state^{72, 76, 209, 401-406}. Quiescence refers to a state of dormancy during which cells resides in G₀. Since many chemotherapeutic agents (e.g. cisplatin, gemcitabine) preferentially kill fast proliferating tumor cells, the lack of cell cycle progression as a result of quiescence largely negates the activity of S-phase targeting drugs. Quiescence can also be reversibly induced in differentiated cells by certain anti-cancer treatments and might represent an adaptive response to adverse metabolic conditions⁴⁰⁷.

Epithelial-mesenchymal transition (EMT) refers to a developmental process in which cells with a predominantly epithelial identity acquire features consistent with a predominantly mesenchymal identity, characterized by decreased cell adhesion (loss of E-cadherin) and increased motility⁴⁰⁸. Although EMT is physiologically important during normal embryonal development, organ formation and wound healing, it can also be pathologically induced in tumors by de-regulated oncogenic signaling pathways (e.g. growth factors, Ras, Wnt/ β -catenin and Notch)⁴⁰⁸. EMT is controlled by a number of transcription factors (e.g. Snail, Slug, Twist, Smads) that collectively promote survival signaling, acquisition of stem cell properties, increased DNA repair (e.g. up-regulation of ERCC1) and metastasis⁴⁰⁹⁻⁴¹¹.

1.7 DDR signaling as a target for chemotherapy sensitization

1.7.1 Abrogation of cell cycle checkpoints

Functional inactivation of the tumor suppressor protein p53 is a recurrent feature in human tumors^{84, 412}. This can happen through deletion of the chromosomal arm where p53 resides, inactivating mutation of p53 itself or over-expression of its chief negative regulator MDM2, which targets p53 for proteasomal degradation. Loss of p53 functions usually lead to increased tumor resistance to DNA damaging agents due to the absence of p53-dependent pro-apoptotic signaling⁴¹³. However, these tumors also lack the ability to initiate checkpoint arrest in G₁, a largely p53-dependent process and become overly reliant on checkpoints in S and G₂ to deal with endogenous DNA damage and replication stress associated with hyper-proliferation⁸⁰. Although p53 is not absolutely required for enforcing cell cycle arrest in S and G₂, it does modulate the functions of these checkpoints, which tend to become less stringent in its absence^{74, 95}. It is therefore anticipated that combining DNA damaging chemotherapy with drugs that abrogate the intra-S and G₂ checkpoints would overwhelm the DNA repair machineries of p53-mutant tumors, leading to enhanced therapeutic efficacy^{414, 415} (Figure 13). The validity of this hypothesis is currently being tested for a number of small molecule inhibitors of Chk1/2 that recently entered clinical trials^{78, 79}.




Figure 13. Examples of strategies for targeting DNA DSB repair.

1.7.2 Inhibition of DNA DSB repair

As most conventional chemotherapeutic agents kill tumor cells by inducing DNA damage, it is widely expected that their efficacy should be enhanced by inactivation of the cellular DNA repair machinery. While this assumption is intuitively attractive, it also presents a number of potential pitfalls. For instance, lowering the DNA repair capacity indiscriminately may cause significant collateral damage to highly DNA damage-sensitive normal proliferative tissues such as the colon mucosa and bone marrow, while inducing mutagenesis in other tissues that are not apoptosis-prone. Moreover, as human cells routinely employ multiple DNA repair pathways in response to chemotherapy, targeting a single pathway may not be sufficient to markedly augment tumor eradication⁴¹⁶. In addition, there is evidence suggesting that functional DNA damage signaling might be required to trigger cell death, particularly when damage is extensive^{218, 219}. Nevertheless, the concept of targeting DNA DSB repair as a means to enhance chemotherapy does have merits and may be highly effective in certain context (see below).

PARP inhibitors and synthetic lethality

Synthetic lethality refers to the state whereby individual inactivation of two genes is tolerated but their compound inactivation causes lethality. The concept of synthetic lethality has gained widespread attention since the discovery of BRCAness in breast and ovarian cancers, a term that has been used to describe functional inactivation of BRCA1/2 or their associated network. BRCAness, which is characterized by deficiencies in HRR, renders tumor cells highly susceptible to PARP inhibition because the loss of PARP-dependent base excision repair (BER) causes the accumulation of DNA single strand breaks (SSB) and their conversion into replication-associated DNA DSBs. Such lesions are normally dealt with by HRR during S phase, but remain unrepaired or misrepaired by NHEJ in BRCA-deficient cells leading to apoptosis⁴¹⁷⁻⁴²⁰ (Figure 13). A multitude of clinical trials have since been initiated to examine the feasibility of using PARP inhibitors as mono-therapy as well as in combination with conventional chemo/radiotherapy. To date, the main focus has been on breast and ovarian cancer where BRCA1/2 deficiency is relatively common, but the scope is beginning to widen following the elucidation of the FA pathway as part of the BRCA network^{332, 421, 422}. Certain tumor-specific mutations and drug treatment also appear to induce conditions akin to BRCAness which are potentially amenable to PARP inhibition^{423, 424}. Finally, several recent studies identified synthetic lethal interactions between PARP and many protein factors not known to participate in BRCA-dependent HRR⁴²⁵⁻⁴²⁷. Collectively, these data suggest that PARP inhibitors may be useful for targeting human tumors with a wide spectrum of DNA repair defects. In addition, the utility of PARP inhibitors in repair-proficient tumors also warrant further investigation, especially in combination with another DNA repair inhibitor⁴²⁸.

DNA-PK modulators

Given the key role of NHEJ for promoting efficient DNA DSB repair, substantial efforts have been invested in the research of DNA-PK inhibitors as novel chemosensitizers⁴²⁹. Unfortunately, the development of DNA-PK inhibitors has stagnated over the past few years, with no compound yet having been approved for clinical trials even though pre-clinical testing has yielded promising results^{357, 430-437}. The main obstacle facing at least one class of experimental small molecule DNA-PK inhibitors appears to be related to poor solubility and short metabolic half-lives⁴³⁸.

DNA-PK inhibitors are thought to potentiate chemo/radiotherapy by increasing the longevity of unrepaired DNA as a result of impaired NHEJ and possibly also HRR⁴³⁹ (Figure 13). Interestingly, an alternative approach involving pharmacologically-induced hyper-activation of DNA-PK has been recently demonstrated to chemosensitize tumor cells^{440, 441}. This strategy employs double-strand DNA bait molecules (Dbait) that act as decoys creating a molecular sink that drains the cellular pool of DNA-PK prior to DNA damaging treatment. Considering that hypo- as well as hyper-phosphorylation of DNA-PK increased cellular DNA damage sensitivity, it follows that perturbation of DNA-PK kinase activity through either inhibition or hyper-activation may have the potential to enhance chemosensitivity in tumors⁴⁴².

1.8 Phenthiazines – What are they and what can they do?

Phenthiazines are a class of heterocyclic dopamine receptor antagonists widely used as anti-psychotic medication and as anti-emetics to relieve post-operative or chemotherapy-induced vomiting⁴⁴³⁻⁴⁴⁵ (Figure 14). They are commonly referred to as typical antipsychotics (aka first generation antipsychotics) to distinguish them from atypical antipsychotics (aka second generation antipsychotics), such as clozapine and risperidone, which target the dopamine pathway more specifically and are considered to have superior safety profiles⁴⁴³. Common mild side effects of phenthiazines include dry mouth (anti-cholinergic effect), sedation (anti-histaminergic effect), weight gain (metabolic effect) and skin photosensitivity^{446, 447}. Long-term treatment with phenthiazines are also associated with the development of extra-pyramidal symptoms (EPS), including akathisia/dyskinesia, muscle tremor and Parkinsonism (anti-dopaminergic effect), which are more debilitating and usually require therapeutic intervention⁴⁴⁸. Neuroleptic malignant syndrome (NMS) and agranulocytosis are two rare but potentially fatal conditions that can be induced by phenthiazine antipsychotics^{449, 450}. The spectrum of adverse effects associated with phenthiazine treatment indicate that these compounds are likely to impact on a multitude of physiological processes in addition to their activity in the nervous system.




Figure 14. Chemical structures of some common phenthiazine compounds.

1.8.1 Molecular targets of phenothiazines

Neurotransmitter receptors

One of the most important clinical indications for phenothiazine-based medication is the treatment of psychotic disorders, which is thought to be mediated selectively through dopamine D₂ receptor antagonism⁴⁴³. However, phenothiazines also bind with significant affinity to several other types of neurotransmitter (e.g. acetylcholine, histamine, serotonin) receptors and the moderate anti-emetic activities of many phenothiazines are likely derived from antagonism of serotonin receptors⁴⁵¹. Notably, high expression levels of neurotransmitter receptors are not restricted to neuronal or endocrine cells, but are also found in a variety of human (tumor) cells of non-neuroendocrine origin (Human Protein Atlas, <http://www.hpr.se>). Therefore, phenothiazines can theoretically influence the behavior of many cell types in a highly complex manner. Interestingly, a recent report showed that phenothiazines can inhibit the ability of neural stem cells and primary brain tumor cells to form neurospheres, suggesting that normal as well as malignant stem/progenitor cells may be sensitive to perturbations in neurotransmission pathways⁴⁵².

Ion channels

The effect of phenothiazines on ion channels has mostly been investigated in the context of its possible contribution to cardiotoxicity in patients on antipsychotic medication. Human cardiomyocytes express a number of ion channels of which hERG, a potassium channel, appears to be selectively inhibited by phenothiazines⁴⁵³. Similar results were also observed in HEK293 and Chinese hamster ovary (CHO) cells transfected with hERG cDNA^{453, 454}. Interestingly, hERG channels are expressed in a variety of tumor cells, including lung carcinomas, and hERG inhibitors have been shown to be of therapeutic value in cancer therapy^{455, 456}.

Drug efflux pumps

The ABC transporters belong to a superfamily of transmembrane proteins that utilize ATP hydrolysis to translocate a variety of substances, including solutes, nutrients and xenobiotics, across biological membranes³⁶⁴. Over-expression of certain ABC transporters, such as p-glycoprotein (pgp), is thought to increase therapy resistance in human tumors by facilitating drug efflux⁴⁵⁷. It is therefore anticipated that efflux blockers may enhance chemotherapy and considerable efforts have been devoted to their development. Early studies showed that many calcium channel blockers (e.g. verapamil) and Ca²⁺/CaM antagonists (e.g. phenothiazines) interfere with pgp-mediated transport of vinca alkaloids (e.g. vincristine) and anthracyclines (e.g. doxorubicin)⁴⁵⁸. Mechanistically, phenothiazines appear to directly bind pgp, possibly at the same site(s) as its natural substrates, although an additional indirect effect due to perturbation of plasma membrane fluidity cannot be excluded⁴⁵⁹. TFP has been reported to increase the permeability of the blood-brain barrier (BBB), where pgp is abundantly expressed, to a number of compounds which normally have limited accessibility to the CNS, such as etoposide and ivermectin^{460, 461}. In another study, however, TFP had no effect on the distribution of vinblastine⁴⁶², suggesting that phenothiazines may not universally enhance CNS penetration of all chemotherapeutic agents that are substrates of pgp. Nevertheless, phenothiazines could enhance plasma retention of doxorubicin and etoposide in patients receiving chemotherapy, probably by inhibiting its clearance via pgp-expressing cells in the renal proximal tubules^{463, 464}. Furthermore, phenothiazines

have been shown to reverse drug resistance in MDR tumor cell lines that over-express different ATP-dependent efflux pumps⁴⁵⁹. While these data clearly demonstrate that phenothiazines are capable of antagonizing drug efflux *in vitro* as well as *in vivo*, several early clinical trials failed to prove conclusively that phenothiazines are useful therapeutically as efflux blockers of anti-cancer drugs⁴⁶⁵⁻⁴⁶⁸. Although the focus of research on phenothiazines have since shifted from cancer treatment to management of MDR in bacteria, some new phenothiazine derivatives with promising anti-tumor MDR reversing activities did emerge recently⁴⁶⁹⁻⁴⁷².

Calcium/calmodulin

Calmodulin (CaM) is a ubiquitously expressed protein that acts as a multifunctional calcium sensor and signal transducer. CaM regulates a variety of cellular processes, including proliferation, metabolism, inflammation, and cell death. It is not clear whether CaM antagonism may underline some aspects of neuromodulation by phenothiazines in psychiatric disorders. However, CaM antagonism appears to a major contributor of phenothiazine-induced cytotoxicity and the order of anti-proliferative potency of phenothiazines closely mirrors their CaM antagonistic activity^{473, 474}. Phenothiazines have also been reported to inhibit the functions of some non-CaM-regulated calcium-binding proteins (e.g. protein kinase C, troponin C)^{475, 476}.

1.8.2 Cellular processes that are affected by phenothiazines

Membrane fluidity

The amphiphilic nature of phenothiazines favors molecular interactions with zwitterionic lipids in biological membranes, such as the plasma membrane⁴⁷⁷ (Figure 15). Insertion of phenothiazines into the lipid bilayer enhances the fluidity and permeability of plasma membrane of epithelial cells and causes shape alterations in erythrocytes^{478, 479}. In line with this, phenothiazines appear to affect cholesterol homeostasis by modulating the expression of genes involved in sterol biosynthesis^{480, 481}. As a result, phenothiazines have been reported to induce dissociation of several membrane-bound signaling proteins, including K-Ras and EGFR⁴⁸²⁻⁴⁸⁴. Furthermore, phenothiazine-induced membrane stress appears to inhibit translation initiation in both yeast and human cells^{485, 486}.

Cytoskeletal dynamics and cell motility

Phenothiazines have been reported to disrupt the organization of cellular microfilament network and hepatic metabolites of chlorpromazine could induce gelation of actin^{487, 488}. Moreover, phenothiazines inhibit the interaction between myosin-IIA and S100A4, a member of the S100 family of small calcium-binding proteins implicated in the regulation of cell motility, suggesting that phenothiazines may suppress metastasis⁴⁸⁹. Interestingly, exposure to phenothiazines resulted in rapid apoptotic cell death in chemotherapy-resistant high-grade primary breast cancer cells that over-express another S100 family member, S100P⁴⁹⁰. Phenothiazines are also known to inhibit migration of lymphocytes and glioblastoma cells, possibly due to impairment of myosin/actin dynamics and/or matrix metalloproteinase activation⁴⁹¹⁻⁴⁹³. Finally, phenothiazine treatment enhances the attachment of human non-small cell lung carcinoma (NSCLC) U1810 cells to the plastic substratum of culture dishes, indicating that phenothiazines may also affect cell adhesion (our unpublished data). It is tempting

to speculate that the cytoskeletal effects of phenothiazines are derived from CaM antagonism (Figure 15). However, definitive proof for this assertion is not available at present.




Figure 15. Examples of cellular processes that are modulated by phenothiazines. Processes that may account for phenothiazine-induced cytotoxicity are in highlighted in bold. Other processes have been implicated in phenothiazine-mediated cytoprotection.

Lysosomal function

Phenothiazines are lysosomotropic compounds that contain weakly basic amine groups attached to a core of largely lipophilic tricyclic ring system (Figures 14 and 15). These properties allow uncharged phenothiazines to freely intercalate into biological membranes or cross it. Once inside acidic lumen of lysosomes, the amine groups of phenothiazines become protonated, thus preventing the now positively charged phenothiazines from diffusing out of lysosomes⁴⁹⁴. Accumulation of lysosomotropic compounds within lysosomes may cause a rise in luminal pH and adversely affect the activities of many lysosomal proteins, such as cathepsins and acidic sphingomyelinases. Consistent with this notion, resistance to chronic TFP treatment in *Saccharomyces cerevisiae* has been correlated to over-expression of components of the vacuolar ATPase which might be required to maintain an adequate level of vacuolar acidification^{495, 496}. In mammalian cells, lysosomotropic compounds (e.g. chloroquine) can inhibit autophagy due to elevation of lysosomal pH and failure of autophagosome maturation⁴⁹⁷. Paradoxically, phenothiazines have recently been identified as activators of autophagy, suggesting that partial disruption of lysosomal function may stimulate compensatory autophagy, while more severe lysosomal perturbation can block it^{498, 499}. High intra-luminal concentrations of lysosomotropic compounds may also cause rupture of lysosomal membrane as a result of excessive osmotic pressure, releasing lysosomal proteases that can initiate apoptosis⁵⁰⁰. Finally, lysosomotropic compounds have been shown to affect intracellular distribution of other drugs with similar chemical

properties^{494, 501}. As such, phenothiazines can theoretically reduce the lysosomal sequestration of certain anti-cancer drugs (e.g. daunorubicin), which may lead to increased therapeutic efficacy or exacerbated toxicity.

Cellular respiration and mitochondrial homeostasis

Phenothiazines have been shown to influence the activities of several metabolic enzymes that participate in glycolysis and the Krebs' cycle⁵⁰². Thus, phenothiazines may disrupt mitochondrial energy production, although the concentrations of TFP (66 μ M) needed to significantly inhibit respiration is well above that required for chemosensitization (10 μ M)⁵⁰³⁻⁵⁰⁵. However, the interplay between phenothiazines and mitochondria is very complex (Figure 15). On the one hand, UVA-induced phenothiazine free radicals disrupt mitochondrial functions and cause cell death; on the other hand, phenothiazines have been shown to exhibit antioxidant activities and protect mitochondria from oxidative damage possibly through inhibition of mitochondrial permeability transition (mPT)⁵⁰⁶⁻⁵⁰⁸. Notably, the impact of phenothiazines on mitochondrial homeostasis and bioenergetics appears to be dose-dependent: at non-cytotoxic concentrations (<10 μ M), phenothiazines behave predominantly as antioxidants, while at cytotoxic concentrations (>10 μ M), phenothiazines promote mitochondrial swelling accompanied by dissipation of mitochondrial transmembrane potential, mPT and release of calcium⁵⁰⁹. Moreover, TFP potentiates DNA damage-induced ROS production and mitochondrial dysfunction in human NSCLC cells but antagonizes hydrogen peroxide-induced oxidative stress in rat pheochromocytoma PC12 cells, indicating that the mitochondrial effect of phenothiazines is likely to be context-dependent^{504, 510}. The potential therapeutic benefits of harnessing both pro- and antioxidant properties of phenothiazines have been demonstrated in experimental models of photodynamic therapy and ischemia/oxidative injury, respectively⁵¹¹⁻⁵¹⁴.

Akt signaling

The PI-3K/Akt pathway has important pro-survival/anti-apoptotic functions, and as such is frequently hyper-activated in human tumors. Interestingly, several lines of evidence suggest that phenothiazines may modulate PI-3K/Akt signaling (Figure 15). In ovarian cancer cells, phenothiazines have been shown to block phosphorylation of Akt on both Thr-308 and Ser-473, which are required for full activation of Akt by upstream kinases^{515, 516}. Phenothiazines have been reported to antagonize de-regulated mTOR activity in lung adenocarcinoma and to selectively induce apoptosis in PTEN-deficient tumors by blocking Akt-dependent export of FOXO1a into the cytosol^{517, 518}. Moreover, phenothiazines are able to interfere the chaperone activity of Hsp70, which in turn causes down-regulation of its client protein Akt⁵¹⁹. Taken together, these data indicate that phenothiazines may impact PI-3K/Akt/mTOR signaling on multiple levels.

Cell cycle progression

As CaM antagonists, phenothiazines are expected to negatively modulate G₁/S transition⁵²⁰ (Figure 15). In line with this, TFP induces p21^{Cip1/Waf1} expression via modulation of its transcriptional regulator Egr-1 in C6 and U87MG glioma cells^{521, 522} as well as in U1810 NSCLC cells via a p53-independent mechanism (our unpublished data). Phenothiazines also influence mitosis (Figure 15). For instance, chlorpromazine

(CPZ) has been shown to be anti-mitotic, especially in combination with pentamidine⁵²³⁻⁵²⁵. The mitotic target of phenothiazines appear to be the Eg5 mitotic kinesin and its inhibition results in the formation of monopolar spindles, mitotic arrest and apoptosis^{525, 526}. However, another report showed that inhibition of mitotic slippage by CPZ after paclitaxel treatment resulted in prolonged mitotic arrest and enhanced survival⁵²⁷. These conflicting results suggest that the outcome of phenothiazine-mediated inhibition of mitotic processes may be cell type- and/or context-dependent.

DNA repair

Evidences of phenothiazines as DNA repair modulators are well-documented (Figure 15). At the molecular level, studies comparing the effects of phenothiazines with non-phenothiazine CaM antagonists have implicated CaM antagonism as a likely mechanism. For instance, TFP and the naphthalene sulphonamide CaM antagonists W7 and W13 could inhibit DNA repair in CHO cells following bleomycin treatment while the much less potent W12 and TFP sulfoxide were largely ineffective⁵²⁸. In addition, TFP and the calcium chelator EGTA appear to interfere with the excision of UV-induced pyrimidine dimers by NER in normal human fibroblasts⁵²⁹. Another study found that intracellular calcium regulates a DNA repair signaling pathway in human mononuclear cells involving protein tyrosine kinase(s), CaM and calcineurin⁵³⁰. In response to IR, H2AX forms molecular complexes with CaM and several other calcium-regulated proteins in a dynamic and temporally distinct pattern, suggesting that Ca²⁺/CaM signaling can modulate DNA damage-induced checkpoint and repair^{531, 532}. Interestingly, the expression of CaM is up-regulated by low-dose IR in murine macrophages and forced over-expression of CaM results in enhanced H2AX phosphorylation without any changes in the extent of DNA damage incursion⁵³³. This mechanism may well account for the enhancement of DNA DSB repair fidelity observed after low-dose irradiation which is completely abolished by W7/W13, lending further support for a regulatory role of CaM in DNA repair⁵³⁴. Nevertheless, the assertion that phenothiazines and other CaM antagonists should act in identical manner (i.e. through CaM antagonism) has its own caveats. First, although CaM undoubtedly participates in certain aspects of the DDR, its relevance to cell survival under stress may be context-dependent, especially considering the special differences between human and rodents. Second, phenothiazines seem to target other cellular processes at concentrations where CaM antagonism is observed; therefore the *de facto* contribution of impaired Ca²⁺/CaM signaling with regard to any observed cellular effects must be interpreted with caution⁵³⁵. This is supported by our own data showing that TFP-mediated augmentation of DDR signaling is not faithfully recapitulated by the CaM antagonists W7 or calmidazolium (CMZ), although all three compounds were used at concentrations corresponding to their respective IC₅₀ for CaM antagonism (our unpublished data). Ultimately, the relevance (if any) of CaM antagonism in phenothiazine-mediated DNA repair modulation can only be defined through manipulation of CaM expression, for instance by siRNA.

Chromatin organization and gene expression

There is circumstantial evidence suggesting that chromatin may be a site of action for phenothiazines (Figure 15). First, ultrastructural studies in Ehrlich ascites carcinoma cells by electron microscopy clearly demonstrated their accumulation within the nuclear compartment, where immuno-positivity of phenothiazines was noted to be scattered in the nuclear matrix as well as in close association with electron-dense

chromatin⁵³⁶. Second, a variety of patient-derived cell types (both CNS and non-CNS) exhibited discernible alterations in chromatin structures following pimozide-based therapy, which is thought to act through similar mechanisms as phenothiazines, i.e., dopamine D₂ receptor antagonism⁵³⁷. Third, the D₂ receptor antagonist haloperidol was shown to induce chromatin remodeling in striatal neurons of both mice and rats⁵³⁸. Finally, *in silico* analysis by Connectivity Map (cmap, this thesis) indicated significant similarities in the gene expression signatures of human cancer cells treated with phenothiazines compared to those treated with several HDAC inhibitors (see Paper III). Consistent with the notion that phenothiazines may be *bona fide* chromatin-active compounds, a recent study identified fluphenazine (FPZ) as a candidate agent that could induce normalization of aberrant gene expression found in malignant neuroblastoma leading to loss of tumor cell viability⁵³⁹. Apart from their putative modulatory actions on chromatin, phenothiazines have also been shown to directly bind nucleic acids. The photodynamic DNA damaging potential of phenothiazines is well-established and is due to generation of free radical species, but their effect on nucleic acids in the absence of photo-activating UVA irradiation is less clear⁵⁴⁰. Although the planar tricyclic rings of phenothiazines can intercalate into the DNA double helix, studies on genotoxicity and mutagenicity have yielded conflicting results⁵⁴¹⁻⁵⁴⁴. While phenothiazines have also been found to bind double-stranded RNA of both viral and human origins, it is not yet known whether phenothiazines can interact with miRNA or other types of non-coding RNA^{545, 546}.

1.8.3 Phenothiazines as potential anti-cancer therapeutics

Clinical experience

Although phenothiazines clearly possess anti-proliferative activities, these compounds have not been systematically evaluated as potential anti-cancer therapeutics^{547, 548}. The major clinical use for phenothiazines is treatment of psychosis and management of chemotherapy-induced emesis^{443, 445}. Interestingly, a number of studies on cancer incidence among patients with schizophrenia point to a possible protective effect of phenothiazines^{549, 550}. There is also indirect and anecdotal evidence supporting a beneficial role of phenothiazines in cancer treatment, at least under certain conditions⁵⁵¹⁻⁵⁵³.

Pre-clinical evidences

Mono-therapy

In contrast to the relatively rare experience with patients, a wealth of studies conducted on human cell lines have clearly demonstrated that phenothiazines possess either cytotoxic or cytostatic potential, depending on the cell lines tested and/or the experimental context (Table 3). There is currently a lack of consensus as to why (and how) phenothiazines induce cell death in certain types of cells but not in others; the confusion stems partly from the fact that phenothiazines are clearly “dirty” drugs with a plethora of putative cellular targets (see below). Since mammalian proteins are subject to complex regulations, their availability and mode(s) of interaction with phenothiazines are not likely to be identical under all experimental conditions. Taking these factors into consideration, it is perhaps more informative to define the activities of phenothiazines as a function of any particular cellular context.

Table 3. Cytostatic and/or cytotoxic potential of phenothiazines.

Phenothiazine(s)	Tumor model/cell line	Effect	Reference
CPZ, FPZ, TFP	U1810, MDA-MB-231	cytostatic or cytotoxic	this thesis
CPZ	High-grade breast tumor cells	cytotoxic	490
PCZ	A549, H23, A427, ACC-LC-94, ACC-LC-319, SK-LC7	cytotoxic	518
TFP	A549	cytotoxic	554
TFP	MDA-MB-231	cytotoxic	555
TRDZ	MCF7, ZR75-1B, T47D, MDA-MB-231	cytostatic	556
CPZ, FPZ, PPZ, TFP, TRDZ	SH-SY5Y, C6, primary mouse neurons and glia	cytotoxic	557
CPZ, FPZ, TFP, TRDZ	HTB16, human peripheral blood leukocytes, L929, chick embryos	cytotoxic	558
CPZ, LVPZ, PMZ, TFP, TRDZ	Raji, Daudi, K562, BALL-1, HPB-ALL, MOLT4, CCRF-HSB2, normal lymphocytes	cytotoxic only in cancer cells	559
CPZ, TFP	HL60, HCT-8, MIA-PaCa, L1210, L5178Y	cytostatic only in cycling cells	474
TFP	SCC12B2, normal foreskin keratinocytes	cytostatic or cytotoxic	560
CPZ, TFP	V79	cytotoxic	561
TFP	C3H10T $\frac{1}{2}$	cytotoxic only in cycling cells	562

Abbreviations: CPZ, chlorpromazine; FPZ, fluphenazine; LVPZ, levopromazine; PMZ, promethazine; PPZ, perphenazine; TFP, trifluoperazine; TRDZ, thioridazine.

Combination therapy – chemosensitization versus chemoprotection

There is an abundance of data demonstrating that phenothiazines are endowed with both chemosensitizing and chemoprotective activities (Tables 4, 5). Two general conclusions can be drawn from the available experimental evidence. First, phenothiazines are most active in combination with chemotherapeutic agents that induce DNA DSBs, while the effect of IR is not always potentiated. Second, cytotoxic agents that cause cellular injury without (markedly) damaging DNA, including heavy metals, non-steroidal anti-inflammatory drugs (in overdose) and microbial toxins, are generally antagonized by phenothiazines. With regards to their known targets, it is clear that phenothiazines should be able to affect cell viability both positively and negatively; the outcome depending on the overall result of the multitudes of individual targeted interactions. Yet this apparent dichotomy in activity is puzzling since exposure to either of the above-mentioned class of cytotoxic agents is associated with oxidative stress. One possibility is that phenothiazines can impede DNA repair while independently stabilizing mitochondria. An alternative but not mutually exclusive scenario is that phenothiazines may alter one or more cellular factors that *per se* are well tolerated by the targeted cells, but which becomes lethal only in the presence of DNA damage, a form of drug-induced contextual synthetic lethality.

Table 4. Chemosensitizing potential of phenothiazines in cell lines.

Cell line	Phenothiazines	Chemo	Potential	Reference
A2780, A2780/CP8, A2780/CP30, A2780/CP70, OVCAR-3, OVCAR-4	TFP	cisplatin	yes (2/6 cell lines)	563
Hep-2	TFP	IR, H ₂ O ₂	yes (IR); no (H ₂ O ₂)	564
U1810, H23	TFP	bleomycin, cisplatin	yes	503, 504
SKOV3, A-253, normal human bone marrow cells	CPZ	bleomycin	yes	565
MCF7/TAM ^R -1	CPZ	tamoxifen	yes	566
MCF7, MDA-MB-468	TFP	tamoxifen	yes	567
U87	PPZ	IR, TMZ, imatinib	yes (imatinib); additive (TMZ); antagonistic (IR)	568
H1299	FPZ-N2- chloroethane	TRAIL	yes	569
Sk-ChA-1	TFP	interferon- γ	yes	570
L1210	TFP, CPZ	bleomycin IR	yes (bleo) ; no (IR)	571, 572
P388/ADM, P388/VCR	TFP	doxorubicin vincristine	yes	458
CHO	TFP	bleomycin	yes	528
V79	CPZ	X-ray	yes	573

Abbreviations: 5-FdUrd, 5-fluorodeoxyuridine; ADM, adriamycin; TMZ, temozolomide; VCR, vincristine.

Rationales for combining phenothiazines with DNA damaging agents

Although lacking a precise molecular mechanism, the ability of phenothiazines to modulate DNA repair makes a convincing case for their inclusion in combinatorial chemotherapy along with DNA damaging agents. However, despite generally favorable outcomes in cell-based studies and pre-clinical animal models (Tables 4, 6), several early clinical trials conducted in the 80s and 90s have yielded disappointing results (Table 7), which led to a dramatic loss of confidence in phenothiazines as chemosensitizers. It is important to point out that the initial premise on which these clinical trials were conducted was not therapeutic DNA repair modulation but rather pharmacologic reversal of efflux pump-mediated drug resistance, as phenothiazines have been shown to enhance intracellular accumulation of chemotherapeutic agents that are substrates of *pgp*^{458, 465-468}. Unfortunately, the majority of these clinical trials were single-armed studies enrolling relatively small numbers of patients who have invariably been heavily pre-treated and whose *pgp* expression status are not generally known, thereby precluding the possibility of comparing phenothiazine-containing regimen to conventional regimen. It is perhaps not surprising that phenothiazines failed to significantly improve the outcome of chemotherapy in these patients.

Table 5. Chemoprotective potential of phenothiazines in pre-clinical animal models.

Human/animal/cell line	Chemo	Phenothiazine	Toxicity combo v single	Reference
ddY mice	CDDP	CPZ	decreased acute nephrotoxicity	574
B ₆ D ₂ F ₁ /J mice, Fisher 344 rats	CDDP	PCZ	decreased nephrotoxicity	575
Swiss albino mice	DOX	CPZ	decreased toxicity	576
Syrian hamsters	BLM	TFP	decreased acute inflammation and lymphocytes in BAL fluid	577
Syrian hamsters	DMBA	CPZ	decreased tumor formation	578
SKH-1 mice (hairless)	UV	CPZ	decreased tumor formation	579
Sprague-Dawley rats	NNM	TFP	decreased tumor formation	580
Albino mice	APAP	TFP	decreased toxicity	581
ddY mice	APAP	TFP	decreased hepatic toxicity	582
CF-1 mice	Cd	CPZ, TFP	decreased testicular damage	583
n.a.	<i>V. vulnificus</i> cytolysin	TFP	increased survival	584

Abbreviations: APAP, acetaminophen; BAL, bronchoalveolar lavage; BLM, bleomycin; *C. albicans*, *Candida albicans*; Cd, cadmium; CDDP, cisplatin; *C. neoformans*, *Cryptococcus neoformans*; DMBA, 9,10-dimethyl-1,2-benzanthrene; DOX, doxorubicin; MB, methylene blue; NM, nitrogen mustard; NNM, N-nitrosomorpholine; VBL, vinblastine; *V. vulnificus*, *Vibrio vulnificus*; n.a., not available.

Our understanding on the molecular intricacies of DNA damage signaling and repair has greatly improved since the days when phenothiazines were first suggested as modulators of DNA repair. Conceptual and methodological advances now allow detailed characterization of the various DDR signaling pathways and sub-modules that may be sensitive to perturbation by phenothiazines. This may enable identification of cellular context as well as biomarkers that predict sensitivity to phenothiazines, allowing more rigorous patient selection for future trials. Given that phenothiazines were generally well-tolerated, further investigation into the clinical utility of phenothiazine-based chemosensitizers is clearly warranted.

Table 6. Phenothiazines as chemosensitizers in pre-clinical animal models.

Tumor type	Recipient	Chemo	Pheno-thiazine	Tumor growth/survival combo v single	Reference
B16 melanoma	C57BL6 mice	BLM	CPZ	decreased growth	585
B16a-Pt melanoma	C56BL6 mice	CDDP	TFP	no difference	586
Ehrlich ascites	BALB/c mice	MMC	CPZ	decreased growth	542
P388D ₁ leukemia	CDF ₁ mice	DOX	CPZ	increased growth	587
sarcoma-180 ascites	ddN mice	CTX	PCZ, PMZ	decreased growth	588
L1210 leukemia	BALB/c x DBA mice	BCNU	CPZ, PCZ, TFP, FPZ	increased survival	589
fibrosarcoma	Swiss mice	X-ray	CPZ, PMZ, PPZ, TPZ	decreased growth	590, 591
Fortner's melanoma	Syrian hamsters	X-ray	CPZ, 7-OH CPZ	decreased growth	592

Abbreviations: BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; CTX, cyclophosphamide; MMC, mitomycin C; PCZ, prochlorperazine; PZ, promazine; TPZ, trimeprazine

Table 7. Clinical trials of phenothiazines as chemosensitizers.

Study type	Tumor type	Chemo	Pheno-thiazine	Response single v combo	Reference
phase II	breast cancer	VBL	TFP	7% vs 6%	466
phase II	breast cancer	DOX	TFP	45%	465
phase II	renal cell carcinoma	DV	TFP	0%	467
phase II	pancreatic cancer	EPI	TFP	13%	468
phase I/II	various	DOX	TFP	19%	593
phase I	various	DOX	PCZ	27%	464
phase II	glioma	BLM	TFP	0%	594
phase I	various	BLM	TFP	23%	595
phase II	malignant melanoma	BDV	CPZ	22%	596
phase II	malignant melanoma	MeCCNU	CPZ ^a	11% vs 12%	597
phase I	various	CV	PCZ ^b	0%	463
phase II	squamous cell carcinoma of the H&N	IR	CPZ ^c	31% vs 59%	598
retrospective	various	5-FU	various	no difference	599

Abbreviations. 5-FU, 5-fluorouracil; BDV, BCNU+decarbazine+vincristine; CV, carboplatin+VP16; CsA, cyclosporine A; DP, dipyridamole; DV, doxorubicin+vinblastine; EPI, epirubicin; H&N, head and neck; MeCCNU, 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea; MMC, mitomycin C; MTD, maximum tolerated dose; RT, radiotherapy
^a CPZ + caffeine; ^b PCZ + dipyridamole + cyclosporine A; ^c CPZ + bleomycin + mitomycin C + nicotinamide + dicoumarol

2 AIMS

The overall aim of this thesis was to evaluate the feasibility of using phenothiazines to enhance the sensitivity of human tumor cells to DNA damaging chemotherapeutic agents. The specific aims of each project were:

- ❖ To determine whether TFP suppresses DNA repair in general and DNA DSB repair in particular in bleomycin-treated NSCLC cells (**Paper I**).
- ❖ To elucidate the downstream apoptotic pathways that account for phenothiazine-mediated chemosensitization in relation to the DNA damage response in NSCLC cells (**Paper II**).
- ❖ To investigate in detail the impact of phenothiazines on DNA damage-induced chromatin-proximal signaling events and its potential importance to chemosensitization in tumor versus normal cells (**Paper III**).
- ❖ To uncover putative molecular determinants that predict responsiveness to phenothiazine-mediated chemosensitization which can be tested experimentally (**Paper III**).
- ❖ To characterize the transcriptional response of platinum-refractory NSCLC cells and to identify putative mechanisms of drug resistance as well as cellular processes that are targeted by TFP to impart chemosensitivity (**Paper IV**).

3 MATERIALS AND METHODS

As illustrated in Figure 16, a variety of molecular biological techniques were used in the current thesis work. This section provides basic information on the assays and the rationale for which they were chosen.




Figure 16. An overview of the experimental setup.

3.1 Cell lines

The human NSCLC cell line U1810 was used as the primary cell model system to study the effects of phenothiazines on chemo- and radiosensitivity⁶⁰⁰. U1810 cells, which do not express functional p53, were reported to be highly resistant to apoptosis induction by IR and cisplatin³⁸⁹. Where indicated, experimental data obtained for U1810 cells were verified in additional cell lines, including A549, H125, H23 (NSCLC), MDA-MB-231, MCF-7, T47D, BT474 (breast cancer), A2780, SKOV3 (ovarian cancer), WI-38 human normal lung fibroblasts, hTERT-RPE1 immortalized human retinal epithelial cells (non-cancerous). Of these, A549, MCF7, A2780, WI-38 and hTERT-RPE1 express wild-type p53 while the remaining cell lines all harbor p53 mutations.

3.2 DNA damaging agents

Bleomycin, an antibiotic compound isolated from *Streptomyces verticillus*⁶⁰¹, was used as a model substance to directly induce DNA DSBs. Where indicated, calicheamicin (an enediyne antibiotic derived from *Micromonospora echinospora*) and IR (Co⁶⁰ source) were used as additional direct-acting DNA DSB inducers. The relative

efficiency of with which these three agents generate DNA DSBs are not identical, with calicheamicin being the most proficient and IR being the least proficient^{602, 603}. Moreover, the chemical and structural complexities of the resultant DNA DSBs also differ, with IR and bleomycin causing more complex DNA DSBs than calicheamicin⁶⁰⁴⁻⁶⁰⁷. Thus, the cellular responses to IR, bleomycin and calicheamicin are not expected to be identical. In addition, cisplatin was used because ICLs generated by platinum compounds can be converted into DNA DSBs during DNA replication and/or ICL repair^{608, 609}. As a comparison, several indirect-acting DNA damaging agents (gemcitabine, etoposide, aphidicolin) as well as a non-DNA damaging agent (staurosporine) were also tested.

3.3 Assessment of cytotoxicity

3.3.1 Short-term assay

3.3.1.1 MTT assay

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is a cell-permeable compound that is reduced by mitochondrial metabolic enzymes into a purple colored formazan precipitate. The formazan crystals can be solubilized in SDS/HCl-containing buffer and conveniently quantified by any spectrophotometer equipped with a 595 nm filter. In **Paper III**, the MTT assay was used to determine whether cell viability after DNA damaging treatment. A drawback for this assay is that it cannot easily distinguish terminally (or even transiently) arrested cells from actively cycling cells. This may explain why phenothiazine appeared to be weaker chemosensitizers in the MTT assay than in the long-term colony formation assay.

3.3.1.2 Propidium iodide exclusion

The plasma membrane of healthy mammalian cells has very limited permeability for propidium iodide (PI). Damage to the plasma membrane, which may be caused by mechanical force, disruption of membrane lipid organization (fluidization) or cell death, will typically lead to increases in the permeability of PI that can be conveniently detected by flow cytometry. This technique was used in **Paper II** as an alternative to the MTT assay to study DNA damage-induced cell death in the short-term. A major drawback for PI exclusion assay is that it cannot readily distinguish late stage apoptosis from necrosis because both are associated with loss of membrane integrity. Therefore, PI exclusion is useful for measuring cell viability but should not be used to study cell death modes.

3.3.2 Long-term assay

The colony formation assay provides a measure of the ability of single cells to produce colonies over time, typically 1-2 weeks⁶¹⁰. A colony is defined as an aggregate of at least 50 cells that are all progenies of the original single cell. It is the method of choice for assessing the long-term cytotoxic effects of a given drug treatment. This is because cells can die with very different kinetics (hours versus days) and by multiple modes (e.g. apoptosis, necrosis, mitotic catastrophe)^{221, 611}. Cells may also become senescent and lose clonogenic potential without actually dying³⁰³. To obtain accurate results, it is imperative that single cells are plated homogeneously over the entire surface area of the culture dish. If necessary, culture dishes can be coated with biomolecules (e.g.

fibronectin) to enhance the attachment of adherent cells. Anchorage-independent growth can be achieved by suspending non-adherent cells in soft agar. The colony formation assay can be performed in two ways. In one, cells are plated first as single cells, allowed to attach (usually overnight) and then exposed to the indicated drug(s) for a pre-determined amount of time. Thereafter, the drug is removed by washing cells gently but thoroughly with sterile PBS and fresh culture medium is added. In the other, cells are grown as monolayer at the desired confluency and exposed to the drug(s) for a pre-determined amount of time. Immediately after drug treatment, cells are harvested, washed and then plated as single cells for colony formation. Both of these approaches have their pros and cons. The first one necessitates the use of drug(s) at low doses due to the small number of sparsely seeded cells but allows the drug(s) to be rapidly removed making it particularly suitable for studying the effects of pulse treatment. Therefore, this approach was adopted throughout the current thesis work (**Papers I-IV**). Conversely, the second approach permits the use of drug(s) at much higher doses but as plating cells after treatment takes some time to perform, it is more suited for assessing the effects of prolonged drug treatment. At the end of the experiment, colonies are fixed and stained with crystal violet for visualization.

3.4 Analysis of DNA damage induction AND DNA repair

3.4.1 Electrophoresis-based assays

Single cell gel electrophoresis (aka comet assay) and pulsed-field gel electrophoresis (PFGE) are two commonly used methods for detecting the physical presence of DNA strand breaks^{612, 613}. They are based on similar principles and both measure the extent of migration of unwound DNA when it is subjected to an electric field, with fragmented DNA migrating further than intact DNA. For comet assay, the pH of lysis (and electrophoresis) buffer determines the type of DNA damage that can be unmasked; neutral pH allows detection of only DNA DSBs while alkaline pH enables detection of DNA SSBs as well as DSBs. In **Paper I**, the alkaline comet assay was used to study the general effect of TFP on DNA strand break repair and PFGE was then conducted to specifically address its impact on DNA DSB repair. One major difference between comet assay and PFGE is the directionality of the electric field during electrophoresis, being constant and uni-directional in comet assay whereas in PFGE the voltage is periodically switched among three directions (along the central axis as well as at 120 degree angles on either side). Another significant difference is that the former is used to quantify DNA damage at the level of individual cells whereas the latter measures DNA damage in a population of cells.

While comet assay and PFGE are suitable for the assessment of DNA repair in intact cells, plasmid-based assays are useful for studying DNA repair *in vitro*. To this end, the plasmid is first digested with a restriction endonuclease to produce dsDNA ends of the desired configuration. In **Paper I**, the plasmid pBR322 was used as a DNA substrate for *Pst*I and *Pvu*II, which generate 3'-staggering and blunt ends, respectively. The linearized plasmid substrate was then purified and added to a reaction mixture optimized for *in vitro* end joining, which contains nuclear extract, nucleotides (dNTPs) and ATP. After the completion of reaction, proteins were digested with proteinase K and the recovered plasmid is separate by standard agarose gel electrophoresis. The material on the gel was transferred onto a nitrocellulose membrane, hybridized to a radio-labeled complementary DNA probe and then visualized using autoradiography.

Alternatively, visualization of rejoined and non-rejoined plasmid can be achieved by direct staining of the gel with a DNA dye (e.g. ethidium bromide, SYBR Green).

3.4.2 Antibody-based assays

Phosphorylation of histone H2AX on serine-139 (called γ H2AX) is one of the earliest molecular events that take place in response to the induction of DNA DSBs⁶¹⁴. The PI-3K-related protein kinases (PIKKs) DNA-PK, ATM and ATR are all capable of phosphorylating H2AX⁶¹⁵⁻⁶¹⁹; their relative contribution to γ H2AX formation depends on complex and not yet fully defined parameters such as the cell cycle stage, the type of DNA DSB (direct versus enzymatically processed repair intermediates) and the relative expression levels of individual PIKKs. In general, DNA-PK, ATM and ATR can functionally compensate for each other with regard to H2AX phosphorylation^{617, 619, 620}. Therefore, specific inhibitors of each of these PIKKs need to be included in the assay to query which of the PIKKs are primarily responsible for DSB-induced H2AX phosphorylation in a given cell line. The extent of H2AX phosphorylation is thought to provide a good estimate of the cellular level of unrepaired DNA DSBs⁶²¹. Consequently, detection of γ H2AX with phospho-specific antibodies (immunoblotting, immunofluorescence and flow cytometry) was carried out in **Papers II and III** to study the formation and resolution of DNA DSBs in tumor cells. On a cautionary note, however, it should be pointed out that formation of γ H2AX can also be triggered by non-DSB type aberrant DNA structures and during mitosis independent of DNA damage⁶²²⁻⁶²⁴. Furthermore, apoptotic DNA fragmentation results in high levels of γ H2AX in a manner that's dependent on c-Jun N-terminal kinase (JNK) or DNA-PK^{625, 626}. To distinguish exogenous drug-elicited DSBs from apoptosis-associated DSBs, dosage of DSB-inducing agents must be carefully titrated to ensure that apoptosis is not triggered within the duration of the experiment.

DNA-PK is an important regulator of NHEJ in mammalian cells. Activation of DNA-PK is associated with multiple autophosphorylation events⁶²⁷. In **Paper III**, activation of DNA-PK kinase activity in intact cells was indirectly determined by its autophosphorylation status at serine-2056 using phospho-specific antibodies.

ATM is a key regulator of DDR by promoting DNA DSB repair, chromatin remodeling and pro-survival signaling^{11, 628}. Activation of ATM is accompanied by its autophosphorylation on serine-1981³⁰, which was conveniently detected by immunoblotting using phospho-specific antibodies in **Paper III**. Similar procedures was used to determine the phosphorylation status of ATM substrates such as H2AX (serine-139), KAP-1 (serine-824), SMC1 (serine-966), NBS1 (serine-343) and Chk2 (threonine-68)^{54, 57, 58, 616, 629-632}.

3.4.3 *In vitro* kinase assays

The central importance of DNA-PK kinase activity for NHEJ has prompted the development of techniques that enable quantification of DNA-PK kinase activity *in vitro*¹⁵³. As outlined in **Paper III**, the kinase activity of purified and endogenous DNA-PK were directly monitored by the SignaTECT[®] DNA-PK kinase assay, which measures the incorporation of radio-labeled phosphate into an optimized substrate peptide in the presence of activating calf thymus DNA (Molecular Probes). These results were later verified using a complementary assay whereby DNA-PK kinase activity was determined indirectly with the EasyLite[®] luminescence ATP detection

system, which measures the amount of ATP remaining after DNA-dependent kinase activation (i.e. ATP consumption) (PerkinElmer).

3.5 Assessment of chromatin accessibility

The tight packing of chromatin potentially limits interaction between DNA and non-chromatin DNA-binding proteins. The timely operation of various chromosome transactions depends on local as well as global modulation of the chromatin structure leading to increased or decreased access for certain regulatory factors. In **Paper III**, acridine orange (AO) was used as a probe to monitor chromatin accessibility. AO is a cell-permeable fluorescent cationic dye that binds DNA as well as RNA and also accumulates in acidic organelles such as endosomes and lysosomes. To ensure that only DNA-associated AO fluorescence is measured, we conducted the assays on RNase A-treated cell nuclei^{633, 634}. In this manner, changes in chromatin accessibility would be reflected by changes in AO retention, which can be readily quantified by flow cytometry.

3.6 Analysis of cell cycle progression

Two general techniques can be used to monitor cell cycle progression. In one, single cells in suspension are sequentially fixed with cold 70% ethanol (overnight), washed free of ethanol, permeabilized and then labeled with DNA-binding dye (e.g. PI)⁶³⁵. Since PI stains both DNA and RNA, it is important to remove RNA prior to or during the labeling process by an RNase, typically RNase A. As long as the concentration of PI is not limiting, its accumulation within cells is proportional to the DNA content, thereby allowing the different cell cycle phases to be distinguished. PI staining was used in **Papers II** and **IV** to analyze cell cycle distribution after DNA damage. However, PI staining does not provide a measure on how fast or slow a population (or sub-population) of cells undergo division. To obtain such information, cells need to be loaded with a tracking dye such as carboxyfluorescein diacetate succinimidyl ester (CFDA-SE)⁶³⁶. CFDA-SE is non-fluorescent and highly cell-permeable. Following its uptake, proteolytic processing by cellular esterases generates a cleaved form called carboxyfluorescein succinimidyl ester (CFSE) which is fluorescent but much less cell-permeable. CFSE is stably retained within cells by forming covalent linkages to intracellular biomolecules. Each time a pre-labeled cell divides, its associated CFSE fluorescence is halved. Therefore, CFSE labeling was used in **Paper II** to assess cell division/mitotic activity after DNA damage. This gives an indication on the reversibility of checkpoint arrest.

3.7 Assessment of apoptosis and mitotic fidelity

Apoptosis and mitosis are both associated with distinct changes in the appearance of chromatin. These morphological changes in the appearance of chromatin can be conveniently traced by a DNA-binding dye, such as 4',6-diamidino-2-phenylindole (DAPI), PI and Hoechst 33342. In particular, condensation of chromatin during both apoptosis and mitosis leads to the accumulation of large amounts of dye molecules in a relatively small space, causing the chromatin to fluoresce intensely bright. This increase in fluorescence signal along with the distinct morphology of the chromatin is very useful for the identification of apoptotic and mitotic cells using a fluorescent microscope.

During early apoptosis, the chromatin becomes markedly condensed and moves towards the periphery of the nucleus (marginalization). This is followed by large scale DNA fragmentation via caspase-dependent and caspase-independent mechanisms^{268, 637}. The cytoplasm and nucleus may subsequently fragment into small membrane-enclosed vesicles containing remnants of cellular components and highly condensed DNA. These vesicles, called apoptotic bodies, are normally rapidly cleared by professional phagocytes *in vivo*. For the purposes of quantifying apoptosis in **Paper II**, cells whose chromatin exhibited clear-cut signs of fragmentation as well as cells which have fragmented into apoptotic bodies were tallied. Cells with marginalized chromatin were not counted as apoptotic.

From late prophase through to metaphase, sister chromatids become attached to mitotic spindles and align themselves at the metaphase plate. During anaphase and telophase, the sister chromatids are pulled towards the opposite poles of the spindle and segregate into two daughter cells. If a chromatid fails to properly attach to the mitotic spindle at its centromere, it might lag behind during anaphase due to a lack of pulling force. A lagging chromosome is most often excluded from the reformed nucleus of either daughter cells and becomes instead enclosed in a small cytoplasmic vesicle called a micronucleus^{638, 639}. Similarly, a chromosome that has two centromeres attached to microtubules emanating from opposite spindle poles or sister chromatids that are fused at their ends usually fail to completely segregate during anaphase, forming “string-like” connections (anaphase bridges) between the two separated daughter cells⁶⁴⁰. For the purpose of assessing mitotic fidelity in **Paper II**, abnormal mitosis was defined as mitotic events that are associated with highly irregular metaphase (mitotic catastrophe), lagging chromosomes or anaphase bridges. Interphase cells containing one or more micronuclei were also counted as abnormal mitosis.

3.8 Analysis of pro-apoptotic signaling

3.8.1 Oxidative stress

Intracellular ROS damages cellular components and macromolecules and its increased production leads to a condition called oxidative stress. In **Paper II**, 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H₂DCFDA) was used to gauge ROS production in live cells. CM-H₂DCFDA diffuses passively into cells, where its acetate groups are cleaved by intracellular esterases and becomes trapped. Subsequent oxidation generates a green fluorescent product that was readily detected by flow cytometry.

3.8.2 Caspase activation and caspase activity

Flow cytometry-based assays

Enzymatic activation of caspases, which is usually required for apoptosis, can be detected by several techniques. There are at least two flow cytometry-based methods using different probes. In one, the probe, known as fluorescent labeled inhibitor of caspases (FLICA), is comprised of a fluorochrome (e.g. FAM) conjugated to a high affinity peptide substrate sequence that is linked to a fluoromethyl ketone (FMK) moiety. Binding of the peptide substrate to the active site of an activated caspase causes an irreversible covalent coupling of FMK to the active site cysteine residue, thereby labeling it with fluorescence. In the other, the probe is an antibody that specifically

recognizes the active form of a caspase. This antibody can be conjugated to a fluorochrome (e.g. PE, FITC) to facilitate direct detection of activated caspases in fixed cells. Both FLICA and active caspase-specific antibodies were used in the current thesis (**Papers II and III**).

Immunoblotting

Full activation of pro-caspases requires proteolytic cleavage. In turn, active caspases cleave a variety of substrates including PARP²⁴⁷. In **Paper II**, these apoptosis-associated events were detected by immunoblotting with commercially available antibodies. Some of these antibodies recognize specifically the cleavage products (caspase-9) while others recognize the non-cleaved as well as the cleaved forms of proteins (caspase-8, PARP).

3.8.3 Organelle dysfunction

Vacuolation

Cytoplasmic vacuolation is a frequently observed phenomenon in cells in response to a variety of stressful stimuli, such as pathogens, toxins and drugs⁶⁴¹. It is generally believed that vacuolation represents an adaptive response that cells mount to limit damage incursion. However, uncontrolled and irreversible vacuolation can cause cell death. In **Paper II**, two methods for measuring vacuolation in live cells were used. The first is direct detection by light microscopy, where vacuoles appear as discrete small membrane-enclosed translucent vesicles. The second approach is indirect detection by flow cytometry. Collision of the incident laser light with granular structures (e.g. vacuoles) within a cell causes it to deflect sideways at wide angles (side scatter) instead of passing straight through or deflect forward at low angles (forward scatter). Therefore, the extent of side scattering of a cell is roughly proportional to its granularity.

Mitochondrial dysfunction

Loss of mitochondrial function is an important step in apoptosis execution²⁴⁹. In healthy cells, mitochondria maintain a negative electric potential across its inner membrane, which is mediated by extrusion of protons from the electron transport chain into the intermembrane space. This electrochemical gradient generates a proton motive force (PMF) that is used by the mitochondrial F_0F_1 ATP synthase to drive ATP synthesis. In response to pro-apoptotic stimuli, the mitochondrial transmembrane potential ($\Delta\Psi_m$) may increase initially as a result of an uncoupling of electron transport from ATP synthesis. If the harmful stimulus cannot be removed, persistent pro-apoptotic signaling eventually leads to the activation of Bak and Bax which triggers MOMP⁶⁴². In turn, MOMP releases a number of apoptogenic factors (e.g. cytochrome c, Smac/Diablo) from the intermembrane space into the cytosol where they promote the activation of caspases^{249, 263}. MOMP can also cause dissipation of $\Delta\Psi_m$ (depolarization) especially in conjunction with active caspases, which can cleave components of the electron transport chain^{642, 643}. In **Paper II**, tetramethylrhodamine ethyl ester (TMRE) was used to gauge $\Delta\Psi_m$ in live cells. TMRE is a cell-permeable cationic fluorescent dye whose extent of accumulation in mitochondria is determined by $\Delta\Psi_m$. Therefore, mitochondrial hyper-polarization and depolarization will cause increased and decreased accumulation of TMRE, respectively. In addition, the

activation of Bak/Bax was assessed in fixed cells using conformation-sensitive antibodies that specifically recognize the active forms of Bak/Bax. For this purpose it is important to use a non-denaturing permeabilizing agent (e.g. digitonin) because some common detergents (e.g. Triton X-100) themselves can elicit conformational changes in Bak/Bax. Both of these events were recorded by flow cytometry.

Lysosomal dysfunction

Lysosomes are the primary organelles involved in the degradation of cellular waste material. The acidic intraluminal pH of lysosomes is maintained by the proton extruding activity of vacuolar ATPases. This is essential for lysosome functions because most of its complement of proteolytic enzymes attain optimal activities at low pH⁶⁴⁴. Compounds that are weak bases tend to accumulate in acidic organelles (lysosomotropism) where they become protonated^{494, 501}. This frequently leads to a decrease in their membrane permeability due to the acquisition of an extra positive charge, which causes such compounds to be retained within the lumen⁴⁹⁴. In **Paper II**, two fluorescent lysosomotropic probes, acridine orange (AO) and LysoTracker Green, were used to study lysosomal function⁶⁴⁵. AO and LysoTracker Green accumulate in lysosomes as well as other acidic organelles such as late endosomes. Their fluorescence correlates with the pH as well as the size of the cellular acidic compartment. Staining with AO and LysoTracker Green was analyzed by flow cytometry and immunofluorescence microscopy, respectively.

3.9 Assessment of gene expression

3.9.1 DNA microarray

DNA microarray is a convenient method for simultaneous measurement of cellular gene expression. A gene chip typically contains >10,000 immobilized probes each of which can recognize a complementary region unique to a transcribed RNA molecule. In **Paper IV**, the Affymetrix® whole transcript GeneChip® Human Gene 1.0 ST Arrays platform, which contains probes for 28,869 genes, was used. RNA was harvested from cells following different treatments, i.e. mock (DMSO), TFP alone, cisplatin alone and cisplatin+TFP. The RNA was reverse transcribed into cDNA and labeled with a fluorescent dye. The labeled cDNA samples were then added to the gene chips allowing complementary sequences to hybridize to the probes. Finally, the gene chips were scanned. The fluorescence signals for each probe was corrected for background and normalized with the median intensity across all chips.

3.9.2 Real time quantitative PCR

Real time quantitative polymerase chain reaction (RT-qPCR) is a technique that allows simultaneous amplification and quantification of a cDNA molecule. The procedure is similar to conventional reverse transcriptase PCR except that the amplified DNA is detected in real time as the reaction progresses. RT-qPCR can be conveniently used to measure mRNA levels in cells or tissues. To this end, mRNA is reverse transcribed into cDNA and then amplified in the presence of primers specific for the gene of interest, a DNA-dependent DNA polymerase (usually Taq polymerase), dNTPs and a fluorescent DNA-binding reporter dye (e.g. SYBR Green) in a PCR reaction mixture. Subsequent thermal cycling is similar to conventional PCR. Comparative expression of the gene of

interest in relation to a reference housekeeping gene (e.g. GAPDH, TBP, 18S) can be calculated with the $2^{-\Delta\Delta C_t}$ method. In **Paper IV**, RT-qPCR was used to measure the mRNA expression levels of selected DNA repair genes in residual clones that survived different treatments (i.e. mock, TFP alone, cisplatin alone, cisplatin+TFP). GAPDH was chosen as the reference gene to correct for unequal loading.

3.9.3 Data mining and bioinformatics analysis

Connectivity map

The Connectivity Map (cmap) is a bioinformatics database developed by the Broad institute that collects microarray data generated from human cell lines treated with a vast array of small molecule compounds (perturbagens)⁴⁸⁰. An instance is defined as the unique gene expression signature induced by a given perturbagen at a particular occasion. Because microarray data for certain perturbagens have been deposited more than once, there are currently 6100 instances corresponding to approximately 1000 perturbagens in the cmap database (Build 01). The fundamental concept behind cmap is that perturbagens with similar mechanism(s) of action have a higher probability of eliciting similar gene expression signatures than perturbagens whose mechanisms of action are dissimilar. The utility of cmap for uncovering mechanism(s) of action of novel anti-cancer drugs and in the rational design of drugs that target signaling pathways specifically de-regulated in tumors have been clearly demonstrated by a number of recent publications^{516, 518, 646-648}. Specifically, cmap allows users to compare the gene expression signature induced by a perturbagen of interest (query) to all other instances^{480, 649}. The degree of gene expression concordance between the query and any given instance is provided by the up/down score. The up score shows the extent of similarity in terms of absolute enrichment and directionality of change for the up-regulated genes between the query and the instance, while the down score does the same with down-regulated genes. A connectivity score is also provided for each instance. This score, which is between 1 and -1, is used to rank all instances with regard to their relative similarities to the query. It is also possible to compute a mean connectivity score and a permutation p-value for all instances corresponding to same perturbagen. This enables the comparison between the query and perturbagen taking into considerations possible confounding factors such as batch, cell line or lab. In **Papers III** and **IV**, cmap was used as a hypothesis generating tool to identify putative cellular targets of phenothiazines.

3.9.4 Hierarchical clustering and principal component analysis

The goal of a cluster analysis is to assign a set of objects or observations into groups such that objects/observations within a cluster are more similar to each other than those in other clusters. Hierarchical clustering is a form of cluster analysis which seeks to order clusters in a hierarchy. In **Paper IV**, hierarchical clustering was performed on the complete Affymetix gene expression datasets encompassing all four treatment conditions, i.e. mock (DMSO), TFP alone, cisplatin alone and cisplatin+TFP. This analysis enabled the comparison of gene expression as a function of treatment.

A large set of observations may be composed of multiple variables, some of which are likely to be redundant because they are correlated with one another. Principal component analysis (PCA) is a mathematical procedure that can be used to remove such redundancy by transforming the original set of variables into a new set of artificial

variables called principal components. By definition, the first component has the largest possible variance and accounts for most of the variance in the original variables. Although the number of principal components is always less than or equal to the number of original variables, in practice, two or three principal components are usually calculated. This is because of two reasons. One, a maximum of three dimensions can be depicted graphically. Two, the first three principal components usually account for the majority of the observed variance. In **Paper IV**, PCA analysis was performed (in three dimensions) on the complete Affymetrix gene expression datasets encompassing all four treatment conditions, i.e. mock (DMSO), TFP alone, cisplatin alone and cisplatin+TFP. This analysis permitted the visualization of gene expression similarities as a function of treatment.

3.9.5 Ingenuity pathway analysis

The Ingenuity pathway analysis (IPA) software (www.ingenuity.com) is a systems biology tool that can be used to analyze and model complex biological data (e.g. gene expression). IPA uses the Ingenuity Knowledge Base, which contains a vast amount of manually curated annotations on biological, chemical and functional relationships between genes, proteins, cells, tissues, drugs and diseases. The IPA core analysis can be conveniently used to identify which signaling pathways, molecular networks and biological processes are most significantly altered in a dataset, usually a list of up- and down-regulated genes. It can also be used to build custom networks from hubs specified by the user. IPA provides probable biological contexts for the observed changes in gene expression and predicts their possible downstream effects. This information is useful for generating testable hypothesis as well as for experimental design. In **Paper III**, publicly available gene expression data was used to perform *in silico* IPA analysis. In **Paper IV**, expression data generated from the aforementioned microarray experiments were uploaded into IPA. These analyses enabled the identification of candidate cellular and biological processes that are preferentially modulated by phenothiazines (*in silico*, **Paper III**), cisplatin alone (**Paper IV**) or cisplatin+TFP (**Paper IV**), respectively.

3.9.6 Gene ontology terms

The Gene Ontology (GO) project is a collaborative effort aimed at standardizing the nomenclature and description of gene products (i.e. annotations). GO terms are used to systematically organize all available information on gene products into a multi-tier matrix comprising of three main categories (biological processes, cellular components, molecular functions) and numerous progressively narrower sub-categories. In **Paper IV**, the GeneTrail software was used to identify sub-categories of biological processes showing enrichment of genes that were found to be differentially expressed by microarray analysis. This facilitated the identification of candidate biological processes that are preferentially targeted by cisplatin alone or cisplatin+TFP.

3.9.7 Gene set enrichment analysis

A DNA microarray experiment typically identifies a large number of differentially regulated genes. Frequently, a few genes showing the greatest magnitude of expression changes are selected as candidates for further analysis. However, this approach does not take into consideration potential interactions between sets of genes within a given signaling pathway. Moreover, as alterations in cellular processes often affect sets of

genes acting in concert, it is usually more informative to analyze the behavior of gene sets rather than single genes. Gene set enrichment analysis (GSEA) is a statistical method that can be used to evaluate gene expression data at the level of gene sets⁶⁵⁰. The gene sets themselves are defined based on *a priori* knowledge, e.g. database annotations, and usually corresponds to cellular processes. The goal of GSEA is to determine whether members of a given gene set show a high degree of concordance in terms of expression changes. If the answer is yes, then that particular gene set, and by extension the cellular process it regulates, is considered to be enriched. In **Paper IV**, the GeneTrail software was used to perform GSEA on genes that were found to be differentially expressed in the microarray analysis. This allowed the identification of cellular processes that are putatively regulated by cisplatin alone or cisplatin+TFP.

4 RESULTS AND DISCUSSION

4.1 Paper I

The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death

The primary aim of this study was to determine the impact of TFP on DNA repair in general and DSB repair in particular. A previous study by Chafouleas et al showed that both TFP and the naphthalene sulfonamide CaM antagonist W13 significantly suppressed the ability of CHO cells to recover from bleomycin-induced potentially lethal damage⁵²⁸. They found that bleomycin-induced DNA damage caused relaxation of supercoiled DNA in nucleoids prepared from CHO cells which reduced its migration during sucrose gradient centrifugation as a result of decreased buoyant density. Subsequent incubation of cells in drug-free culture medium allowed DNA repair and restored DNA supercoiling, but this effect was largely abolished in the presence of W13, suggesting that CaM antagonists might inhibit DNA repair. However, this study did not assess the effect of TFP on restoration of repair-associated DNA supercoiling. Therefore, we decided to investigate the impact of TFP on DNA repair by directly measuring DNA strand break induction and resolution.

We used a colony formation assay to verify that TFP could indeed impart bleomycin sensitivity in the human NSCLC cell line U1810. In this case, a non-toxic concentration of TFP (10 μ M) was given concurrently with bleomycin as a one hour pulse treatment. Since TFP was not present during recovery, the results indicated that rapid inhibition of DNA repair by TFP during the one hour when cells were exposed to bleomycin might be enough to markedly suppress clonogenic potential. Consistent with this notion, alkaline comet assay showed that bleomycin-treated U1810 cells accumulated significantly higher levels of DNA strand breaks in the presence of TFP. Notably, when TFP was present also during recovery, differences in the level of DNA strand breaks became even more pronounced. Since the cytotoxicity of bleomycin is thought to be mostly dependent on its ability to generate DNA DSBs, we then employed PFGE to specifically address the effect of TFP on DSB repair. In line with our alkaline comet assay data, we found that TFP significantly impeded the repair of DNA DSBs. Unlike DNA SSBs, however, TFP did not affect the initial level of DNA DSBs immediately after bleomycin. These data suggest that TFP might interfere with SSB as well as DSB repair. The difference in the initial levels of DNA SSB and DSB could be explained by the fact that SSB repair likely proceed with faster kinetics than DSB repair because the latter may require enzymatic end processing before ligation can occur^{604, 607}. Consequently, TFP preferentially inhibited SSB repair at early time points while its effects on DSB repair only became apparent at later time points. Significantly, TFP-mediated inhibition of DSB repair was observed long after TFP itself was removed from the culture medium. These data suggest two non-mutually exclusive possibilities. One, intracellular TFP might be able to remain active in cells following its uptake for prolonged periods of time, or two, TFP might perturb an early response to DNA damage that is not easily reversed. In the latter case, one can envision a scenario whereby TFP might bind DNA and alter the chromatin response to DNA damage. Regardless, the inhibitory effect TFP exerted on DNA DSB rejoining indicated a possible block in NHEJ since mammalian cells deficient in Ku-dependent NHEJ are known to be hypersensitive to bleomycin⁶⁵¹⁻⁶⁵³. In line with this, TFP (100 μ M)

significantly reduced the ability of crude U1810 nuclear extract to support end-to-end joining of restriction endonuclease-linearized plasmids *in vitro*. Importantly, TFP did not affect plasmid cleavage by bleomycin, suggesting that its effect on the accumulation of DNA strand breaks was a result of repair inhibition and not enhanced DNA damage induction. Collectively, our data clearly demonstrated that TFP could inhibit DNA strand break repair and provided a plausible mechanism to account for its chemosensitizing activity.

4.2 Paper II

Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γ H2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation

The primary aim of this paper was to determine the consequences of TFP-mediated DNA repair modulation on cell fate after DNA damaging treatment. We conducted our studies on two human NSCLC cell lines, the chemo-/radioresistant U1810 and the inherently more chemo-/radiosensitive H23. This enabled us to explore whether TFP may differentially affect tumor cells based on their relative chemo-/radiosensitivities. Although bleomycin was used the primary DNA DSB inducing agent, we also tested TFP in combination with cisplatin, a drug commonly used in the clinical regimen for NSCLC. Moreover, we extended our work on TFP by analyzing whether its chemosensitizing potential might be shared with other structurally related phenothiazine compounds (e.g. FPZ, triflupromazine, TFPZ). The scheduling of TFP was also modified so that TFP was given 1 h before DNA damaging treatment and was allowed to remain for up to 24 h afterwards, even though the length of exposure to bleomycin or cisplatin was still limited to one hour. This adjustment in scheduling was done in order to ascertain whether the chemosensitizing (and DNA repair inhibitory) activity of TFP can be improved by increasing the length of exposure. Indeed, the modified schedule imparted stronger bleomycin sensitization than the previous one, albeit the gain was relatively modest.

Using colony formation assay, we first confirmed that TFP was active in combination with either bleomycin or cisplatin against both NSCLC cell lines. As our previous work implicated NHEJ and possibly DNA-PK as a putative target of TFP^{503, 654}, we included in the analyses a commercially available DNA-PK kinase inhibitor, NU7026⁴³². Our data showed that at an equivalent concentration (10 μ M) TFP performed better than NU7026 in terms of chemosensitization in U1810 cells. Importantly, we found that both FPZ and TFPZ imparted platinum sensitivity in NSCLC cells, indicating that chemosensitization was a property shared amongst phenothiazines with different side chain structures. Moreover, both TFP and TFPZ impaired cellular recovery from bleomycin exposure as their presence significantly delayed the resolution of γ H2AX, a surrogate marker of unrepaired DNA DSBs⁶⁵⁵. TFP also impeded γ H2AX resolution after cisplatin treatment. The patterns of γ H2AX formation and clearance in U1810 cells was consistent with the notion that bleomycin rapidly induced DNA DSBs independent of the cell cycle phase whereas cisplatin-induced γ H2AX peaked at 6-12 h post-treatment, which coincided with S phase accumulation. TFP enhanced the arrest of bleomycin-treated U1810 cells in G₂-M and cisplatin-treated cells in S phase. In the absence of TFP, bleomycin-induced initial G₂-M arrest lasted for about 12 h, after

which cells began to divide again. After exposure to cisplatin, the initial S phase arrest began at somewhere between 6-12 h post-treatment and lasted until 18 h post-treatment, after which cells entered G₂-M. TFP significantly delayed the resumption of cell cycle progression in U1810 cells following the initial checkpoint arrest. These cells could still recover, albeit more slowly, as evidenced by the decrease in CFSE fluorescence after 24 h. Over the next 72 h, the proliferation rates of cells treated with mock, TFP alone or bleomycin alone were comparable, suggesting that bleomycin at the dose used (2.5 µg/ml) had no lasting effect on cell cycle competency. In striking contrast, U1810 cells co-treated with bleomycin and TFP (or TFPZ) showed a delayed drop in proliferation, with a subset of cells displaying signs consistent with secondary arrest. Notably, the frequency of abnormal mitosis increased significantly among TFP co-treated cells, which might be a cause for the delayed activation of checkpoint mechanisms. In agreement with this notion, we observed that TFP co-treatment was associated with a delayed activation of the G₂ checkpoint effectors p21^{Cip1/Waf1} and p38MAPK in U1810 cells.

In addition to its impact on mitotic fidelity, TFP co-treatment led to marked increases in apoptosis. This effect was time-dependent and became apparent 48 and 72 h after exposure to bleomycin and cisplatin, respectively. Consequently, it appears that DNA damage-induced apoptosis in U1810 cells was linked to cell cycle progression after initial checkpoint adaptation. Apoptosis in these cells was mediated by multiple caspases, including the initiator caspases-8 and -9 as well as the effector caspase-3. Notably, increased caspase-3 activation after TFP co-treatment was mostly observed in U1810 cells with 4n DNA content, suggesting that mitotic defects and/or secondary checkpoint arrest might trigger apoptosis. At approximately 18 h post bleomycin treatment when TFP co-treated cells were still locked in G₂-M arrest, a subset apparently underwent LMP, as shown by their diminished accumulation of AO. This was not observed in U1810 cells exposed to bleomycin alone, which had just begun to recommence cell cycle progression following the initial checkpoint arrest. Since LMP occurred prior to the onset of apoptosis, it is tempting to speculate that it might contribute to caspase activation²⁵⁵. However, this early wave of LMP after TFP co-treatment was followed by a progressive vacuolation phase that was readily discernible by light microscopy as well as flow cytometry (i.e. increased side scattering). Over time, TFP co-treated U1810 cells retained significantly higher amounts of AO, which accumulates preferentially in acidic organelles such as endosomes or lysosomes. In line with this, TFP co-treated cells fluoresced more brightly when labeled with LysoTracker Green, indicating an expansion of the lysosomal compartment. Notably, abrogation of this process by bafilomycin A1, an inhibitor of vacuolar ATPases, markedly reduced caspase-3 activation in these cells, suggesting that early LMP might trigger compensatory lysosomal expansion which ultimately leads to caspase activation.

We found that TFP co-treatment was associated with an early induction of oxidative stress whose onset at 12-16 h post bleomycin treatment slightly preceded that of LMP. Therefore, it is possible that LMP was caused by increased oxidative damage to the lysosomal membrane. In this case, the most likely site of ROS production was mitochondria, which were markedly hyper-polarized in TFP co-treated U1810 cells. Moreover, mitochondrial depolarization occurred coincidentally with the induction of oxidative stress and both became progressively more severe over time with similar kinetics. Enhanced conformation-driven activation of Bak/Bax was observed in TFP co-treated cells within the same time frame as caspase activation, suggesting that oxidative stress and LMP might cooperate to trigger the intrinsic apoptotic pathway. In line with this, the antioxidant compound N-acetylcysteine (NAC) was able to partially

rescue both the short-term viability and the long-term clonogenicity of TFP co-treated cells. Collectively, these data support a scenario whereby inhibition of DNA DSB repair by TFP leads to oxidative stress and organelle dysfunction which is exacerbated upon checkpoint adaptation leading to caspase-mediated apoptosis.

4.3 Paper III:

Identification of phenothiazines as putative regulators of the chromatin response to DNA damage provides a rationale for context-dependent chemosensitization

The primary aim of this paper was to uncover the molecular mechanism(s) by which TFP and related phenothiazines affect DNA repair. Our previous works showed that TFP could antagonize the repair of DNA SSBs, DSBs as well as ICLs. Moreover, our data indicated that the effect TFP exerted on DNA repair was very rapid and was not easily reversed upon drug wash-out. Therefore, we hypothesized that TFP might modulate an early component of the DDR, such as damage-induced chromatin remodeling, rather than directly inhibiting a repair enzyme.

A compound's mechanism of action is likely to be reflected by changes in the pattern of gene expression in treated cells. This is simply because any extraneous stimulus that disturbs cellular homeostasis would elicit a reaction that attempts to restore status quo. We downloaded two publicly available gene signatures (i.e. up- and down-regulated genes) associated with phenothiazine treatment and used them as queries to search for similarities against 6100 unique gene expression signatures corresponding to >1000 small molecule compounds that were deposited in the cmap database (build 01)^{480, 656}. The signature taken from Lamb et al was derived from cell lines after short-term drug exposure (4 h), while the signature taken from Choi et al was derived from deceased patients that have presumably been exposed to the drugs for longer time. Interestingly, our analysis revealed gene expression similarities between phenothiazines and several HDAC inhibitors, such as trichostatin A and vorinostat. To confirm this finding, we reciprocated the analysis using two publicly available gene signatures associated with HDAC treatment as queries. The signature taken from Glaser et al was a composite derived from cell lines after 24 h drug exposure. By contrast, the signature taken from Ellis et al was agent-specific and derived from patients suffering from cutaneous T-cell lymphoma who were undergoing treatment with panobinostat^{657, 658}. Despite these differences, both query signatures were able to identify a number of phenothiazines, including thioridazine (TRDZ) and TFP. Thus, phenothiazines and HDAC inhibitors appear to induce similar gene expression changes in cells and tissues suggesting that phenothiazines might be chromatin-active compounds. In line with this, exposure of U1810 cells to 10 μ M TFP or the HDAC inhibitor valproic acid (VPA, 5 mM) for 24 h resulted in increased nuclear DNA intercalation by AO, indicating that TFP might enhance chromatin accessibility. However, when the length of exposure was shortened to 5 h, TFP treatment had only a modest effect on AO intercalation. While this short-term exposure to TFP was sufficient to enhance bleomycin-induced caspase-3 activation, it did not cause any discernible changes in the acetylation status of histone H4. These data suggest that TFP treatment might alter chromatin compaction without affecting histone acetylation.

We tested the hypothesis that TFP may interfere with chromatin-proximal DDR signaling. Notably, when U1810 cells were exposed to bleomycin in the presence of TFP, significantly increased DNA-PKcs autophosphorylation (S2056) was observed. Similarly, TFP enhanced the DNA damage-induced phosphorylation of several chromatin-proximal ATM substrates, such as H2AX (S139), NBS1 (S343), KAP-1 (S824), SMC1 (S966) and to a lesser extent ATM itself (S1981). By contrast, phosphorylation of the ATM substrate Chk2 (T68), which does not accumulate at DNA DSB sites and whose function is not thought to involve DNA damage-associated chromatin remodeling, was not affected by TFP. To establish the generality of our findings, we compared the impact of TFP on bleomycin-induced DDR signaling in two tumor (U1810, MDA-MB-231) and two non-transformed (hTERT-RPE1, WI-38) cell lines. We found that TFP augmented DNA-PK/ATM signaling in both tumor cell lines as well as in the immortalized hTERT-RPE1 cells. However, this effect was not observed in the non-immortalized WI-38 cells. These data suggest that the process of immortalization, which represents the first step towards malignant transformation, might induce chromatin re-organization in a manner that renders cells more susceptible to perturbations by TFP. Several structurally related phenothiazines also augmented bleomycin-induced DDR signaling in U1810 cells. Furthermore, TFP enhanced DNA-PK/ATM signaling in response to calicheamicin and cisplatin. These results raise the interesting prospect that such combinations might be used to potentiate the therapeutic efficacy of platinum and calicheamicin in lung cancer and AML (in the context of gemtuzumab ozogamicin), respectively^{659, 660}. On the other hand, TFP did not augment DNA-PK/ATM signaling in response to IR, etoposide or aphidicolin nor did it increase their cytotoxicity. Therefore, our data suggest that DNA damaging agents which are thought to produce similar types of lesions might in fact trigger very different DDR responses.

Given that TFP delayed cell cycle recovery after DNA damaging treatment, we next assessed whether TFP might affect the resolution of DDR signaling. To this end, U1810 cells were pulse-treated with bleomycin in the presence of TFP and then allowed to recover either in drug-free medium or medium containing TFP for various lengths of time. Notably, TFP co-treated cells had consistently higher levels of phosphorylated DNA-PKcs, KAP-1 and H2AX than counterparts that were treated with bleomycin alone. This difference was evident for at least 18 h after removal of bleomycin, indicating that TFP co-treatment was associated with prolonged DDR signaling. Moreover, TFP largely abrogated the DNA damage-induced up-regulation in WRN and FANCD2 in U1810 cells over time. This response was specific since TFP did not overtly affect the expression of several other DNA repair proteins (e.g. Ku70, Ku80, XRCC4, DNA Ligase IV, Rad51, PARP-1), suggesting that TFP might also interfere with transcriptional response to DNA damage. Regardless of the mechanism, TFP-mediated augmentation of DNA-PK autophosphorylation was observed over a wide range of bleomycin concentrations and was recapitulated in all of the tumor cell lines that we tested (e.g. H23, H125, MCF7, MDA-MB-231, T47D, BT474, SKOV3). Once again, TFP did not affect the level of DNA-PK autophosphorylation in the non-cancerous hTERT-RPE1 and WI-38 cells. These data indicated that TFP may selectively inhibit DNA DSB repair in tumor cells without affecting the response of normal cells to chemotherapy. In line with this notion, TFP delayed the re-acetylation of H3K56 in U1810 and MDA-MB-231 cells after exposure to bleomycin and cisplatin, respectively, suggesting that chromatin reassembly which normally accompany DNA repair was compromised in the presence of TFP.

As not all clinically used chemotherapeutic agents act directly on chromatin to induce DNA damage, we next examined the ability of TFP to perturb DNA-PK/ATM signaling in response to the indirect-acting DNA damaging agents etoposide, gemcitabine and aphidicolin. We found that these agents induced DNA-PK autophosphorylation poorly unless used at very high concentrations. Furthermore, TFP did not affect the phosphorylation of DNA-PK or KAP-1 even after prolonged exposure to these indirect-acting DNA damaging agents. This was in stark contrast to the rapid and overt augmentation of DNA-PK/ATM signaling observed when TFP was used in combination with the direct-acting DNA damaging agents bleomycin, calicheamicin and cisplatin. A possible interpretation of this data is that direct-acting DNA damaging agents may activate DNA-PK/ATM signaling in a TFP-sensitive manner that is different from DNA-PK/ATM activation in response to indirect-acting DNA damaging agents. To determine the functional relevance of this differential modulation of DDR signaling by TFP, we compared the chemosensitizing potential of TFP in a panel of tumor and non-cancerous cell lines treated with direct-acting or indirect-acting DNA damaging agents. Three general conclusions could be drawn from this analysis. First, TFP significantly sensitized all p53-deficient tumor cells to at least one direct-acting DNA damaging agent, while it had no such effect in p53 wild-type tumor or non-cancerous cells. Second, none of the test cell lines were sensitized by TFP to any of the indirect-acting DNA damaging agents, regardless of the p53 status. Third, TFP might confer protection against the non-DNA damaging agent staurosporine as well as the indirect-acting DNA damaging agent aphidicolin. There were two apparent exceptions to this generalization. One, TFP was able to sensitize MCF7 cells to direct-acting DNA damaging agents, although these cells express wild-type p53. Two, TFP did not confer radiosensitization in any of the cell lines despite IR being a direct-acting DNA damaging agent. With respect to the function of p53 in MCF7 cells, a study recently reported subtle defects in the DNA damage-induced p53 transcriptional response of MCF7, including the inability to maintain p21^{Cip1/Waf1} expression. It is therefore possible that the wild-type p53 in MCF7 cells is deficient in some aspects of DDR signaling which might explain why MCF7 cells were responsive to TFP-mediated chemosensitization. The second discrepancy is more puzzling because bleomycin is considered to be a radiomimetic⁶⁰⁴. We found that TFP did not affect IR-induced DNA-PK/ATM signaling but the reason for this is not clear at the moment. Taken together, our data suggest the combination of two parameters determines whether a particular cell line would respond to TFP-mediated chemosensitization; the optimal context appears to be a direct-acting DNA damaging agent that elicits TFP-amplifiable DNA-PK/ATM signaling in a tumor cell line with deficient p53 function.

To further explore the consequence of DDR hyper-activation, we utilized specific small molecule inhibitors to forcibly abolish DNA-PK/ATM signaling in TFP co-treated U1810 cells. To our surprise, suppression of DNA-PK or ATM activity by NU7026 and KU55993, respectively, resulted in further chemosensitization, suggesting that the hyper-activation of DNA-PK/ATM signaling was likely an adaptive response to TFP co-treatment. Consistent with this notion, at concentrations below 100 μ M TFP *per se* had no effect on DNA-PK kinase activity *in vitro*. Similarly, augmentation of bleomycin-induced DNA-PKs autophosphorylation by TFP did not appear to involve a direct effect of TFP on cellular protein phosphatases. Moreover, saponin-permeabilization of U1810 and MDA-MB-231 cells did not affect TFP-mediated chemosensitization, indicating that the membrane perturbing activity of TFP could not account for its ability to confer chemosensitization. Collectively, our data suggest that the most likely cause of TFP-mediated chemosensitization is DNA repair inhibition as a result of disturbed chromatin responses. We propose that cancer types for which

bleomycin, cisplatin or calicheamicin-containing regimen is routinely used, such as NSCLC, breast cancer, ovarian cancer, melanoma, glioblastoma and AML, should be considered for future clinical trials to evaluate the clinical efficacy of phenothiazine-based chemosensitizers.

4.4 Paper IV

Gene expression analysis reveals DNA repair pathway modulation as a potential mechanism for phenothiazine-mediated long term cisplatin sensitization in NSCLC

Platinum doublets, usually in combination with gemcitabine, are commonly used for the treatment of NSCLC but their therapeutic efficacies are limited by intrinsic or acquired drug resistance⁶⁶¹. The primary aim of this paper was to explore possible mechanism(s) of platinum resistance in NSCLC and ascertain whether TFP could confer long term chemosensitization by antagonizing such processes. To this end, we pulse-treated NSCLC U1810 cells with a therapeutically relevant dose of cisplatin (10 μ M) either alone or in combination with 10 μ M TFP and then allowed them to form colonies. In the absence of TFP, U1810 cells were relatively insensitive to treatment with cisplatin at this concentration (<20% suppression of clonogenic capacity). Notably, while TFP alone did not affect clonogenic capacity (<5% suppression of clonogenic capacity), it significantly increased the sensitivity of U1810 cells to cisplatin. After nine days, the surviving colonies (residual clones) were harvested from which RNA was extracted. The RNA samples were used to obtain gene expression profiles of the residual clones in response to each treatment, i.e. mock, TFP alone, cisplatin alone, cisplatin/TFP.

We found that the highest number of differentially regulated genes (1141 up, 1290 down) was observed in residual clones that survived cisplatin treatment, followed by residual clones that survived cisplatin/TFP co-treatment (882 up, 491 down) and finally residual clones that survived TFP treatment (139 up, 351 down). Analysis of the gene expression data by PCA and hierarchical clustering indicated that the gene expression profile of residual clones that survived cisplatin/TFP co-treatment showed features intermediate to the gene expression profiles induced by either TFP or cisplatin. In line with this, functional analysis by GSEA showed that while cisplatin treatment led to the enrichment in residual clones of genes involved DNA-dependent DNA replication/replication initiation and DNA metabolic processes, no such enrichment of was found in residual clones that survived cisplatin/TFP co-treatment. These data suggest that TFP may fundamentally affect the ability of cells to modulate certain cellular signaling pathways in response to cisplatin. Intriguingly, we have shown in Paper III using a publicly available gene expression data set⁴⁸⁰ that short-term exposure of MCF7 cells to phenothiazines resulted in down-regulation of a number of genes implicated in mRNA metabolism. Therefore, it seems plausible that TFP might broadly counteract the transcriptional response to cisplatin by modulating the mRNA synthesis and translation. Interestingly, when we performed IPA analysis on genes that were up-regulated in residual clones that survived cisplatin treatment, the top scored networks were found to contain components of several DNA repair pathways, including NER

(TFIIH), MMR (MSH2), FA-ICL repair (FANCD2, FANCI), HRR (MRE11A) and NHEJ (MRE11A, PRKDC), suggesting that survival from cisplatin may require parallel de-regulation of multiple repair modules. Consistent with this notion, Nojima et al reported that tolerance to cross-linking agents (e.g. cisplatin) in avian DT40 cells is mediated by multiple DNA repair pathways, including translesion synthesis (TLS), FA-ICL repair, HRR and to a lesser extent NER⁴¹⁶. Notably, the top scored networks of genes up-regulated residual clones that survived cisplatin/TFP co-treatment did not contain any of the above-mentioned DNA repair genes, suggesting that TFP-mediated chemosensitization might be related to disruption of cisplatin-induced compensatory up-regulation of tumor DNA repair capacity.

To validate our findings from gene expression analysis, we determined the mRNA and protein expression for a number of DNA repair genes identified as up-regulated in cisplatin-resistant residual clones. Some of these (PRKDC, FANCI, FANCD2, MRE11A) were found in the top scored networks while others (RRM1, RRM2, RAD51) were not but have nevertheless been implicated in the clinical responsiveness of platinum-based therapy. Our preliminary data demonstrated that DNA-PKcs (encoded by PRKDC) also increased in protein expression. The other five candidates showed discrepant mRNA-protein expression and a possible explanation is that a significant proportion of mRNAs in cisplatin-surviving residual clones may not be translated. A recent report showed that the development of treatment-induced platinum resistance in ovarian carcinoma is accompanied by an increased activity of the DNA-PK/Akt pathway⁶⁶². Similarly, we have previously shown that acquired resistance to radiotherapy in cervical carcinoma was associated with increased expression of all three components of the DNA-PK complex in residual tumors³⁶¹. Therefore, it seems that enhanced DNA repair capacity is a major contributor of acquired platinum resistance although it might not necessarily be involved in the maintenance of intrinsic platinum resistance. When U1810 residual clones were replated and subjected to a second round of cisplatin treatment, we found that residual clones which survived the first round of cisplatin treatment were also resistant in response to a second round of cisplatin treatment. However, the relative platinum sensitivity of parental U1810 cells and cisplatin-surviving residual clones were similar (70% versus 73%), suggesting that while U1810 cells were intrinsically resistant to cisplatin, residual clones that survived the first round of cisplatin treatment did not acquire additional resistance. These data might explain the paucity of over-expressed DNA repair proteins in residual clones that survived cisplatin treatment. However, it is also possible that a single round of cisplatin treatment was not sufficient to elicit acquired resistance. We found that CDK12 was up-regulated in cisplatin-surviving residual clones. A CDK12/cyclin K complex was recently shown to promote RNA polymerase II-dependent transcription of many genes involved in the maintenance of genomic stability, such as ATR, FANCD2 and FANCI⁶⁶³, all of which were concurrently up-regulated in cisplatin-resistant residual clones. It is therefore conceivable that de-regulation of DNA repair proteins other than or in addition to the ones tested might progressively induce the development of acquired platinum resistance upon repeated (two or more) drug exposure. More studies are needed to determine the functional relevance of de-regulated expression of DNA repair genes with regard to intrinsic as well as acquired platinum resistance.

In agreement with our findings that TFP may antagonize the adaptive transcriptional response to cisplatin treatment, residual clones that survived an initial round of cisplatin/TFP co-treatment exhibited greater relative platinum sensitivity than cisplatin-

surviving residual clones when re-exposed to cisplatin for a second treatment round (60% versus 73%). Moreover, we found that U1810 cells exposed to an initial round of cisplatin/TFP co-treatment had reduced clonogenic capacity in the absence of a second round of treatment, suggesting that TFP may induce a long-lasting state of cellular stress. We reasoned that this effect might be reflected in their pattern of gene expression. Indeed, residual clones that survived cisplatin/TFP co-treatment showed a preferential up-regulation of stress-inducible genes involved in chromatin remodeling (e.g. ASF1A, ASF1B, KAT2A/GCN5) and replication (e.g. MCM2, MCM5, MCM6), suggesting that TFP may interfere with chromatin-related processes that normally operate in response to cisplatin-induced DNA damage. In addition, these residual clones contained increased transcripts of genes implicated in ribosome/RNA metabolism (e.g. RAE1, RPL32, RPL27L, SSB, UPF3B, NPM3). Since CPZ treatment was previously shown to trigger a rapid shutdown of translation in yeast and mammalian cells, it is plausible that this late increase in the expression of genes involved in RNA biosynthesis may represent a compensatory response to an earlier translational stress⁴⁸⁵. As mentioned earlier, the top scored networks of differentially regulated genes in residual clones that survived cisplatin/TFP co-treatment contained few DNA repair components, although it is not clear whether this effect was caused by the disturbance in RNA metabolism. Notably, the mRNA and protein expression of PRKDC were also elevated in residual clones that survived cisplatin/TFP co-treatment, albeit not to the same extent as in cisplatin-surviving residual clones. Moreover, the transcript levels of several predicted interaction partners of PRKDC were also elevated in residual clones that survived cisplatin/TFP co-treatment, including KAT2A (GCN5) and USF1. DNA-PK has been shown to phosphorylate the protein products of these two genes, which resulted in transcriptional repression and activation, respectively^{664, 665}. It is therefore possible that the transcriptional response of cisplatin-surviving residual clones might be partly driven by the up-regulation of DNA-PK. Interestingly, we found that TFP augmented DNA-PKs autophosphorylation in response to cisplatin. It remains to be determined whether TFP could also modulate DNA-PK-mediated phosphorylation of GCN5 or USF1 and whether this might contribute to the increased platinum sensitivity of TFP co-treated cells.

In summary, we present evidence that global genomic profiling of residual clones that survived cisplatin treatment can be used in tandem with pathway analysis to identify putative mechanism(s) driving platinum resistance. Collectively, our data showed that concurrently transcriptional de-regulation of multiple DNA repair genes in cisplatin-surviving NSCLC residual clones might facilitate the development of acquired resistance upon additional drug exposure. Finally, we found that alterations in the cisplatin-induced adaptive transcriptional responses by TFP might account for its ability to confer platinum sensitization. Our data raise the possibility that TFP may be useful for sensitizing intrinsically platinum-resistant tumors as well as for circumventing the development of acquired platinum resistance in initially sensitive tumors.

5 CONCLUSIONS & FUTURE PERSPECTIVE

5.1 Our main conclusions

In **Paper I**, we demonstrate that TFP-mediated augmentation of bleomycin sensitivity in human NSCLC cells is associated with its ability to inhibit DNA strand break repair *in vitro* and *in situ*. In **Paper II**, we show that TFP and related phenothiazines impair γ H2AX resolution in human NSCLC cells leading to prolonged checkpoint arrest and delayed check proliferative recovery after exposure to bleomycin or cisplatin. We further demonstrate that defective DNA DSB repair in TFP co-treated cells is associated with abnormal mitosis, secondary arrest and caspase-mediated apoptosis initiating from the G₂-M phase. We provide evidence that severe oxidative stress in conjunction with extensive lysosomal/mitochondrial dysfunction elicit caspase-3 activation and loss of cell viability. In **Paper III**, we provide evidence based on *in silico* predictions that phenothiazines are putative chromatin-active agents. Our analyses indicate that TFP selectively sensitize cancer cells to direct-acting DNA damaging agents. We show that TFP disrupts DDR signaling and its resolution by inducing hyper-activation of DNA-PK and ATM preferentially in cancer cells. We demonstrate that TFP-induced hyper-activation of DNA damage-induced DDR signaling represents an adaptive response that can be targeted with DNA-PK or ATM inhibitors to further enhance tumor killing. Finally, in **Paper IV**, we demonstrate that TFP profoundly alters the cisplatin-induced transcriptional survival responses leading to sustained suppression of clonogenicity. Based on these data, a tentative model for phenothiazine-mediated chemosensitization is constructed (Figure 17).




Figure 17. A tentative model of phenothiazine-mediated chemosensitization based on results presented in this thesis.

5.2 Unresolved questions and future perspectives

5.2.1 Intracellular localization of phenothiazines

The pharmacologic activity of a compound is determined by its localization. The chance for it to interact with multiple targets increases if the compound accumulates in different subcellular compartments. Conversely, confinement to a single location increases the likelihood that it would interact with high specificity with a single target. The precise cellular localization of phenothiazines is not known. Ultrastructural studies using electron microscopy have revealed diffuse phenothiazine immunopositivity associated with many subcellular structures, including chromatin, nuclear matrix, cytosol, ER, ribosomes and mitochondria⁵³⁶. Moreover, phenothiazines have also been shown to partition into model membranes whose lipid composition resembles that of the plasma membrane. Consequently, phenothiazines have many potential interaction partners throughout the cell. However, it is not known whether phenothiazines would accumulate at the different sites with the same relative ratio or if there might be a preference for one or more cellular compartment. In this thesis we have shown that TFP can modulate DNA damage-induced DNA-PK/ATM signaling, suggesting that it can localize to chromatin, but whether TFP localized elsewhere in the cell contribute significantly to chemosensitization is still an open question. Conjugating phenothiazines with a fluorescence tag may help resolve this issue if the tag does not appreciably alter the chemical and pharmacological properties of its host molecule. This can be nevertheless be tricky due to the low molecular weight (e.g. TFP, MW 480) of phenothiazines because and the relatively large sizes of most conventional fluorescent tags (e.g. FITC, MW 389). Furthermore, most clinically used phenothiazine anti-psychotics lack an amine functional group that needed for chemical conjugation, which requires the use of specialized derivatives (e.g. 10-[2-(aminooxy)ethyl]-10H-phenothiazine) whose activities must first be rigorous tested and confirmed to resemble that of traditional phenothiazines. As an alternative strategy, it is possible to radioactively label phenothiazines. However, it is not possible to detect radiolabeled phenothiazines *in situ* and fractionation is a labor-intensive and crude way of separating subcellular compartments which is prone to cross-contamination. A third strategy is to generate antibodies that specifically recognize phenothiazines. In this respect, it is important that the antibodies should bind to its target in the context of free phenothiazines as well as phenothiazines that exist in complex with other biomolecules. Although this does not permit real time tracking, it would allow detection of phenothiazines *in situ*. Regardless of the strategy, elucidating the subcellular localization(s) of phenothiazines may go a long way to help defining their molecular targets.

5.2.2 Analysis of TFP-interacting partners

Given that phenothiazines are likely to have multiple cellular targets, which of these are most relevant for chemosensitization? Our data suggest one or more chromatin-localized proteins. To answer this question fully, however, we need to first establish the identities of all the proteins that bind to phenothiazines (i.e. the interactome). To this end, two different approaches may be applied. In one, phenothiazines with suitable amine group would be conjugated onto a sepharose column. Total cell lysates or fractions thereof can then be passed through the column. After extensive washing, any proteins that were bound to the immobilized phenothiazine can be eluted by disrupting the binding with high concentrations of salt and their identities determined by mass spectrometry. Alternatively, if a high affinity monoclonal antibody can be raised

against a particular phenothiazine, it may be used to immunoprecipitate phenothiazine-binding proteins. A potential pitfall here is that the antibody may not be able to recognize phenothiazine-binding protein that have deep substrate binding pockets or that the interactions are weak and/or transient. Once the phenothiazine-interactome is established, one can then systematically study the most likely candidates and their relative contribution to chemosensitization. This issue needs to be urgently addressed before structure-activity relationship (SAR) which is required for the development of a clinically optimized compound that can be used for chemotherapy sensitizing purposes.

5.2.3 TFP in combination chemotherapy

Drug combinations

A survey amongst published reports showed that phenothiazines were always active in combination with bleomycin in tumor cells whose p53 status were either null (C6 rat glioma⁶⁶⁶) or mutant (L1210 mouse leukemia^{571, 572, 667}, SKOV3 human ovarian cancer⁵⁶⁵). The chemosensitizing activity of phenothiazines in p53 wild-type cells was more ambiguous, with CPZ shown to potentiate bleomycin in B16 mouse melanoma⁵⁸⁵ while TFP was largely ineffective in EMT6 mouse breast cancer⁶⁶⁸. These data corroborate our own results which showed that TFP conferred bleomycin sensitization in p53-deficient (U1810, H23, MDA-MB-231) but not p53 wild-type (A549, hTERT-RPE1) cells. As mentioned previously, MCF7 cells exhibited a subtle defect in p53 signaling despite being wild-type for p53, which might explain its responsiveness to TFP-mediated chemosensitization⁶⁶⁹. The proficiency of wild-type p53 in B16 melanoma cells have not been thoroughly assessed, although it is tempting to speculate that it may also be functionally sub-optimal. Importantly, we and others have shown that phenothiazines did not increase bleomycin sensitivity in non-cancerous cells (Paper III)⁶⁷⁰. Taken together, the available data suggest that bleomycin should be an excellent candidate chemotherapeutic agent for use in combination with phenothiazine-based chemosensitizers.

The few studies that examined the efficacy of phenothiazines as cisplatin sensitizers yielded results that were not entirely consistent with our own data. Onoda et al found that TFP did not affect the growth of p53 wild-type B16 melanoma cells⁵⁸⁶, which was in line with our findings that TFP lacked effect in A549, A2780 and hTERT-RPE1 cells. On the contrary, Perez et al reported that TFP did impart cisplatin sensitization in A2780 parental cells as well as two of its platinum-resistant sub-clones⁵⁶³. Moreover, they showed that TFP was ineffective against OVCAR-3 which is mutant for p53, while our data (Paper III) showed that TFP sensitized all of the three p53-mutant cell lines that we have tested so far (U1810, H125, MDA-MB-231). The reason for this discrepancy is not clear. As Perez et al did not provide an outline of their drug treatment scheme it is not possible to determine whether TFP scheduling could be the cause of these contrasting results. More studies are needed to fully establish the utility of phenothiazines as cisplatin sensitizers. Notably, there is a substantial amount of data supporting a potential protective effect of phenothiazines on cisplatin-induced nephrotoxicity and ototoxicity, two major dose-limiting side effects of cisplatin encountered in the clinical setting^{574, 575}. Therefore, phenothiazines might be useful for increasing the therapeutic indices of platinum-based regimens.

Based on our works, it appears that TFP has little or no effect in combination with chemotherapeutic drugs which do not directly damage DNA, such as etoposide or

doxorubicin. There is no consensus on this subject in the literature where seemingly conflicting reports have been published. Nevertheless, we discovered upon closer scrutiny that phenothiazines selectively re-sensitized a variety of doxorubicin-resistant cancer cells *in vitro* as well as *in vivo* but had no effect in any of the parental cell lines except MCG101-AA, a chemically-induced mouse sarcoma whose relative sensitivity to anthracyclines was not known^{469, 587, 671-676}. Strikingly, while adding TFP to doxorubicin-based regimen failed to demonstrate any extra benefit amongst unselected patient populations^{465, 467, 468}, in a phase I/II trial, the combination of doxorubicin and TFP produced clinical responses in 7 of 36 patients (19%) with acquired drug resistance (previous response followed by relapse) but in none of the 21 patients with intrinsic drug resistance (no previous response)⁵⁹³. Similarly, TFP was found to cross-sensitize doxorubicin-resistant sub-clones but not parental cells to etoposide^{572, 677, 678}. Several potential mechanisms have been proposed, including but limited to enhanced drug retention, increased induction of DNA damage and down-regulation of pgp expression. On a cautionary note, however, phenothiazine-mediated sensitization to anthracyclines was also observed in non-cancerous V79-379A hamster lung fibroblasts, LLC-PK1/MDR1 porcine kidney cells and primary human kidney cells that express pgp^{470, 670, 679}. In addition, prolonged exposure of doxorubicin-sensitive parental L1210 cells to TFP in combination with low doses of doxorubicin was associated with compensatory up-regulation of pgp expression and development of cross resistance to other drugs (e.g. etoposide, amsacrine, vincristine)⁶⁸⁰. Moreover, when mice bearing MDR P388 leukemia were treated with drugs that are substrates of pgp, such as vincristine, taxol or the TFP-related compound trans-flupenthixol, it led to metastasis, faster tumor progression and decreased survival⁶⁸¹. There are also uncertainties as to what impact phenothiazines might have on the acute toxicity of anthracyclines, with one study showing a protective effect in C57/BL6 mice and another study showing exacerbated toxicity in ddY mice^{673, 682}. Collectively, these data suggest that phenothiazines might be useful as resistance modifiers in the second line for a subset of patients whose tumors show acquired resistance to anthracyclines or etoposide. Due to the high risk of collateral damage to normal tissues and inadvertent exacerbation of disease progression, we propose that any use of phenothiazines as general sensitizers for doxorubicin should be avoided.

Tumor types

The works described in this thesis provide a partial answer to this issue. Thus, we demonstrated that TFP is an effective chemosensitizer in tumor cell lines with deficient p53 functions but it has little or no effect in p53-proficient cells. Notably, the particular cause of p53 deficiency did not seem to impact on TFP responsiveness, be it non-sense mutation (U1810), missense mutations (e.g. H23, MDA-MB-231) or even subtle functional deficiency of the wild type protein (MCF7)⁶⁶⁹. These data suggest that a fully functional p53-dependent transcriptional program might be required to counteract the actions of TFP. This is unlikely to involve p53-mediated checkpoint maintenance, given that cell cycle arrest was longer in TFP co-treated U1810 and MDA-MB-231 cells. Rather, TFP may be selectively active when cells are unable to activate p53-mediated processes that promote DNA repair, survival or checkpoint recovery⁶⁸³⁻⁶⁸⁵. Regardless of the exact mechanism, our results indicate that p53-mutant tumors should be considered for phenothiazine-mediated chemosensitization. Tumors that are wild type for p53 but which are functionally deficient due to over-expression of its negative regulators (e.g. MDM2) may also be sensitive to TFP. Additional experiments are needed to test this hypothesis.

In this thesis, we showed that TFP and structurally related phenothiazines are potent sensitizers of direct-acting DNA damaging agents in multiple cell lines derived from different solid tumors, including NSCLC, breast cancer and ovarian cancer. Are there any tumor types that may be responsive to phenothiazine-based chemosensitization? Because phenothiazines have a demonstrable affinity for melanin, we propose that malignant melanomas can be a good candidate for testing the efficacy of phenothiazine as chemosensitizers. There are three main arguments for choosing melanomas. First, CPZ clearly accumulated in rodent melanocytes *in vivo*^{686, 687}; depending on the experimental system, CPZ was either cytotoxic *per se* or conferred sensitization towards chemotherapy and radiation^{585, 592, 688-694}. Second, p53 mutations are very common in human melanomas^{695, 696}. Finally, bleomycin and cisplatin are both routinely used in melanoma treatment as part of multi-drug chemotherapy regimens (CVD, cisplatin-vinblastine-dacarbazine; BOLD, bleomycin-vincristine-lomustine-dacarbazine) and their toxicity profiles are known in these settings. Moreover, previous clinical trials have demonstrated that phenothiazines can be given safely in combination with bleomycin⁵⁹⁴. Since our analyses showed that TFP significantly sensitized p53-deficient tumor cells towards bleomycin and cisplatin, it might be worthwhile to evaluate the efficacy of such combination chemotherapy in human melanomas.

Another group of patients that might benefit from TFP-mediated chemosensitization are those that have CNS tumors. This is due to two properties of phenothiazines. One, phenothiazines are amphiphilic at physiologic pH and this allows them to freely cross the BBB. Two, phenothiazines could potentially disrupt the barrier function of the BBB by virtue of its ability to inhibit ABC transporters, which are highly expressed in endothelial cells. This phenomenon has been demonstrated in mice and rats where TFP enhanced the CNS accumulation of etoposide and ivermectin but not vinblastine⁴⁶⁰⁻⁴⁶². Neither bleomycin nor cisplatin is particularly active against gliomas and it is not known whether phenothiazines could increase their CNS penetration. In this regard, both electrochemotherapy (ECT) and direct intracranial injection have been tested for their abilities to enhance bleomycin accumulation in the CNS. These studies concluded that high dose bleomycin can be given safely. Exposure of human and rat glioma cell lines to diverse phenothiazines *in vitro* resulted in either growth arrest or cell death^{521, 557, 697} and there is also some evidence for phenothiazine-mediated sensitization towards bleomycin and nitrosoureas^{666, 698}. By contrast, the effect of phenothiazines in combination with temozolomide or IR, which are the mainstay of treatment for glioma, was additive and sub-additive, respectively⁵⁶⁸. These data are consistent with our own results showing that TFP preferentially sensitized tumor cells to direct-acting DNA damaging agents. The particular combination of bleomycin and TFP has been tested in a phase II clinical trial previously and was not associated with any objective responses⁵⁹⁴. However, that study was conducted in patients with high grade gliomas who had been heavily pre-treated, making it uncertain that they would have responded to any type of treatment. Moreover, the study was single-armed making it impossible to assess any potential advantage from the combination treatment. We therefore propose that phenothiazines should be re-evaluated for their efficacy as chemosensitizers in a more selected patient population whose tumors are of lower grade and harbor defined p53 mutations. In light of our findings that TFP could enhance the cytotoxicity of calicheamicin and the ICL-inducing agent cisplatin, it is tempting to speculate that phenothiazines may be useful in combination with gemtuzumab ozogamicin (GO, an antibody-conjugate of calicheamicin) or melphalan (an ICL-inducing agent) for the treatment of AML and multiple myeloma, respectively.

Scheduling of TFP

To obtain a thorough overview on the temporal patterns of TFP-mediated chemosensitization, we expanded our TFP scheduling schemes and tested various combinations of pre- and/or post-incubation for their ability to augment caspase-3 activation in U1810 cells after a pulse treatment with bleomycin or cisplatin. We found that when the duration of TFP post-incubation was kept constant, cells that were also pre-incubated or received TFP concurrently with a DNA damaging agent had significantly higher levels of active caspase-3 than counterparts that were only post-incubated. Similarly, when TFP pre-incubation was applied, caspase-3 activation increased with the lengths of post-incubation. These data suggest that TFP-mediated chemosensitization has two temporal components. The early component is likely to be related to its ability to perturb DDR signaling. In line with this, we showed that if cells were first exposed to bleomycin and then post-incubated with TFP upon bleomycin removal, TFP could no longer augment DNA-PKcs autophosphorylation. Our data is also corroborated by the findings of Kwok and Twentyman, who reported that if TFP was given after bleomycin exposure, it had no effect on the survival of EMT6 cells⁶⁹⁹. It is not yet clear which process or processes might be involved in the late component of TFP-mediated chemosensitization. One possibility is that it could be related to inhibition of mitotic kinesins by TFP^{525, 526}. Collectively, the available data suggest that in order to maximum efficacy, TFP needs be given prior to or concurrently with a direct-acting DNA damaging agent and should remain for at least as long as the latter is present. Future studies with animal models will be required to test the validity of this hypothesis.

Concentration of TFP *in vivo*

The minimal concentration of TFP that produces a discernible effect on DDR signaling in bleomycin-treated U1810 cells was 5 μM (our unpublished data), while 10 μM was required to significantly suppress their clonogenic potential. Are these concentrations achievable *in vivo*? There are no simple answers to this question. Previous studies have established the maximum tolerated doses (MTD) of TFP and prochlorperazine (PCZ) as 60 mg/d (orally 15 mg four times per day) and 180 mg/m² (intravenously 2 h infusion), respectively^{464, 593}. Based on these schedules, the maximum plasma level of TFP was approximately 130 ng/ml, which corresponds to about 0.32 μM (MW 407.5)⁵⁹³. The peak plasma levels of PCZ varied greatly between patients (91-3215 ng/ml), which corresponds to a range of 0.24-8.6 μM (MW 373.9)⁴⁶⁴. Hence, the plasma concentrations of TFP are well below the 10 μM needed for chemosensitization *in vitro* while for PCZ it might be achievable in some patients. However, phenothiazines generally have very large volumes of distribution (e.g. 350.1 \pm 183.8 L/m² for PCZ) due to their high lipophilicity⁴⁶⁴. Moreover, phenothiazines may exhibit tissue tropism. An example of this is CPZ, which has affinity for melanin. In hamsters and mice bearing transplantable melanomas, CPZ showed >100 fold greater accumulation in melanoma than in muscle or blood⁶⁸⁶. Therefore, the plasma level of phenothiazines might not adequately reflect their concentration in tissues. It is possible that concentrations of phenothiazines sufficiently high to confer therapeutic chemosensitization can be achieved in at least some tumors. More studies are required to determine if this is the case.

5.3 A unified view of phenothiazine-mediated chemosensitization

Due to a large number of potential target sites and molecular interaction partners, it is rather difficult to obtain a unified view of phenothiazine-mediated chemosensitization. To this end, we propose a tentative ranking system where each known target site or interaction partner acts as an independent molecular checkpoint and the sum total of all interactions determine whether phenothiazine-mediated chemosensitization is likely to be observed or not (Table 8). This analysis suggests that colon cancer Caco-2 cells are likely to be sensitized to cisplatin by phenothiazines. Additional experiments are needed to verify the validity of this prediction.

Table 8. A tentative ranking system for predicting phenothiazine-mediated chemosensitization.

Cell line		U1810	U1810	U1810	MB-231	A2780	Caco-2
Treatment		BLM	VP16	STS	CDDP	CDDP	CDDP
p53^a	mutant 3p	3	3	3	3		3
	wild-type 0p					0	
Type of DNA lesion	DSB 2p	2					
	ICL 2p				2	2	2
	SSB 0.5p	0.5	0.5		0.5	0.5	0.5
	oxidative damage 0.5p	0.5					
	replication lesions 0.5p		0.5		0.5	0.5	0.5
	none 0p			0			
Mode of damage induction	direct 2p	2			2	2	2
	indirect 0.5p		0.5				
	none 0p			0			
Transport by efflux pumps	yes 1p ^b						1
	no 0p	0	0	0	0	0	
Expression of efflux pumps	yes 1p						1
	no 0p	0	0	0	0	0	
Total Sensitization		8 yes	5 no	0 no	8.5 yes	4.5 no	10.5 n.d.

Abbreviations: STS, staurosporine; MB-231, MDA-MB-231; n.d., not determined.

^afunctional proficiency or deficiency; ^bThe point is given on if the cell also expresses ATP-dependent efflux pumps.

5.4 CONCLUDING REMARKS

Phenothiazines have demonstrable cytotoxic and/or chemosensitizing activities against a wide range of human tumor cells. Their apparent failure to recapitulate these effects in a series of earlier clinical trials is likely due a scarcity of knowledge about the molecular determinants of phenothiazine-mediated chemosensitization. As described in this thesis work, such parameters are beginning to be elucidated and this will allow a more refined definition of patients who are most likely to benefit from phenothiazine-containing regimen. Moreover, the ability of phenothiazines to allviate disease-related anxiety, suppress chemotherapy-induced emesis and potentially limit collateral damage to normal tissues can all be harnessed to improve the quality of life of cancer patients. It is time give this class of “old” drugs a second chance what show us what they are really capable of.

6 ACKNOWLEDGEMENTS

I extend my warmest thanks to...

My co-authors and the funding agencies

I'd like to thank all the **co-authors** for their invaluable contributions to phenothiazine project. The studies presented in this thesis are supported from grants from the **Swedish Cancer Society**, the **Stockholm Cancer Society**, the **Swedish Research Foundation**, the **Swedish National Board of Health and Welfare**, the **Stockholm County Council**, the **Karolinska Institutet Research Fund** and the **European Union**. Thanks also to the **Stiftelsen Konung Gustaf V:s Jubileumsfond** for providing travel grants that enabled me to participate in international cancer conferences.

My supervisors

Kristina Viktorsson. My main supervisor and the brain of the lab. Your drive and your thirst for knowledge make everyone around you want to match your ambitions. You gave me freedom to foster my own research ideas but always came to the rescue when they turned out to be too wacky. You encouraged me to break into new frontiers but always made sure that I don't wade hastily into some unrealistic side project, which I tend to do quite often. Your supervision kept me motivated and focused. It is fair to say that without your help I would not have been able to complete my PhD education so smoothly and enjoying it so much at the same time.

Rolf "Roffe" Lewensohn. My co-supervisor and the head of the lab. Your work rate is just phenomenal and you exude such enthusiasm about all aspects of research it is infectious. Even with such a (alarmingly?) tight daily schedule, you've always found time to discuss with me the most recent scientific development in relation to our own work. Now that you've shown me the allure of translational research I don't know if I can ever bring myself to do basic research in the future...

Petra "mini-supervisor" Hååg. My co-supervisor and the arm of the lab. I call you my mini supervisor because of your relaxed style. But you do have a big heart and you're always keen to help and gave advices on everything I throw at you. I especially like your "no nonsense" attitude in the lab as well as on the football pitch. I'm a bit worried now that you spend so much time holed up inside your office writing grants. I do happen to know your real playground is in the lab...

Åsa Holgersson. My ex-supervisor who opened the door of the lab to a slightly confused greenhorn (myself) looking for a place to do his master thesis all those (6!) years ago. You taught me the first techniques and got me ease into the lab routines. Thank you for helping establish a solid foundation for my future research in the short time we worked together.

My wonderful colleagues and labmates at KBC

Especially the small “critters” (pluttisar) of the lab, **Hogir “Hogge Hoggelito” Salim, Ghazal “Gaga” Efazat, Therese “Tess” Juntti and Claudia “Claudilainen” Selck**, who are really my brothers and sisters. We’ve had so much fun in and out of the lab I’m surprised my tummy hasn’t burst from all that laughter. You guys complemented each other so well. Hogge with his many funny little tales, Gaga with her unerring ability to mishear everything I say, Tess with her twisted jokes and Claudilainen with her beautiful songbird voice. Life is never dull around you guys. I’m gonna miss you all. Please come to the U.S. to visit me sometimes and don’t forget to invite me for your weddings ☺

Lovisa “Lova” Lundholm, Birgitta “Gittis” Mörk, Jelve Zendegani, Katarzyna “Kat” Zielinska-Chomej, Chitralkha “Chitra” Mohanty, Alexandros Arvanitis, Marita Lagergren Lindberg and Leif Stenke, thanks for all the encouragement and support over the years and many hours of stimulating discussions on just about anything under the sun including science. Now you know why I eat so slowly when you guys are around... **Marianne “Meeri” Langéen**, for being ever so helpful with all the administrative stuff and always having a nice story to share during fika. **Christina von Gertten**, I’m impressed by your work efficiency and your ability to contradict almost anything I say and I really enjoyed our verbal sparring even though no one else understood what was going on. **Reidun “the Norwegian bomber” Aesoy**, you’re so gentle in the lab but when it comes to volleyball you’re tougher than Xena the warrior princess. We gotta have a rematch when you come back.

Many thanks also to our nearest neighbor labs for creating a fun and pleasant working atmosphere, in particular **Sanaz, Ingrid, Lin, Min, Serhiy, Natalia, Olena, Kie, Rui, Elena, Ann-Sofi, Dina, Henrik, Sara S, Hanna, Maria, Jenny, Helena B, Sven, Patrick, Ernesto, Bettina, Åsa W, Susanne, Sofia, Birgitta Sundelin and Anna K.**

My friends at CCK

Everyone at CCK deserve credit for making it such an enjoyable place to work, in particular **Agnes, Anna Kock, Anna Maria, Lova, Helena G, Lotta, John-Inge, Baldur, Bertha, Hanif, Xiaonan, Slavica, Pdraig, Maria, Seema, Roku, Helena T, Erik, Sara H, Nathalie, Martin, Elin, Per, Ma Ran, Naveen, Dudi, Ahmed, Alireza, Margherita, Sylvia, Sofia, Elisabeth, Marianne, Cinzia, Zhang Qiang, Emarndeena, Inga, Toota, Liu Tong, Peng, Reza**, as well as **Anna V, Nimesh, Shahab and Ersen.**

The Opus editorial team. Although I was recruited while not entirely sober it’s been a pleasure working with you guys. I really enjoyed this little journalistic experience and the tiny salary it brings was also most welcome. **The CCK Champions football team.** A big thanks to all the dedicated players in the past seasons and let’s bring glory back to CCK this year! **The CCK pub crew.** You guys really made me look forward to Wednesdays. Don’t worry I will pay my debt soon. **The CCK administration, IT support, shop and logistics crew.** The real unsung heroes, your work makes it

possible for us to concentrate on research. Thanks also for organizing the annual conference and dinner.

My friends outside of CCK

Especially **Di & Mod, Davor & Melanie, Nomi, Maya, Colin, Danilo, Janos, Anya, Anna W, Anna Z, Pinar, Karolina “Lili”, Yin-Choy, Jingwen, Yanhao, Alison, Aram & Nadeem**. I’m so glad to have such an awesome band of friends.

And special thanks to...

Nimrod “Ti” Kiss and **Ninib “the family guy” Baryawno** (aka professor Ninib), my brothers and travel buddies. Nostalgia is just the foreword when I look at the pictures of us standing at Intipunku overlooking Macchu Picchu. Ti, you’re one of my closest friend, my best man, flat mate, training buddy and wingman all in one. I admire the way you combine intellectual brilliance with outdoor prowess; you should probably be renamed Rambo Einstein. I hope you find a good job in New Zealand soon, where I know your heart truly lies. Ninib, my good friend and a man of great wisdom. You are just as likely to crack an outrageously hilarious joke as to hatch the most superb scientific idea. I admire your steadfast commitment to your principles and personal integrity. I wish you the best of luck in Boston and let’s try to win the Nobel Prize in 20 years time together. And don’t forget to invite me for BBQ ribs this time...

Alexei “Dr Alex” Leonov & Andrey Leonov, my brothers from way back in primary school. I can spend hours reminiscing on the good time we had growing up together! You guys spur me on with your work ethics and I admire your confidence and persistence in whatever enterprise you choose to partake. Many thanks for sharing your insights on everything from politics and business to philosophy and science, and I really enjoyed our many Baltic Sea cruise trips. I wish you guys the best of luck in life and business. And Andrey man, you really need to quit smoking those cancer sticks...

Betzy “sucio” Chavez, my ex-office mate and a master of gello shots! Even though you didn’t smile the first time we met ☹, we soon became good friends (it had nothing to do with gello and all to do with your charm). I enjoyed talking with you so much it delayed my own PhD studies and you somehow ended up finishing before me (unforgivable!). I wish you the best of luck in your job hunt. You and Alex are always welcome to join us in the U.S.

Therese Högfelddt, my ex-neighbor at KBC and good friend. You are such a nice person it almost hurts to tease you, but somehow I keep on doing it anyway (bad!). Thanks for the fun times at KBC and at conferences abroad; and congrats to your marriage. Man I still think of you as a Jacobson...

Wang Xin, my favorite Chinese friend! Thanks for helping me improve my Chinese (or did I drag down your level?) and sharing with me your vast experience about where to find the best Chinese restaurants in Stockholm and elsewhere. You and Zheng Xiaofeng should really come to the States, they’ve got the best Asian food outside Asia!

Barry Wolahan, my good Irish friend! Thanks for organizing the Beer & Whiskey tasting every year and teaching us to dance Irish folk dance. Also appreciated all the advice I got about lab matters. I wish you and Rachel all the best in the future.

Jelena “Jelis” Milosevic, my Serbian big sister! Thanks for always looking after me at work and on travels. And for teaching me everything about astrology (I still don’t get most of it ☺) and introducing me to “Jugge fest”. You, Mila and the family are just so sweet. Good luck with your PhD studies now and then come work with me!

Mahdi Mojallal, **Jeroen Frijhoff**, **Nimrod Kiss** and **Walid Fayad**, aka the gentlemen’s club. Nothing dirty, mind you, these are all true gentlemen. It’s been great fun to go clubbing with you guys... ah, good old times...

Salah & Diana, the model couple at CCK for many years. Thanks for all the fun parties and for sharing with me insights on how to take care of a baby (hey it may come handy!). Enjoy your time in the States and see you guys soon (once I get my driver’s license).

Ismael “Iso” Gritli & Mayu, the other model couple. Congrats on becoming parents. Iso, who could have thought a few years back that you’ll be a Japanese dad!!! Makes me think back about all those good old waterpipe-sharing times. I’m so happy for you and wish you the best of luck with your PhD studies.

Priya Mathews, my special American friend! You came here as Dara’s best friend but ended up being my closest ally. I guess we owe you one... When the time comes, I promise I will return the favor ☺. In the meantime, good luck with your studies.



And my family

My dear parents **Zong Weiyong** and **Liu Yuping**, for all those years of patient nurturing and unwavering love when I’m at my rebellious worst. And for the personal sacrifice you endured just to create the best conditions for me. You taught me the importance of hard work and humility and encouraged me to set myself on a path I enjoy. I’m truly indebted...

My dear parents-in-law **Damrong Wangsa & Premchit Wangsa**, for their love and for making me feel instantly that I belong to the family. And for fostering such a wonderful daughter. I’m sorry I had to steal her from you...

And finally my sweet and beautiful wifey **Darawalee Wangsa Zong**, for being the star of my life. Your patient support and unconditional love helped me through my darkest hours, not to mention all the practical things you did for me throughout the years. Although you’re far away across the ocean, I feel your cheerful spirit and vibrant energy so up close it is as if you’re right next to me urging me on. You truly bring the best out of me. I love you...

7 REFERENCES

1. Jemal, A. et al. Global cancer statistics. *CA Cancer J Clin* 61, 69-90 (2011).
2. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. *Nature* 411, 366-74 (2001).
3. Frankenberg-Schwager, M. & Frankenberg, D. DNA double-strand breaks: their repair and relationship to cell killing in yeast. *Int J Radiat Biol* 58, 569-75 (1990).
4. Georgakilas, A. G. Processing of DNA damage clusters in human cells: current status of knowledge. *Mol Biosyst* 4, 30-5 (2008).
5. Sage, E. & Harrison, L. Clustered DNA lesion repair in eukaryotes: relevance to mutagenesis and cell survival. *Mutat Res* 711, 123-33 (2011).
6. Bensimon, A., Aebersold, R. & Shiloh, Y. Beyond ATM: the protein kinase landscape of the DNA damage response. *FEBS Lett* 585, 1625-39 (2011).
7. Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. *Mol Cell* 40, 179-204 (2010).
8. Giglia-Mari, G., Zotter, A. & Vermeulen, W. DNA damage response. *Cold Spring Harb Perspect Biol* 3, a000745 (2011).
9. Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. *Nature* 461, 1071-8 (2009).
10. Ljungman, M. The DNA damage response--repair or despair? *Environ Mol Mutagen* 51, 879-89 (2010).
11. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 316, 1160-6 (2007).
12. d'Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. *Nature* 426, 194-8 (2003).
13. Toledo, L. I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signaling can drive cells into senescence in the absence of DNA breaks. *Genes Dev* 22, 297-302 (2008).
14. Zhang, Y. et al. The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. *Adv Immunol* 106, 93-133 (2010).
15. de Jager, M. et al. Human Rad50/Mre11 is a flexible complex that can tether DNA ends. *Mol Cell* 8, 1129-35 (2001).
16. D'Silva, I. et al. Relative affinities of poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. *Biochim Biophys Acta* 1430, 119-26 (1999).
17. Gottlieb, T. M. & Jackson, S. P. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. *Cell* 72, 131-42 (1993).
18. Van Dyck, E., Stasiak, A. Z., Stasiak, A. & West, S. C. Binding of double-strand breaks in DNA by human Rad52 protein. *Nature* 398, 728-31 (1999).
19. Cheng, Q. et al. Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. *Nucleic Acids Res* 39, 9605-19 (2011).
20. Wang, M. et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. *Nucleic Acids Res* 34, 6170-82 (2006).
21. Sun, J., Lee, K. J., Davis, A. J. & Chen, D. J. Human Ku70/80 Protein Blocks Exonuclease 1-mediated DNA Resection in the Presence of Human Mre11 or Mre11/Rad50 Protein Complex. *J Biol Chem* 287, 4936-45 (2012).
22. Bell, O., Tiwari, V. K., Thoma, N. H. & Schubeler, D. Determinants and dynamics of genome accessibility. *Nat Rev Genet* 12, 554-64 (2011).
23. Greenberg, R. A. Histone tails: Directing the chromatin response to DNA damage. *FEBS Lett* 585, 2883-90 (2011).
24. van Attikum, H. & Gasser, S. M. Crosstalk between histone modifications during the DNA damage response. *Trends Cell Biol* 19, 207-17 (2009).
25. Osley, M. A., Tsukuda, T. & Nickoloff, J. A. ATP-dependent chromatin remodeling factors and DNA damage repair. *Mutat Res* 618, 65-80 (2007).
26. Schar, P. & Fritsch, O. DNA repair and the control of DNA methylation. *Prog Drug Res* 67, 51-68 (2011).
27. Groth, A., Rocha, W., Verreault, A. & Almouzni, G. Chromatin challenges during DNA replication and repair. *Cell* 128, 721-33 (2007).
28. Hamilton, C., Hayward, R. L. & Gilbert, N. Global chromatin fibre compaction in response to DNA damage. *Biochem Biophys Res Commun* 414, 820-5 (2011).

29. Kruhlak, M. J. et al. Changes in chromatin structure and mobility in living cells at sites of DNA double-strand breaks. *J Cell Biol* 172, 823-34 (2006).
30. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. *Nature* 421, 499-506 (2003).
31. Savic, V., Sanborn, K. B., Orange, J. S. & Bassing, C. H. Chipping away at gamma-H2AX foci. *Cell Cycle* 8, 3285-90 (2009).
32. Ayoub, N., Jeyasekharan, A. D., Bernal, J. A. & Venkitaraman, A. R. Paving the way for H2AX phosphorylation: chromatin changes in the DNA damage response. *Cell Cycle* 8, 1494-500 (2009).
33. Sun, Y., Jiang, X. & Price, B. D. Tip60: connecting chromatin to DNA damage signaling. *Cell Cycle* 9, 930-6 (2010).
34. Kim, Y. C. et al. Activation of ATM depends on chromatin interactions occurring before induction of DNA damage. *Nat Cell Biol* 11, 92-6 (2009).
35. Paull, T. T. et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. *Curr Biol* 10, 886-95 (2000).
36. Lee, H. S., Park, J. H., Kim, S. J., Kwon, S. J. & Kwon, J. A cooperative activation loop among SWI/SNF, gamma-H2AX and H3 acetylation for DNA double-strand break repair. *EMBO J* 29, 1434-45 (2010).
37. Berkovich, E., Monnat, R. J., Jr. & Kastan, M. B. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. *Nat Cell Biol* 9, 683-90 (2007).
38. Peng, G. et al. BRIT1/MCPH1 links chromatin remodelling to DNA damage response. *Nat Cell Biol* 11, 865-72 (2009).
39. Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. *J Cell Biol* 146, 905-16 (1999).
40. Falck, J., Coates, J. & Jackson, S. P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. *Nature* 434, 605-11 (2005).
41. Huen, M. S. et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. *Cell* 131, 901-14 (2007).
42. Mailand, N. et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. *Cell* 131, 887-900 (2007).
43. Yan, J. & Jetten, A. M. RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. *Cancer Lett* 271, 179-90 (2008).
44. Kolas, N. K. et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. *Science* 318, 1637-40 (2007).
45. Xu, Y. & Price, B. D. Chromatin dynamics and the repair of DNA double strand breaks. *Cell Cycle* 10, 261-7 (2011).
46. Botuyan, M. V. et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. *Cell* 127, 1361-73 (2006).
47. Huyen, Y. et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. *Nature* 432, 406-11 (2004).
48. Pei, H. et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. *Nature* 470, 124-8 (2011).
49. Wakeman, T. P., Wang, Q., Feng, J. & Wang, X. F. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. *EMBO J* (2012).
50. Acs, K. et al. The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. *Nat Struct Mol Biol* 18, 1345-50 (2011).
51. Mallette, F. A. et al. RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. *EMBO J* (2012).
52. Sy, S. M., Chen, J. & Huen, M. S. The 53BP1-EXPAND1 connection in chromatin structure regulation. *Nucleus* 1, 472-4 (2010).
53. Goodarzi, A. A., Kurka, T. & Jeggo, P. A. KAP-1 phosphorylation regulates CHD3 nucleosome remodeling during the DNA double-strand break response. *Nat Struct Mol Biol* 18, 831-9 (2011).
54. Ziv, Y. et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. *Nat Cell Biol* 8, 870-6 (2006).
55. Bauerschmidt, C. et al. Cohesin phosphorylation and mobility of SMC1 at ionizing radiation-induced DNA double-strand breaks in human cells. *Exp Cell Res* 317, 330-7 (2011).
56. Kim, B. J. et al. Genome-wide reinforcement of cohesin binding at pre-existing cohesin sites in response to ionizing radiation in human cells. *J Biol Chem* 285, 22784-92 (2010).

57. Kim, S. T., Xu, B. & Kastan, M. B. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. *Genes Dev* 16, 560-70 (2002).
58. Yazdi, P. T. et al. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. *Genes Dev* 16, 571-82 (2002).
59. Falk, M., Lukasova, E., Gabrielova, B., Ondrej, V. & Kozubek, S. Chromatin dynamics during DSB repair. *Biochim Biophys Acta* 1773, 1534-45 (2007).
60. Jakob, B., Splinter, J. & Taucher-Scholz, G. Positional stability of damaged chromatin domains along radiation tracks in mammalian cells. *Radiat Res* 171, 405-18 (2009).
61. Soutoglou, E. et al. Positional stability of single double-strand breaks in mammalian cells. *Nat Cell Biol* 9, 675-82 (2007).
62. Shiloh, Y., Shema, E., Moyal, L. & Oren, M. RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response. *FEBS Lett* 585, 2795-802 (2011).
63. Nakamura, K. et al. Regulation of homologous recombination by RNF20-dependent H2B ubiquitination. *Mol Cell* 41, 515-28 (2011).
64. Moyal, L. et al. Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. *Mol Cell* 41, 529-42 (2011).
65. Ogiwara, H. et al. Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. *Oncogene* 30, 2135-46 (2011).
66. Miller, K. M. et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. *Nat Struct Mol Biol* 17, 1144-51 (2010).
67. Rouleau, M., Aubin, R. A. & Poirier, G. G. Poly(ADP-ribosyl)ated chromatin domains: access granted. *J Cell Sci* 117, 815-25 (2004).
68. Chou, D. M. et al. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. *Proc Natl Acad Sci U S A* 107, 18475-80 (2010).
69. Polo, S. E., Kaidi, A., Baskcomb, L., Galanty, Y. & Jackson, S. P. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. *EMBO J* 29, 3130-9 (2010).
70. Ahel, D. et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. *Science* 325, 1240-3 (2009).
71. Lan, L. et al. The ACF1 complex is required for DNA double-strand break repair in human cells. *Mol Cell* 40, 976-87 (2010).
72. Facchino, S., Abdouh, M., Chatoos, W. & Bernier, G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. *J Neurosci* 30, 10096-111 (2010).
73. Yin, D. T. et al. Germline stem cell gene PIWIL2 mediates DNA repair through relaxation of chromatin. *PLoS One* 6, e27154 (2011).
74. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K. & Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu Rev Biochem* 73, 39-85 (2004).
75. Clarke, P. R. & Allan, L. A. Cell-cycle control in the face of damage--a matter of life or death. *Trends Cell Biol* 19, 89-98 (2009).
76. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 444, 756-60 (2006).
77. Didier, C. et al. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. *Oncogene* 27, 3811-20 (2008).
78. Garrett, M. D. & Collins, I. Anticancer therapy with checkpoint inhibitors: what, where and when? *Trends Pharmacol Sci* 32, 308-16.
79. Ma, C. X., Janetka, J. W. & Pivnicka-Worms, H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. *Trends Mol Med* 17, 88-96 (2011).
80. Bartek, J. & Lukas, J. Pathways governing G1/S transition and their response to DNA damage. *FEBS Lett* 490, 117-22 (2001).
81. Beckerman, R. & Prives, C. Transcriptional regulation by p53. *Cold Spring Harb Perspect Biol* 2, a000935 (2010).
82. Riley, T., Sontag, E., Chen, P. & Levine, A. Transcriptional control of human p53-regulated genes. *Nat Rev Mol Cell Biol* 9, 402-12 (2008).
83. Zhang, H. Molecular signaling and genetic pathways of senescence: Its role in tumorigenesis and aging. *J Cell Physiol* 210, 567-74 (2007).

84. Junttila, M. R. & Evan, G. I. p53--a Jack of all trades but master of none. *Nat Rev Cancer* 9, 821-9 (2009).
85. Segurado, M. & Tercero, J. A. The S-phase checkpoint: targeting the replication fork. *Biol Cell* 101, 617-27 (2009).
86. Zegerman, P. & Diffley, J. F. DNA replication as a target of the DNA damage checkpoint. *DNA Repair (Amst)* 8, 1077-88 (2009).
87. Flynn, R. L. & Zou, L. ATR: a master conductor of cellular responses to DNA replication stress. *Trends Biochem Sci* 36, 133-40 (2011).
88. Chini, C. C. & Chen, J. Claspin, a regulator of Chk1 in DNA replication stress pathway. *DNA Repair (Amst)* 3, 1033-7 (2004).
89. Lam, M. H. & Rosen, J. M. Chk1 versus Cdc25: chking one's levels of cellular proliferation. *Cell Cycle* 3, 1355-7 (2004).
90. Mordes, D. A. & Cortez, D. Activation of ATR and related PIKKs. *Cell Cycle* 7, 2809-12 (2008).
91. Navadgi-Patil, V. M. & Burgers, P. M. Cell-cycle-specific activators of the Mec1/ATR checkpoint kinase. *Biochem Soc Trans* 39, 600-5 (2011).
92. Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* 300, 1542-8 (2003).
93. Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? *Nat Rev Cancer* 7, 495-507 (2007).
94. Lindqvist, A., Rodriguez-Bravo, V. & Medema, R. H. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. *J Cell Biol* 185, 193-202 (2009).
95. Taylor, W. R. & Stark, G. R. Regulation of the G2/M transition by p53. *Oncogene* 20, 1803-15 (2001).
96. Thornton, T. M. & Rincon, M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. *Int J Biol Sci* 5, 44-51 (2009).
97. Reinhardt, H. C. & Yaffe, M. B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. *Curr Opin Cell Biol* 21, 245-55 (2009).
98. Bahassi el, M. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. *Exp Biol Med (Maywood)* 236, 648-57 (2011).
99. Hirose, Y., Katayama, M., Mirzoeva, O. K., Berger, M. S. & Pieper, R. O. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. *Cancer Res* 65, 4861-9 (2005).
100. King, F. W., Skeen, J., Hay, N. & Shtivelman, E. Inhibition of Chk1 by activated PKB/Akt. *Cell Cycle* 3, 634-7 (2004).
101. Mikhailov, A., Patel, D., McCance, D. J. & Rieder, C. L. The G2 p38-mediated stress-activated checkpoint pathway becomes attenuated in transformed cells. *Curr Biol* 17, 2162-8 (2007).
102. Takaki, T., Trenz, K., Costanzo, V. & Petronczki, M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. *Curr Opin Cell Biol* 20, 650-60 (2008).
103. Xu, N. et al. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. *J Cell Biol* 190, 297-305 (2010).
104. Chin, C. F. & Yeong, F. M. Safeguarding entry into mitosis: the antephase checkpoint. *Mol Cell Biol* 30, 22-32 (2010).
105. Mikhailov, A., Shinohara, M. & Rieder, C. L. The p38-mediated stress-activated checkpoint. A rapid response system for delaying progression through antephase and entry into mitosis. *Cell Cycle* 4, 57-62 (2005).
106. Damelin, M. & Bestor, T. H. The decatenation checkpoint. *Br J Cancer* 96, 201-5 (2007).
107. Skoufias, D. A., Lacroix, F. B., Andreassen, P. R., Wilson, L. & Margolis, R. L. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. *Mol Cell* 15, 977-90 (2004).
108. Matsusaka, T. & Pines, J. Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells. *J Cell Biol* 166, 507-16 (2004).
109. Hendzel, M. J. et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. *Chromosoma* 106, 348-60 (1997).
110. Musacchio, A. & Salmon, E. D. The spindle-assembly checkpoint in space and time. *Nat Rev Mol Cell Biol* 8, 379-93 (2007).
111. Nezi, L. & Musacchio, A. Sister chromatid tension and the spindle assembly checkpoint. *Curr Opin Cell Biol* 21, 785-95 (2009).

112. van Leuken, R., Clijsters, L. & Wolthuis, R. To cell cycle, swing the APC/C. *Biochim Biophys Acta* 1786, 49-59 (2008).
113. Nicholson, J. M. & Cimini, D. How mitotic errors contribute to karyotypic diversity in cancer. *Adv Cancer Res* 112, 43-75 (2011).
114. Wang, X., Cheung, H. W., Chun, A. C., Jin, D. Y. & Wong, Y. C. Mitotic checkpoint defects in human cancers and their implications to chemotherapy. *Front Biosci* 13, 2103-14 (2008).
115. Andreassen, P. R., Lohez, O. D. & Margolis, R. L. G2 and spindle assembly checkpoint adaptation, and tetraploidy arrest: implications for intrinsic and chemically induced genomic instability. *Mutat Res* 532, 245-53 (2003).
116. Rieder, C. L. & Maiato, H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. *Dev Cell* 7, 637-51 (2004).
117. Rossio, V., Galati, E. & Piatti, S. Adapt or die: how eukaryotic cells respond to prolonged activation of the spindle assembly checkpoint. *Biochem Soc Trans* 38, 1645-9 (2010).
118. Bekier, M. E., Fischbach, R., Lee, J. & Taylor, W. R. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. *Mol Cancer Ther* 8, 1646-54 (2009).
119. Blagosklonny, M. V. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. *Cell Cycle* 6, 70-4 (2007).
120. Huang, H. C., Shi, J., Orth, J. D. & Mitchison, T. J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. *Cancer Cell* 16, 347-58 (2009).
121. Bartek, J. & Lukas, J. DNA damage checkpoints: from initiation to recovery or adaptation. *Curr Opin Cell Biol* 19, 238-45 (2007).
122. Clemenson, C. & Marsolier-Kergoat, M. C. DNA damage checkpoint inactivation: adaptation and recovery. *DNA Repair (Amst)* 8, 1101-9 (2009).
123. Harrison, J. C. & Haber, J. E. Surviving the breakup: the DNA damage checkpoint. *Annu Rev Genet* 40, 209-35 (2006).
124. Medema, R. H. & Macurek, L. Checkpoint control and cancer. *Oncogene* (2011).
125. Medema, R. H. & Macurek, L. Checkpoint recovery in cells: how a molecular understanding can help in the fight against cancer. *F1000 Biol Rep* 3, 10 (2011).
126. Chowdhury, D. et al. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. *Mol Cell* 20, 801-9 (2005).
127. Douglas, P. et al. Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates gamma-H2AX. *Mol Cell Biol* 30, 1368-81 (2010).
128. Moon, S. H., Nguyen, T. A., Darlington, Y., Lu, X. & Donehower, L. A. Dephosphorylation of gamma-H2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control. *Cell Cycle* 9, 2092-6 (2010).
129. Nakada, S., Chen, G. I., Gingras, A. C. & Durocher, D. PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint. *EMBO Rep* 9, 1019-26 (2008).
130. Battu, A., Ray, A. & Wani, A. A. ASF1A and ATM regulate H3K56-mediated cell-cycle checkpoint recovery in response to UV irradiation. *Nucleic Acids Res* 39, 7931-45 (2011).
131. Chen, C. C. et al. Acetylated lysine 56 on histone H3 drives chromatin assembly after repair and signals for the completion of repair. *Cell* 134, 231-43 (2008).
132. Macurek, L. et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. *Nature* 455, 119-23 (2008).
133. Mailand, N., Bekker-Jensen, S., Bartek, J. & Lukas, J. Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. *Mol Cell* 23, 307-18 (2006).
134. Mamely, I. et al. Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. *Curr Biol* 16, 1950-5 (2006).
135. Alvarez-Fernandez, M., Medema, R. H. & Lindqvist, A. Transcriptional regulation underlying recovery from a DNA damage-induced arrest. *Transcription* 1, 32-35.
136. Mannefeld, M., Klassen, E. & Gaubatz, S. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. *Cancer Res* 69, 4073-80 (2009).
137. Syljuasen, R. G. Checkpoint adaptation in human cells. *Oncogene* 26, 5833-9 (2007).
138. Galgoczy, D. J. & Toczyski, D. P. Checkpoint adaptation precedes spontaneous and damage-induced genomic instability in yeast. *Mol Cell Biol* 21, 1710-8 (2001).
139. Syljuasen, R. G., Jensen, S., Bartek, J. & Lukas, J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. *Cancer Res* 66, 10253-7 (2006).

140. Strebhardt, K. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. *Nat Rev Cancer* 6, 321-30 (2006).
141. Lieber, M. R. The mechanism of human nonhomologous DNA end joining. *J Biol Chem* 283, 1-5 (2008).
142. San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous recombination. *Annu Rev Biochem* 77, 229-57 (2008).
143. Allen, C., Kurimasa, A., Brenneman, M. A., Chen, D. J. & Nickoloff, J. A. DNA-dependent protein kinase suppresses double-strand break-induced and spontaneous homologous recombination. *Proc Natl Acad Sci U S A* 99, 3758-63 (2002).
144. Frank-Vaillant, M. & Marcand, S. Transient stability of DNA ends allows nonhomologous end joining to precede homologous recombination. *Mol Cell* 10, 1189-99 (2002).
145. Kim, J. S. et al. Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells. *J Cell Biol* 170, 341-7 (2005).
146. Rapp, A. & Greulich, K. O. After double-strand break induction by UV-A, homologous recombination and nonhomologous end joining cooperate at the same DSB if both systems are available. *J Cell Sci* 117, 4935-45 (2004).
147. Perrault, R., Wang, H., Wang, M., Rosidi, B. & Iliakis, G. Backup pathways of NHEJ are suppressed by DNA-PK. *J Cell Biochem* 92, 781-94 (2004).
148. Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. *Embo J* 20, 4704-16 (2001).
149. Walker, J. R., Corpina, R. A. & Goldberg, J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. *Nature* 412, 607-14 (2001).
150. DeFazio, L. G., Stansel, R. M., Griffith, J. D. & Chu, G. Synapsis of DNA ends by DNA-dependent protein kinase. *Embo J* 21, 3192-200 (2002).
151. Weterings, E., Verkaik, N. S., Bruggenwirth, H. T., Hoeijmakers, J. H. & van Gent, D. C. The role of DNA dependent protein kinase in synapsis of DNA ends. *Nucleic Acids Res* 31, 7238-46 (2003).
152. Weterings, E. & Chen, D. J. DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys? *J Cell Biol* 179, 183-6 (2007).
153. Kurimasa, A. et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. *Mol Cell Biol* 19, 3877-84 (1999).
154. Lieber, M. R., Lu, H., Gu, J. & Schwarz, K. Flexibility in the order of action and in the enzymology of the nuclease, polymerases, and ligase of vertebrate non-homologous DNA end joining: relevance to cancer, aging, and the immune system. *Cell Res* 18, 125-33 (2008).
155. Roberts, S. A. et al. Ku is a 5'-dRP/AP lyase that excises nucleotide damage near broken ends. *Nature* 464, 1214-7 (2010).
156. Schellenberg, M. J. & Williams, R. S. DNA end processing by polynucleotide kinase/phosphatase. *Proc Natl Acad Sci U S A* 108, 20855-6 (2011).
157. Calsou, P. et al. The DNA-dependent protein kinase catalytic activity regulates DNA end processing by means of Ku entry into DNA. *J Biol Chem* 274, 7848-56 (1999).
158. Yoo, S. & Dynan, W. S. Geometry of a complex formed by double strand break repair proteins at a single DNA end: recruitment of DNA-PKcs induces inward translocation of Ku protein. *Nucleic Acids Res* 27, 4679-86 (1999).
159. Gu, J. & Lieber, M. R. Mechanistic flexibility as a conserved theme across 3 billion years of nonhomologous DNA end-joining. *Genes Dev* 22, 411-5 (2008).
160. Mari, P. O. et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. *Proc Natl Acad Sci U S A* 103, 18597-602 (2006).
161. Uematsu, N. et al. Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. *J Cell Biol* 177, 219-29 (2007).
162. Feng, L. & Chen, J. The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. *Nat Struct Mol Biol* 19, 201-6 (2012).
163. Postow, L. et al. Ku80 removal from DNA through double strand break-induced ubiquitylation. *J Cell Biol* 182, 467-79 (2008).
164. Merkle, D. et al. The DNA-dependent protein kinase interacts with DNA to form a protein-DNA complex that is disrupted by phosphorylation. *Biochemistry* 41, 12706-14 (2002).
165. Langerak, P., Mejia-Ramirez, E., Limbo, O. & Russell, P. Release of Ku and MRN from DNA ends by Mre11 nuclease activity and Ctp1 is required for homologous recombination repair of double-strand breaks. *PLoS Genet* 7, e1002271 (2011).
166. Wang, H., Perrault, A. R., Takeda, Y., Qin, W. & Iliakis, G. Biochemical evidence for Ku-independent backup pathways of NHEJ. *Nucleic Acids Res* 31, 5377-88 (2003).

167. Bennardo, N., Cheng, A., Huang, N. & Stark, J. M. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. *PLoS Genet* 4, e1000110 (2008).
168. Mansour, W. Y., Rhein, T. & Dahm-Daphi, J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. *Nucleic Acids Res* 38, 6065-77 (2010).
169. McVey, M. & Lee, S. E. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. *Trends Genet* 24, 529-38 (2008).
170. Audebert, M., Salles, B. & Calsou, P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. *J Biol Chem* 279, 55117-26 (2004).
171. Della-Maria, J. et al. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. *J Biol Chem* 286, 33845-53 (2011).
172. Fattah, F. et al. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. *PLoS Genet* 6, e1000855 (2010).
173. Neal, J. A. & Meek, K. Choosing the right path: Does DNA-PK help make the decision? *Mutat Res* 711, 73-86.
174. Sallmyr, A., Tomkinson, A. E. & Rassool, F. V. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. *Blood* 112, 1413-23 (2008).
175. Simsek, D. et al. DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. *PLoS Genet* 7, e1002080 (2011).
176. Zha, S., Boboila, C. & Alt, F. W. Mre11: roles in DNA repair beyond homologous recombination. *Nat Struct Mol Biol* 16, 798-800 (2009).
177. Zhang, Y. & Jasin, M. An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway. *Nat Struct Mol Biol* 18, 80-4 (2011).
178. Ferguson, D. O. et al. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. *Proc Natl Acad Sci U S A* 97, 6630-3 (2000).
179. Lieber, M. R. NHEJ and its backup pathways in chromosomal translocations. *Nat Struct Mol Biol* 17, 393-5 (2010).
180. Nussenzweig, A. & Nussenzweig, M. C. A backup DNA repair pathway moves to the forefront. *Cell* 131, 223-5 (2007).
181. Heyer, W. D., Ehmsen, K. T. & Liu, J. Regulation of homologous recombination in eukaryotes. *Annu Rev Genet* 44, 113-39 (2010).
182. Huertas, P. DNA resection in eukaryotes: deciding how to fix the break. *Nat Struct Mol Biol* 17, 11-6 (2010).
183. Longhese, M. P., Bonetti, D., Manfrini, N. & Clerici, M. Mechanisms and regulation of DNA end resection. *EMBO J* 29, 2864-74 (2010).
184. Mimitou, E. P. & Symington, L. S. DNA end resection: many nucleases make light work. *DNA Repair (Amst)* 8, 983-95 (2009).
185. Huertas, P. & Jackson, S. P. Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. *J Biol Chem* 284, 9558-65 (2009).
186. Shao, Z. et al. Persistently bound Ku at DNA ends attenuates DNA end resection and homologous recombination. *DNA Repair (Amst)* 11, 310-6 (2012).
187. Zhang, Y., Shim, E. Y., Davis, M. & Lee, S. E. Regulation of repair choice: Cdk1 suppresses recruitment of end joining factors at DNA breaks. *DNA Repair (Amst)* 8, 1235-41 (2009).
188. Holthausen, J. T., Wyman, C. & Kanaar, R. Regulation of DNA strand exchange in homologous recombination. *DNA Repair (Amst)* 9, 1264-72 (2010).
189. Holloman, W. K. Unraveling the mechanism of BRCA2 in homologous recombination. *Nat Struct Mol Biol* 18, 748-54 (2011).
190. Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. *Nat Rev Mol Cell Biol* 11, 196-207 (2010).
191. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat Rev Cancer* 12, 68-78 (2012).
192. Suwaki, N., Klare, K. & Tarsounas, M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. *Semin Cell Dev Biol* 22, 898-905 (2011).
193. Nimonkar, A. V. & Kowalczykowski, S. C. Second-end DNA capture in double-strand break repair: how to catch a DNA by its tail. *Cell Cycle* 8, 1816-7 (2009).

194. Mazin, A. V., Mazina, O. M., Bugreev, D. V. & Rossi, M. J. Rad54, the motor of homologous recombination. *DNA Repair (Amst)* 9, 286-302 (2010).
195. Klein, H. L. & Symington, L. S. Breaking up just got easier to do. *Cell* 138, 20-2 (2009).
196. West, S. C. The search for a human Holliday junction resolvase. *Biochem Soc Trans* 37, 519-26 (2009).
197. Llorente, B., Smith, C. E. & Symington, L. S. Break-induced replication: what is it and what is it for? *Cell Cycle* 7, 859-64 (2008).
198. Andreassen, P. R. & Ren, K. Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. *Curr Cancer Drug Targets* 9, 101-17 (2009).
199. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. *Nat Rev Cancer* 11, 467-80.
200. Muniandy, P. A., Liu, J., Majumdar, A., Liu, S. T. & Seidman, M. M. DNA interstrand crosslink repair in mammalian cells: step by step. *Crit Rev Biochem Mol Biol* 45, 23-49.
201. de Winter, J. P. & Joenje, H. The genetic and molecular basis of Fanconi anemia. *Mutat Res* 668, 11-9 (2009).
202. Pichierri, P. & Rosselli, F. Fanconi anemia proteins and the s phase checkpoint. *Cell Cycle* 3, 698-700 (2004).
203. Thompson, L. H. & Hinz, J. M. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. *Mutat Res* 668, 54-72 (2009).
204. Moldovan, G. L. & D'Andrea, A. D. How the fanconi anemia pathway guards the genome. *Annu Rev Genet* 43, 223-49 (2009).
205. Garner, E. & Smogorzewska, A. Ubiquitylation and the Fanconi anemia pathway. *FEBS Lett* 585, 2853-60.
206. Kee, Y. & D'Andrea, A. D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. *Genes Dev* 24, 1680-94.
207. Rego, M. A., Kolling, F. W. t. & Howlett, N. G. The Fanconi anemia protein interaction network: casting a wide net. *Mutat Res* 668, 27-41 (2009).
208. Maddika, S. et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. *Drug Resist Updat* 10, 13-29 (2007).
209. Ropolo, M. et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. *Mol Cancer Res* 7, 383-92 (2009).
210. Nahas, S. A. & Gatti, R. A. DNA double strand break repair defects, primary immunodeficiency disorders, and 'radiosensitivity'. *Curr Opin Allergy Clin Immunol* 9, 510-6 (2009).
211. Fung, H. & Weinstock, D. M. Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. *PLoS One* 6, e20514.
212. Maynard, S. et al. Human embryonic stem cells have enhanced repair of multiple forms of DNA damage. *Stem Cells* 26, 2266-74 (2008).
213. Saretzki, G. et al. Downregulation of multiple stress defense mechanisms during differentiation of human embryonic stem cells. *Stem Cells* 26, 455-64 (2008).
214. De Milito, A. & Fais, S. Tumor acidity, chemoresistance and proton pump inhibitors. *Future Oncol* 1, 779-86 (2005).
215. Shinohara, E. T. & Maity, A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. *Curr Mol Med* 9, 1034-45 (2009).
216. El-Deiry, W. S. The role of p53 in chemosensitivity and radiosensitivity. *Oncogene* 22, 7486-95 (2003).
217. Engelmann, D. & Putzer, B. M. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. *Drug Resist Updat* 13, 119-31 (2010).
218. Abe, T. et al. KU70/80, DNA-PKcs, and Artemis are essential for the rapid induction of apoptosis after massive DSB formation. *Cell Signal* 20, 1978-85 (2008).
219. Biton, S. & Ashkenazi, A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. *Cell* 145, 92-103.
220. Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q. & Thompson, C. B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev* 18, 1272-82 (2004).
221. Shinomiya, N. New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'. *J Cell Mol Med* 5, 240-53 (2001).
222. Deckbar, D., Jeggo, P. A. & Lobrich, M. Understanding the limitations of radiation-induced cell cycle checkpoints. *Crit Rev Biochem Mol Biol* 46, 271-83 (2011).

223. van Vugt, M. A. & Yaffe, M. B. Cell cycle re-entry mechanisms after DNA damage checkpoints: giving it some gas to shut off the breaks! *Cell Cycle* 9, 2097-101.
224. Roos, W. P. & Kaina, B. DNA damage-induced cell death by apoptosis. *Trends Mol Med* 12, 440-50 (2006).
225. Vakifahmetoglu, H., Olsson, M. & Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. *Cell Death Differ* 15, 1153-62 (2008).
226. Rodriguez-Rocha, H., Garcia-Garcia, A., Panayiotidis, M. I. & Franco, R. DNA damage and autophagy. *Mutat Res* 711, 158-66.
227. Paglin, S. et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. *Cancer Res* 61, 439-44 (2001).
228. Abedin, M. J., Wang, D., McDonnell, M. A., Lehmann, U. & Kelekar, A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. *Cell Death Differ* 14, 500-10 (2007).
229. Puig, P. E. et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. *Cell Biol Int* 32, 1031-43 (2008).
230. Illidge, T. M., Cragg, M. S., Fringes, B., Olive, P. & Erenpreisa, J. A. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. *Cell Biol Int* 24, 621-33 (2000).
231. Katayama, M., Kawaguchi, T., Berger, M. S. & Pieper, R. O. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. *Cell Death Differ* 14, 548-58 (2007).
232. Shay, J. W. & Wright, W. E. Role of telomeres and telomerase in cancer. *Semin Cancer Biol* 21, 349-53 (2011).
233. Amaravadi, R. K. & Thompson, C. B. The roles of therapy-induced autophagy and necrosis in cancer treatment. *Clin Cancer Res* 13, 7271-9 (2007).
234. Beausejour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. *Embo J* 22, 4212-22 (2003).
235. Gonzalez-Polo, R. A. et al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. *J Cell Sci* 118, 3091-102 (2005).
236. Chen, Y., McMillan-Ward, E., Kong, J., Israels, S. J. & Gibson, S. B. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. *Cell Death Differ* 15, 171-82 (2008).
237. Di, X., Shiu, R. P., Newsham, I. F. & Gewirtz, D. A. Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to adriamycin. *Biochem Pharmacol* 77, 1139-50 (2009).
238. Eom, Y. W. et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. *Oncogene* 24, 4765-77 (2005).
239. Tounekti, O., Pron, G., Belehradec, J., Jr. & Mir, L. M. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. *Cancer Res* 53, 5462-9 (1993).
240. Vakifahmetoglu, H. et al. DNA damage induces two distinct modes of cell death in ovarian carcinomas. *Cell Death Differ* 15, 555-66 (2008).
241. Galluzzi, L. et al. Cell death modalities: classification and pathophysiological implications. *Cell Death Differ* 14, 1237-43 (2007).
242. Galluzzi, L. et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death Differ* 19, 107-20 (2012).
243. Kumar, S. Caspase function in programmed cell death. *Cell Death Differ* 14, 32-43 (2007).
244. Mace, P. D. & Riedl, S. J. Molecular cell death platforms and assemblies. *Curr Opin Cell Biol* 22, 828-36 (2010).
245. Pop, C. & Salvesen, G. S. Human caspases: activation, specificity, and regulation. *J Biol Chem* 284, 21777-81 (2009).
246. Crawford, E. D. & Wells, J. A. Caspase substrates and cellular remodeling. *Annu Rev Biochem* 80, 1055-87 (2011).
247. Fischer, U., Janicke, R. U. & Schulze-Osthoff, K. Many cuts to ruin: a comprehensive update of caspase substrates. *Cell Death Differ* 10, 76-100 (2003).
248. Guicciardi, M. E. & Gores, G. J. Life and death by death receptors. *FASEB J* 23, 1625-37 (2009).
249. Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. *Physiol Rev* 87, 99-163 (2007).

250. Tait, S. W. & Green, D. R. Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat Rev Mol Cell Biol* 11, 621-32 (2010).
251. Kantari, C. & Walczak, H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. *Biochim Biophys Acta* 1813, 558-63 (2011).
252. Wieder, T. et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. *Blood* 97, 1378-87 (2001).
253. Ferri, K. F. & Kroemer, G. Organelle-specific initiation of cell death pathways. *Nat Cell Biol* 3, E255-63 (2001).
254. Terman, A., Kurz, T., Gustafsson, B. & Brunk, U. T. Lysosomal labilization. *IUBMB Life* 58, 531-9 (2006).
255. Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. *Oncogene* 27, 6434-51 (2008).
256. Vandenamee, P., Orrenius, S. & Zhivotovsky, B. Serine proteases and calpains fulfill important supporting roles in the apoptotic tragedy of the cellular opera. *Cell Death Differ* 12, 1219-24 (2005).
257. Bouchier-Hayes, L. & Green, D. R. Caspase-2: the orphan caspase. *Cell Death Differ* 19, 51-7 (2012).
258. Kitevska, T., Spencer, D. M. & Hawkins, C. J. Caspase-2: controversial killer or checkpoint controller? *Apoptosis* 14, 829-48 (2009).
259. Krumschnabel, G., Sohm, B., Bock, F., Manzl, C. & Villunger, A. The enigma of caspase-2: the laymen's view. *Cell Death Differ* 16, 195-207 (2009).
260. Kumar, S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? *Nat Rev Cancer* 9, 897-903 (2009).
261. Vakifahmetoglu-Norberg, H. & Zhivotovsky, B. The unpredictable caspase-2: what can it do? *Trends Cell Biol* 20, 150-9 (2010).
262. Bagnoli, M., Canevari, S. & Mezzanzanica, D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. *Int J Biochem Cell Biol* 42, 210-3 (2010).
263. Chipuk, J. E. & Green, D. R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? *Trends Cell Biol* 18, 157-64 (2008).
264. Duronio, V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. *Biochem J* 415, 333-44 (2008).
265. Vousden, K. H. & Prives, C. Blinded by the Light: The Growing Complexity of p53. *Cell* 137, 413-31 (2009).
266. Green, D. R. & Kroemer, G. Cytoplasmic functions of the tumour suppressor p53. *Nature* 458, 1127-30 (2009).
267. Vaseva, A. V. & Moll, U. M. The mitochondrial p53 pathway. *Biochim Biophys Acta* 1787, 414-20 (2009).
268. Delavallee, L., Cabon, L., Galan-Malo, P., Lorenzo, H. K. & Susin, S. A. AIF-mediated caspase-independent necroptosis: a new chance for targeted therapeutics. *IUBMB Life* 63, 221-32 (2011).
269. Tu, H. C. et al. The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. *Proc Natl Acad Sci U S A* 106, 1093-8 (2009).
270. Vandenamee, P., Declercq, W., Van Herreweghe, F. & Vandenberghe, T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. *Sci Signal* 3, re4 (2010).
271. Berghe, T. V. et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. *Cell Death Differ* 17, 922-30 (2010).
272. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. *Oncogene* 23, 2825-37 (2004).
273. Castedo, M. et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. *Oncogene* 23, 4353-61 (2004).
274. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W. & Vogelstein, B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. *Nature* 401, 616-20 (1999).
275. Castedo, M. et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. *Oncogene* 23, 4362-70 (2004).
276. Erenpreisa, J. & Cragg, M. S. MOS, aneuploidy and the ploidy cycle of cancer cells. *Oncogene* 29, 5447-51 (2010).
277. Salmina, K. et al. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. *Exp Cell Res* 316, 2099-112 (2010).

278. Ianzini, F. et al. Activation of meiosis-specific genes is associated with depolyploidization of human tumor cells following radiation-induced mitotic catastrophe. *Cancer Res* 69, 2296-304 (2009).
279. Rajaraman, R., Guernsey, D. L., Rajaraman, M. M. & Rajaraman, S. R. Stem cells, senescence, neosis and self-renewal in cancer. *Cancer Cell Int* 6, 25 (2006).
280. Mansilla, S., Bataller, M. & Portugal, J. A nuclear budding mechanism in transiently arrested cells generates drug-sensitive and drug-resistant cells. *Biochem Pharmacol* 78, 123-32 (2009).
281. Erenpreisa, J. et al. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. *Cell Biol Int* 35, 687-95 (2011).
282. He, C. & Klionsky, D. J. Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet* 43, 67-93 (2009).
283. Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. *Cell* 132, 27-42 (2008).
284. Ravikumar, B. et al. Regulation of mammalian autophagy in physiology and pathophysiology. *Physiol Rev* 90, 1383-435 (2010).
285. Kroemer, G., Marino, G. & Levine, B. Autophagy and the integrated stress response. *Mol Cell* 40, 280-93 (2010).
286. Kanzawa, T. et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. *Cell Death Differ* 11, 448-57 (2004).
287. Lee, S. B., Tong, S. Y., Kim, J. J., Um, S. J. & Park, J. S. Caspase-independent autophagic cytotoxicity in etoposide-treated CaSki cervical carcinoma cells. *DNA Cell Biol* 26, 713-20 (2007).
288. Notte, A., Leclere, L. & Michiels, C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. *Biochem Pharmacol* 82, 427-34 (2011).
289. Fimia, G. M. & Piacentini, M. Regulation of autophagy in mammals and its interplay with apoptosis. *Cell Mol Life Sci* 67, 1581-8 (2010).
290. Yu, L. et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. *Science* 304, 1500-2 (2004).
291. Pattingre, S. et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* 122, 927-39 (2005).
292. Kang, R., Zeh, H. J., Lotze, M. T. & Tang, D. The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ* 18, 571-80 (2011).
293. Kimmelman, A. C. The dynamic nature of autophagy in cancer. *Genes Dev* 25, 1999-2010 (2011).
294. Mathew, R. & White, E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. *Curr Opin Genet Dev* 21, 113-9 (2011).
295. Janku, F., McConkey, D. J., Hong, D. S. & Kurzrock, R. Autophagy as a target for anticancer therapy. *Nat Rev Clin Oncol* 8, 528-39 (2011).
296. Chen, S. et al. Autophagy is a therapeutic target in anticancer drug resistance. *Biochim Biophys Acta* 1806, 220-9 (2010).
297. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A* 92, 9363-7 (1995).
298. Aubert, G. & Lansdorp, P. M. Telomeres and aging. *Physiol Rev* 88, 557-79 (2008).
299. Palm, W. & de Lange, T. How shelterin protects mammalian telomeres. *Annu Rev Genet* 42, 301-34 (2008).
300. Ju, Z. & Rudolph, K. L. Telomeres and telomerase in stem cells during aging and disease. *Genome Dyn* 1, 84-103 (2006).
301. Hayflick, L. The Limited in Vitro Lifetime of Human Diploid Cell Strains. *Exp Cell Res* 37, 614-36 (1965).
302. Cesare, A. J. & Reddel, R. R. Alternative lengthening of telomeres: models, mechanisms and implications. *Nat Rev Genet* 11, 319-30 (2010).
303. Chang, B. D. et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. *Cancer Res* 59, 3761-7 (1999).
304. Gewirtz, D. A., Holt, S. E. & Elmore, L. W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. *Biochem Pharmacol* 76, 947-57 (2008).
305. Mallette, F. A. & Ferbeyre, G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. *Cell Cycle* 6, 1831-6 (2007).
306. Chang, B. D. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. *Oncogene* 18, 4808-18 (1999).
307. Chang, B. D. et al. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. *Proc Natl Acad Sci U S A* 99, 389-94 (2002).

308. McDuff, F. K. & Turner, S. D. Jailbreak: oncogene-induced senescence and its evasion. *Cell Signal* 23, 6-13 (2011).
309. Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. *Nat Rev Cancer* 10, 51-7 (2010).
310. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. *Cell* 109, 335-46 (2002).
311. Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S. Y. & Wu, D. Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. *Cancer Res* 65, 2795-803 (2005).
312. Campisi, J. Cellular senescence: putting the paradoxes in perspective. *Curr Opin Genet Dev* 21, 107-12 (2011).
313. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. *Science* 319, 1352-5 (2008).
314. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* 434, 864-70 (2005).
315. Di Micco, R. et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 444, 638-42 (2006).
316. Bartek, J., Lukas, J. & Bartkova, J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. *Cell Cycle* 6, 2344-7 (2007).
317. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability--an evolving hallmark of cancer. *Nat Rev Mol Cell Biol* 11, 220-8 (2010).
318. Nuciforo, P. G., Luise, C., Capra, M., Pelosi, G. & d'Adda di Fagagna, F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. *Carcinogenesis* 28, 2082-8 (2007).
319. O'Driscoll, M. Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders. *Curr Genomics* 9, 137-46 (2008).
320. Antoni, L., Sodha, N., Collins, I. & Garrett, M. D. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? *Nat Rev Cancer* 7, 925-36 (2007).
321. Richardson, C. RAD51, genomic stability, and tumorigenesis. *Cancer Lett* 218, 127-39 (2005).
322. Gossage, L. & Madhusudan, S. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. *Mol Diagn Ther* 11, 361-80 (2007).
323. Ralhan, R., Kaur, J., Kreienberg, R. & Wiesmuller, L. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. *Cancer Lett* 248, 1-17 (2007).
324. Thacker, J. The RAD51 gene family, genetic instability and cancer. *Cancer Lett* 219, 125-35 (2005).
325. Friedenson, B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. *BMC Cancer* 7, 152 (2007).
326. Gorbunova, V., Seluanov, A., Mao, Z. & Hine, C. Changes in DNA repair during aging. *Nucleic Acids Res* 35, 7466-74 (2007).
327. Lavin, M. F. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. *Nat Rev Mol Cell Biol* 9, 759-69 (2008).
328. O'Driscoll, M., Gennery, A. R., Seidel, J., Concannon, P. & Jeggo, P. A. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. *DNA Repair (Amst)* 3, 1227-35 (2004).
329. Antoccia, A., Kobayashi, J., Tauchi, H., Matsuura, S. & Komatsu, K. Nijmegen breakage syndrome and functions of the responsible protein, NBS1. *Genome Dyn* 1, 191-205 (2006).
330. Taylor, A. M., Groom, A. & Byrd, P. J. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. *DNA Repair (Amst)* 3, 1219-25 (2004).
331. Varley, J. TP53, hChk2, and the Li-Fraumeni syndrome. *Methods Mol Biol* 222, 117-29 (2003).
332. D'Andrea, A. D. Susceptibility pathways in Fanconi's anemia and breast cancer. *N Engl J Med* 362, 1909-19.
333. Nusbaum, R., Vogel, K. J. & Ready, K. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. *Breast Dis* 27, 21-50 (2006).
334. Pennington, K. P. & Swisher, E. M. Hereditary ovarian cancer: beyond the usual suspects. *Gynecol Oncol* 124, 347-53.
335. O'Driscoll, M., Jackson, A. P. & Jeggo, P. A. Microcephalin: a causal link between impaired damage response signalling and microcephaly. *Cell Cycle* 5, 2339-44 (2006).
336. van der Burg, M., van Dongen, J. J. & van Gent, D. C. DNA-PKcs deficiency in human: long predicted, finally found. *Curr Opin Allergy Clin Immunol* 9, 503-9 (2009).

337. Revy, P., Malivert, L. & de Villartay, J. P. Cernunnos-XLF, a recently identified non-homologous end-joining factor required for the development of the immune system. *Curr Opin Allergy Clin Immunol* 6, 416-20 (2006).
338. Stewart, G. S. Solving the RIDDLE of 53BP1 recruitment to sites of damage. *Cell Cycle* 8, 1532-8 (2009).
339. Bernstein, K. A., Gangloff, S. & Rothstein, R. The RecQ DNA helicases in DNA repair. *Annu Rev Genet* 44, 393-417.
340. Bentley, J., Diggle, C. P., Harnden, P., Knowles, M. A. & Kiltie, A. E. DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. *Nucleic Acids Res* 32, 5249-59 (2004).
341. Windhofer, F., Krause, S., Hader, C., Schulz, W. A. & Florl, A. R. Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. *Mutat Res* 638, 56-65 (2008).
342. Penserga, E. T. & Skorski, T. Fusion tyrosine kinases: a result and cause of genomic instability. *Oncogene* 26, 11-20 (2007).
343. Sallmyr, A., Fan, J. & Rassool, F. V. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. *Cancer Lett* 270, 1-9 (2008).
344. Shamma, M. A. et al. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. *Blood* 113, 2290-7 (2009).
345. Yang, C., Betti, C., Singh, S., Toor, A. & Vaughan, A. Impaired NHEJ function in multiple myeloma. *Mutat Res* 660, 66-73 (2009).
346. Klein, H. L. The consequences of Rad51 overexpression for normal and tumor cells. *DNA Repair (Amst)* 7, 686-93 (2008).
347. Reliene, R., Bishop, A. J. & Schiestl, R. H. Involvement of homologous recombination in carcinogenesis. *Adv Genet* 58, 67-87 (2007).
348. Salles, D., Menciaha, A. L., Ireno, I. C., Wiesmuller, L. & Abdelhay, E. BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP. *Carcinogenesis* 32, 27-34.
349. Slupianek, A. et al. BCR/ABL stimulates WRN to promote survival and genomic instability. *Cancer Res* 71, 842-51.
350. Chan, N., Koch, C. J. & Bristow, R. G. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. *Curr Mol Med* 9, 401-10 (2009).
351. Rai, R. et al. The function of classical and alternative non-homologous end-joining pathways in the fusion of dysfunctional telomeres. *Embo J* 29, 2598-610.
352. Al-Ejeh, F. et al. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. *Oncogene* 29, 6085-98.
353. Darzynkiewicz, Z., Traganos, F. & Wlodkowic, D. Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. *Eur J Pharmacol* 625, 143-50 (2009).
354. Shin, A. et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. *Asian Pac J Cancer Prev* 9, 501-5 (2008).
355. Roddam, P. L. et al. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. *Br J Haematol* 149, 258-62.
356. Takeyama, K. et al. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. *Oncogene* 27, 318-22 (2008).
357. Willmore, E. et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. *Clin Cancer Res* 14, 3984-92 (2008).
358. Pucci, S. et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. *Oncogene* 20, 739-47 (2001).
359. Maacke, H. et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. *Int J Cancer* 88, 907-13 (2000).
360. Martin, R. W. et al. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. *Cancer Res* 67, 9658-65 (2007).
361. Beskow, C. et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. *Br J Cancer* 101, 816-21 (2009).
362. Noguchi, T. et al. DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. *Ann Surg Oncol* 9, 1017-22 (2002).

363. Hall, M. D., Okabe, M., Shen, D. W., Liang, X. J. & Gottesman, M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. *Annu Rev Pharmacol Toxicol* 48, 495-535 (2008).
364. Sharom, F. J. ABC multidrug transporters: structure, function and role in chemoresistance. *Pharmacogenomics* 9, 105-27 (2008).
365. Landriscina, M., Maddalena, F., Laudiero, G. & Esposito, F. Adaptation to oxidative stress, chemoresistance, and cell survival. *Antioxid Redox Signal* 11, 2701-16 (2009).
366. Larsen, A. K., Escargueil, A. E. & Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. *Pharmacol Ther* 85, 217-29 (2000).
367. McKinnon, P. J. & Caldecott, K. W. DNA strand break repair and human genetic disease. *Annu Rev Genomics Hum Genet* 8, 37-55 (2007).
368. O'Driscoll, M. & Jeggo, P. A. The role of double-strand break repair - insights from human genetics. *Nat Rev Genet* 7, 45-54 (2006).
369. Felip, E. & Rosell, R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. *Expert Rev Mol Diagn* 7, 261-8 (2007).
370. Miyagawa, K. Clinical relevance of the homologous recombination machinery in cancer therapy. *Cancer Sci* 99, 187-94 (2008).
371. Kaina, B., Christmann, M., Naumann, S. & Roos, W. P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. *DNA Repair (Amst)* 6, 1079-99 (2007).
372. Muller, C., Christodoulopoulos, G., Salles, B. & Panasci, L. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. *Blood* 92, 2213-9 (1998).
373. Chen, Q., Van der Sluis, P. C., Boulware, D., Hazlehurst, L. A. & Dalton, W. S. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. *Blood* 106, 698-705 (2005).
374. Spanswick, V. J. et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. *Blood* 100, 224-9 (2002).
375. Pirker, R. & Minar, W. Chemotherapy of advanced non-small cell lung cancer. *Front Radiat Ther Oncol* 42, 157-63 (2010).
376. Meyn, R. E., Munshi, A., Haymach, J. V., Milas, L. & Ang, K. K. Receptor signaling as a regulatory mechanism of DNA repair. *Radiother Oncol* 92, 316-22 (2009).
377. Mukherjee, B., Choy, H., Nirodi, C. & Burma, S. Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. *Semin Radiat Oncol* 20, 250-7 (2010).
378. Schild, D. & Wiese, C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. *Nucleic Acids Res* 38, 1061-70 (2010).
379. Cosaceanu, D. et al. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. *Oncogene* 26, 2423-34 (2007).
380. Boone, J. J., Bhosle, J., Tilby, M. J., Hartley, J. A. & Hochhauser, D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. *Mol Cancer Ther* 8, 3015-23 (2009).
381. Liccardi, G., Hartley, J. A. & Hochhauser, D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. *Cancer Res* 71, 1103-14.
382. Schulte, J. H. et al. Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells. *DNA Repair (Amst)* 7, 1757-64 (2008).
383. De Bacco, F. et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. *J Natl Cancer Inst* 103, 645-61 (2011).
384. Viktorsson, K., Lewensohn, R. & Zhivotovsky, B. Apoptotic pathways and therapy resistance in human malignancies. *Adv Cancer Res* 94, 143-96 (2005).
385. Plati, J., Bucur, O. & Khosravi-Far, R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. *J Cell Biochem* 104, 1124-49 (2008).
386. Okouoyo, S. et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. *Int J Cancer* 108, 580-7 (2004).
387. Rogers, K. M. et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. *Mol Cancer Ther* 6, 1544-51 (2007).

388. Erler, J. T. et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. *Mol Cell Biol* 24, 2875-89 (2004).
389. Viktorsson, K. et al. Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. *Exp Cell Res* 289, 256-64 (2003).
390. Ji, M. et al. Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. *Br J Haematol* 145, 648-56 (2009).
391. Lestini, B. J. et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. *Cancer Biol Ther* 8, 1587-95 (2009).
392. Hsu, H. S. et al. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. *Cancer* 117, 1516-28.
393. Tokunaga, E. et al. Deregulation of the Akt pathway in human cancer. *Curr Cancer Drug Targets* 8, 27-36 (2008).
394. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* 144, 646-74 (2011).
395. Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. *Nat Rev Cancer* 8, 180-92 (2008).
396. O'Brien, C. A., Kreso, A. & Dick, J. E. Cancer stem cells in solid tumors: an overview. *Semin Radiat Oncol* 19, 71-7 (2009).
397. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 8, 755-68 (2008).
398. Eramo, A. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ* 15, 504-14 (2008).
399. Keysar, S. B. & Jimeno, A. More than markers: biological significance of cancer stem cell-defining molecules. *Mol Cancer Ther* 9, 2450-7 (2010).
400. Kashyap, V. et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. *Stem Cells Dev* 18, 1093-108 (2009).
401. Bertolini, G. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci U S A* 106, 16281-6 (2009).
402. Gallmeier, E. et al. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. *Stem Cells* 29, 418-29 (2011).
403. Blanpain, C., Mohrin, M., Sotiropoulou, P. A. & Passegue, E. DNA-damage response in tissue-specific and cancer stem cells. *Cell Stem Cell* 8, 16-29.
404. Burness, M. L. & Sipkins, D. A. The stem cell niche in health and malignancy. *Semin Cancer Biol* 20, 107-15 (2010).
405. Li, L. & Bhatia, R. Stem cell quiescence. *Clin Cancer Res* 17, 4936-41 (2011).
406. Saito, Y. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. *Nat Biotechnol* 28, 275-80 (2010).
407. Linke, S. P., Clarkin, K. C., Di Leonardo, A., Tsou, A. & Wahl, G. M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. *Genes Dev* 10, 934-47 (1996).
408. Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer* 9, 265-73 (2009).
409. Floor, S., van Staveren, W. C., Larsimont, D., Dumont, J. E. & Maenhaut, C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. *Oncogene* 30, 4609-21 (2011).
410. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene* 29, 4741-51 (2010).
411. Hsu, D. S. et al. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. *Clin Cancer Res* 16, 4561-71 (2010).
412. Soussi, T. p53 alterations in human cancer: more questions than answers. *Oncogene* 26, 2145-56 (2007).
413. Chari, N. S. et al. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. *Apoptosis* 14, 336-47 (2009).
414. Chen, T., Stephens, P. A., Middleton, F. K. & Curtin, N. J. Targeting the S and G2 checkpoint to treat cancer. *Drug Discov Today*.
415. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. *Mol Cancer Ther* 3, 513-9 (2004).

416. Nojima, K. et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. *Cancer Res* 65, 11704-11 (2005).
417. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 434, 913-7 (2005).
418. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 434, 917-21 (2005).
419. Patel, A. G., Sarkaria, J. N. & Kaufmann, S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. *Proc Natl Acad Sci U S A* 108, 3406-11.
420. Aly, A. & Ganesan, S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. *J Mol Cell Biol* 3, 66-74.
421. Wang, W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. *Nat Rev Genet* 8, 735-48 (2007).
422. Rehman, F. L., Lord, C. J. & Ashworth, A. Synthetic lethal approaches to breast cancer therapy. *Nat Rev Clin Oncol* 7, 718-24.
423. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. *Cancer Cell* 19, 664-78.
424. Neri, P. et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. *Blood* 118, 6368-79.
425. Lord, C. J., McDonald, S., Swift, S., Turner, N. C. & Ashworth, A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. *DNA Repair (Amst)* 7, 2010-9 (2008).
426. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. *EMBO Mol Med* 1, 315-22 (2009).
427. Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. *Embo J* 27, 1368-77 (2008).
428. Boulton, S., Kyle, S. & Durkacz, B. W. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. *Carcinogenesis* 20, 199-203 (1999).
429. Salles, B., Calsou, P., Frit, P. & Muller, C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. *Pathol Biol (Paris)* 54, 185-93 (2006).
430. Cowell, I. G., Durkacz, B. W. & Tilby, M. J. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. *Biochem Pharmacol* 71, 13-20 (2005).
431. Davidson, D. et al. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. *Invest New Drugs*.
432. Deriano, L. et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. *Blood* 105, 4776-83 (2005).
433. Elliott, S. L. et al. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. *Br J Haematol* 152, 61-71.
434. Kashishian, A. et al. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. *Mol Cancer Ther* 2, 1257-64 (2003).
435. Shaheen, F. S. et al. Targeting the DNA double strand break repair machinery in prostate cancer. *PLoS One* 6, e20311.
436. Willmore, E. et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. *Blood* 103, 4659-65 (2004).
437. Zhao, Y. et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. *Cancer Res* 66, 5354-62 (2006).
438. Nutley, B. P. et al. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. *Br J Cancer* 93, 1011-8 (2005).
439. Tavecchio, M., Munck, J. M., Cano, C., Newell, D. R. & Curtin, N. J. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. *Cancer Chemother Pharmacol* 69, 155-64.
440. Devun, F. et al. Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. *J Gastroenterol* (2011).

441. Quanz, M. et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. *Clin Cancer Res* 15, 1308-16 (2009).
442. Wechsler, T. et al. DNA-PKcs function regulated specifically by protein phosphatase 5. *Proc Natl Acad Sci U S A* 101, 1247-52 (2004).
443. Shen, W. W. A history of antipsychotic drug development. *Compr Psychiatry* 40, 407-14 (1999).
444. Axelrod, R. S. Antiemetic therapy. *Compr Ther* 23, 539-45 (1997).
445. Allan, S. G. Mechanisms and management of chemotherapy-induced nausea and vomiting. *Blood Rev* 1, 50-7 (1987).
446. Viola, G. & Dall'Acqua, F. Photosensitization of biomolecules by phenothiazine derivatives. *Curr Drug Targets* 7, 1135-54 (2006).
447. Kato, M. M. & Goodnick, P. J. Antipsychotic medication: effects on regulation of glucose and lipids. *Expert Opin Pharmacother* 2, 1571-82 (2001).
448. Wirshing, W. C. Movement disorders associated with neuroleptic treatment. *J Clin Psychiatry* 62 Suppl 21, 15-8 (2001).
449. Flanagan, R. J. & Dunk, L. Haematological toxicity of drugs used in psychiatry. *Hum Psychopharmacol* 23 Suppl 1, 27-41 (2008).
450. Pelonero, A. L., Levenson, J. L. & Pandurangi, A. K. Neuroleptic malignant syndrome: a review. *Psychiatr Serv* 49, 1163-72 (1998).
451. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov* 3, 353-9 (2004).
452. Diamandis, P. et al. Chemical genetics reveals a complex functional ground state of neural stem cells. *Nat Chem Biol* 3, 268-73 (2007).
453. Crumb, W. J., Jr. et al. Effects of antipsychotic drugs on I(to), I(Na), I(sus), I(K1), and hERG: QT prolongation, structure activity relationship, and network analysis. *Pharm Res* 23, 1133-43 (2006).
454. Kim, K. S. & Kim, E. J. The phenothiazine drugs inhibit hERG potassium channels. *Drug Chem Toxicol* 28, 303-13 (2005).
455. Chen, S. Z., Jiang, M. & Zhen, Y. S. HERG K⁺ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. *Cancer Chemother Pharmacol* 56, 212-20 (2005).
456. Jehle, J., Schweizer, P. A., Katus, H. A. & Thomas, D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. *Cell Death Dis* 2, e193.
457. Robey, R. W., Massey, P. R., Amiri-Kordestani, L. & Bates, S. E. ABC transporters: unvalidated therapeutic targets in cancer and the CNS. *Anticancer Agents Med Chem* 10, 625-33.
458. Tsuruo, T., Iida, H., Tsukagoshi, S. & Sakurai, Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. *Cancer Res* 42, 4730-3 (1982).
459. Tsakovska, I. & Pajeva, I. Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. *Curr Drug Targets* 7, 1123-34 (2006).
460. Burgio, D. E., Gosland, M. P. & McNamara, P. J. Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. *J Pharmacol Exp Ther* 287, 911-7 (1998).
461. Marques-Santos, L. F., Bernardo, R. R., de Paula, E. F. & Rumjanek, V. M. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. *Pharmacol Toxicol* 84, 125-9 (1999).
462. Arboix, M., Paz, O. G., Colombo, T. & D'Incalci, M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. *J Pharmacol Exp Ther* 281, 1226-30 (1997).
463. Raschko, J. W. et al. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. *Cancer Chemother Pharmacol* 46, 403-10 (2000).
464. Sridhar, K. S. et al. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. *Cancer Chemother Pharmacol* 34, 377-84 (1994).
465. Budd, G. T. et al. Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. *Invest New Drugs* 11, 75-9 (1993).
466. Murren, J. R. et al. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. *Cancer Chemother Pharmacol* 38, 65-70 (1996).

467. Schroder, L. E., Blumenstein, B. A., Flanigan, R. L., Borst, J. R. & David Crawford, E. Phase II evaluation of doxorubicin/vinblastine combined with inhibitors trifluoperazine/verapamil of P-glycoprotein in patients with advanced renal carcinoma. *Urol Oncol* 3, 94-8 (1997).
468. Abad, A. et al. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group. *Eur J Cancer* 30A, 1043 (1994).
469. Bisi, A. et al. Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives. *Bioorg Med Chem* 16, 6474-82 (2008).
470. Schmidt, M. et al. Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents. *Arch Pharm (Weinheim)* 341, 624-38 (2008).
471. Kristiansen, J. E. et al. Reversal of resistance in microorganisms by help of non-antibiotics. *J Antimicrob Chemother* 59, 1271-9 (2007).
472. Sharma, S. & Singh, A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. *Expert Opin Investig Drugs* 20, 1665-76.
473. Hait, W. N. & Lazo, J. S. Calmodulin: a potential target for cancer chemotherapeutic agents. *J Clin Oncol* 4, 994-1012 (1986).
474. Hait, W. N. & Lee, G. L. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. *Biochem Pharmacol* 34, 3973-8 (1985).
475. Aftab, D. T., Ballas, L. M., Loomis, C. R. & Hait, W. N. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. *Mol Pharmacol* 40, 798-805 (1991).
476. Marshak, D. R., Watterson, D. M. & Van Eldik, L. J. Calcium-dependent interaction of S100b, troponin C, and calmodulin with an immobilized phenothiazine. *Proc Natl Acad Sci U S A* 78, 6793-7 (1981).
477. Michalak, K., Wesolowska, O., Motohashi, N., Molnar, J. & Hendrich, A. B. Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. *Curr Drug Targets* 7, 1095-105 (2006).
478. Suwalsky, M., Villena, F., Sotomayor, C. P., Bolognin, S. & Zatta, P. Human cells and cell membrane molecular models are affected in vitro by chlorpromazine. *Biophys Chem* 135, 7-13 (2008).
479. Drori, S., Eytan, G. D. & Assaraf, Y. G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. *Eur J Biochem* 228, 1020-9 (1995).
480. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* 313, 1929-35 (2006).
481. Wiklund, E. D. et al. Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. *Int J Cancer* 126, 28-40.
482. DiPaola, M., Keith, C. H., Feldman, D., Tycko, B. & Maxfield, F. R. Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides. *J Cell Physiol* 118, 193-202 (1984).
483. Sengupta, P. et al. Membrane-permeable calmodulin inhibitors (e.g. W-7/W-13) bind to membranes, changing the electrostatic surface potential: dual effect of W-13 on epidermal growth factor receptor activation. *J Biol Chem* 282, 8474-86 (2007).
484. Eisenberg, S., Giehl, K., Henis, Y. I. & Ehrlich, M. Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth. *J Biol Chem* 283, 27279-88 (2008).
485. De Filippi, L. et al. Membrane stress is coupled to a rapid translational control of gene expression in chlorpromazine-treated cells. *Curr Genet* 52, 171-85 (2007).
486. Deloche, O., de la Cruz, J., Kressler, D., Doere, M. & Linder, P. A membrane transport defect leads to a rapid attenuation of translation initiation in *Saccharomyces cerevisiae*. *Mol Cell* 13, 357-66 (2004).
487. Elias, E. & Boyer, J. L. Chlorpromazine and its metabolites alter polymerization and gelation of actin. *Science* 206, 1404-6 (1979).
488. Osborn, M. & Weber, K. Damage of cellular functions by trifluoperazine, a calmodulin-specific drug. *Exp Cell Res* 130, 484-8 (1980).
489. Malashkevich, V. N. et al. Phenothiazines inhibit S100A4 function by inducing protein oligomerization. *Proc Natl Acad Sci U S A* 107, 8605-10.
490. Dairkee, S. H. et al. Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. *Cancer Res* 69, 7826-34 (2009).

491. Annabi, B., Pilorget, A., Bousquet-Gagnon, N., Gingras, D. & Beliveau, R. Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells. *Biochem J* 359, 325-33 (2001).
492. Grabski, R. et al. Inhibition of T-cell invasion across cultured fibroblast monolayers by phenothiazine-related calmodulin inhibitors: impairment of lymphocyte motility by trifluoperazine and chlorpromazine, and alteration of the monolayer by pimozide. *Biochem Pharmacol* 61, 1313-7 (2001).
493. Matthews, N., Franklin, R. J. & Kendrick, D. A. Structure-activity relationships of phenothiazines in inhibiting lymphocyte motility as determined by a novel flow cytometric assay. *Biochem Pharmacol* 50, 1053-61 (1995).
494. Kaufmann, A. M. & Krise, J. P. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. *J Pharm Sci* 96, 729-46 (2007).
495. Shih, C. K., Kwong, J., Montalvo, E. & Neff, N. Expression of a proteolipid gene from a high-copy-number plasmid confers trifluoperazine resistance to *Saccharomyces cerevisiae*. *Mol Cell Biol* 10, 3397-404 (1990).
496. Shih, C. K., Wagner, R., Feinstein, S., Kanik-Ennulat, C. & Neff, N. A dominant trifluoperazine resistance gene from *Saccharomyces cerevisiae* has homology with F0F1 ATP synthase and confers calcium-sensitive growth. *Mol Cell Biol* 8, 3094-103 (1988).
497. Poole, B. & Ohkuma, S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. *J Cell Biol* 90, 665-9 (1981).
498. Indelicato, M. et al. Role of hypoxia and autophagy in MDA-MB-231 invasiveness. *J Cell Physiol* 223, 359-68.
499. Zhang, L. et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. *Proc Natl Acad Sci U S A* 104, 19023-8 (2007).
500. Boya, P. et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. *Oncogene* 22, 3927-36 (2003).
501. Daniel, W. A. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. *Prog Neuropsychopharmacol Biol Psychiatry* 27, 65-73 (2003).
502. Glass-Marmor, L. & Beitner, R. Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists. *Eur J Pharmacol* 328, 241-8 (1997).
503. Polischouk, A. G. et al. The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death. *Mol Cancer Ther* 6, 2303-9 (2007).
504. Zong, D., Haag, P., Yakymovych, I., Lewensohn, R. & Viktorsson, K. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of gammaH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. *Cell Death Dis* 2, e181.
505. Ruben, L. & Rasmussen, H. Phenothiazines and related compounds disrupt mitochondrial energy production by a calmodulin-independent reaction. *Biochim Biophys Acta* 637, 415-22 (1981).
506. Rodrigues, T. et al. Thioridazine interacts with the membrane of mitochondria acquiring antioxidant activity toward apoptosis--potentially implicated mechanisms. *Br J Pharmacol* 136, 136-42 (2002).
507. Bastianon, C., Zanoni, R., Miolo, G., Caffieri, S. & Reddi, E. Mitochondria and plasma membrane as targets of UVA-induced toxicity of neuroleptic drugs fluphenazine, perphenazine and thioridazine. *Int J Biochem Cell Biol* 37, 901-8 (2005).
508. Borges, M. B. et al. Characterization of hydrophobic interaction and antioxidant properties of the phenothiazine nucleus in mitochondrial and model membranes. *Free Radic Res* 44, 1054-63.
509. Cruz, T. S. et al. On the mechanisms of phenothiazine-induced mitochondrial permeability transition: Thiol oxidation, strict Ca²⁺ dependence, and cyt c release. *Biochem Pharmacol* 80, 1284-95.
510. Liu, S., Han, Y., Zhang, T. & Yang, Z. Protective effect of trifluoperazine on hydrogen peroxide-induced apoptosis in PC12 cells. *Brain Res Bull* 84, 183-8.
511. Atamna, H. et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. *Faseb J* 22, 703-12 (2008).
512. Chen, Y. et al. Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics. *Cancer Sci* 99, 2019-27 (2008).
513. Stavrovskaya, I. G. et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. *J Exp Med* 200, 211-22 (2004).

514. Wainwright, M. & Crossley, K. B. Methylene Blue--a therapeutic dye for all seasons? *J Chemother* 14, 431-43 (2002).
515. Choi, J. H. et al. Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. *Ann N Y Acad Sci* 1138, 393-403 (2008).
516. Rho, S. B., Kim, B. R. & Kang, S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. *Gynecol Oncol* 120, 121-7.
517. Kau, T. R. et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. *Cancer Cell* 4, 463-76 (2003).
518. Ebi, H. et al. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. *Cancer Res* 69, 4027-35 (2009).
519. Koren, J., 3rd et al. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. *J Biol Chem* 285, 2498-505.
520. Chafouleas, J. G., Bolton, W. E., Hidaka, H., Boyd, A. E., 3rd & Means, A. R. Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression. *Cell* 28, 41-50 (1982).
521. Shin, S. Y., Kim, C. G., Hong, D. D., Kim, J. H. & Lee, Y. H. Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U87MG glioma cells. *Exp Mol Med* 36, 380-6 (2004).
522. Shin, S. Y. et al. Chlorpromazine activates p21Waf1/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells. *Exp Mol Med* 42, 395-405.
523. Boder, G. B., Paul, D. C. & Williams, D. C. Chlorpromazine inhibits mitosis of mammalian cells. *Eur J Cell Biol* 31, 349-53 (1983).
524. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. *Proc Natl Acad Sci U S A* 100, 7977-82 (2003).
525. Lee, M. S. et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. *Cancer Res* 67, 11359-67 (2007).
526. Okumura, H. et al. Phenothiazine and carbazole-related compounds inhibit mitotic kinesin Eg5 and trigger apoptosis in transformed culture cells. *Toxicol Lett* 166, 44-52 (2006).
527. Riffell, J. L., Zimmerman, C., Khong, A., McHardy, L. M. & Roberge, M. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. *Cell Cycle* 8, 3025-38 (2009).
528. Chafouleas, J. G., Bolton, W. E. & Means, A. R. Potentiation of bleomycin lethality by anticalmodulin drugs: a role for calmodulin in DNA repair. *Science* 224, 1346-8 (1984).
529. Charp, P. A. & Regan, J. D. Inhibition of DNA repair by trifluoperazine. *Biochim Biophys Acta* 824, 34-9 (1985).
530. Ori, Y. et al. Spontaneous DNA repair in human mononuclear cells is calcium-dependent. *Biochem Biophys Res Commun* 336, 842-6 (2005).
531. Du, Y. C. et al. The dynamic alterations of H2AX complex during DNA repair detected by a proteomic approach reveal the critical roles of Ca(2+)/calmodulin in the ionizing radiation-induced cell cycle arrest. *Mol Cell Proteomics* 5, 1033-44 (2006).
532. Yang, X. et al. Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma. *J Proteome Res* 9, 1402-15.
533. Smallwood, H. S., Lopez-Ferrer, D., Eberlein, P. E., Watson, D. J. & Squier, T. C. Calmodulin mediates DNA repair pathways involving H2AX in response to low-dose radiation exposure of RAW 264.7 macrophages. *Chem Res Toxicol* 22, 460-70 (2009).
534. Wang, Y., Mallya, S. M. & Sikpi, M. O. Calmodulin antagonists and cAMP inhibit ionizing-radiation-enhancement of double-strand-break repair in human cells. *Mutat Res* 460, 29-39 (2000).
535. Veigl, M. L., Klevit, R. E. & Sedwick, W. D. The uses and limitations of calmodulin antagonists. *Pharmacol Ther* 44, 181-239 (1989).
536. Hoff, S. F. & MacInnis, A. J. Ultrastructural localization of phenothiazines and tetracycline: a new histochemical approach. *J Histochem Cytochem* 31, 613-25 (1983).
537. Stefanis, C. N. & Issidorides, M. R. Short and long-term effects of neuroleptics in relation to their cellular mechanism of action. *Prog Neuropsychopharmacol* 3, 259-69 (1979).
538. Li, J. et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. *J Neurochem* 90, 1117-31 (2004).
539. De Preter, K. et al. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. *Clin Cancer Res* 15, 3690-6 (2009).

540. Harris, F., Chatfield, L. K. & Phoenix, D. A. Phenothiazinium based photosensitisers-- photodynamic agents with a multiplicity of cellular targets and clinical applications. *Curr Drug Targets* 6, 615-27 (2005).
541. Cohen, M. M., Lieber, E. & Schwartz, H. N. In-vivo cytogenetic effects of perphenazine and chlorpromazine: a negative study. *Br Med J* 3, 21-3 (1972).
542. Lialiaris, T. S., Papachristou, F., Mourelatos, C. & Simopoulou, M. Antineoplastic and cytogenetic effects of chlorpromazine on human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. *Anticancer Drugs* 20, 746-51 (2009).
543. Nielsen, J., Friedrich, U. & Tsuboi, T. Chromosome abnormalities in patients treated with chlorpromazine, perphenazine, and lysergide. *Br Med J* 3, 634-6 (1969).
544. Pantazaki, A. A. & Lialiaris, T. S. A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids. *Mutagenesis* 14, 243-8 (1999).
545. Mayer, M. & James, T. L. NMR-based characterization of phenothiazines as a RNA binding scaffold. *J Am Chem Soc* 126, 4453-60 (2004).
546. Pinto, I. G., Guilbert, C., Ulyanov, N. B., Stearns, J. & James, T. L. Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR. *J Med Chem* 51, 7205-15 (2008).
547. Motohashi, N., Kawase, M., Satoh, K. & Sakagami, H. Cytotoxic potential of phenothiazines. *Curr Drug Targets* 7, 1055-66 (2006).
548. Nordenberg, J., Fenig, E., Landau, M., Weizman, R. & Weizman, A. Effects of psychotropic drugs on cell proliferation and differentiation. *Biochem Pharmacol* 58, 1229-36 (1999).
549. Barak, Y., Achiron, A., Mandel, M., Mirecki, I. & Aizenberg, D. Reduced cancer incidence among patients with schizophrenia. *Cancer* 104, 2817-21 (2005).
550. Dalton, S. O. et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. *Br J Cancer* 95, 934-9 (2006).
551. Csatory, L. K. Chlorpromazines and cancer. *Lancet* 2, 338-9 (1972).
552. Herbergs, A. Thioridazine: a radiation enhancer in advanced cervical cancer? *Lancet* 2, 737 (1988).
553. Jones, G. R. Successful cancer therapy with promethazine: the rationale. *Med Hypotheses* 46, 25-9 (1996).
554. Chen, Q. Y. et al. Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. *Mol Med Report* 2, 811-7 (2009).
555. Wei, J. W., Hickie, R. A. & Klaassen, D. J. Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. *Cancer Chemother Pharmacol* 11, 86-90 (1983).
556. Strobl, J. S. et al. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. *Cancer Res* 50, 5399-405 (1990).
557. Gil-Ad, I. et al. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. *J Mol Neurosci* 22, 189-98 (2004).
558. Munyon, W. H., Salo, R. & Briones, D. F. Cytotoxic effects of neuroleptic drugs. *Psychopharmacology (Berl)* 91, 182-8 (1987).
559. Zhelev, Z. et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. *Phenothiazines and leukemia. Cancer Chemother Pharmacol* 53, 267-75 (2004).
560. Grief, F., Soroff, H. S., Albers, K. M. & Taichman, L. B. The effect of trifluoperazine, a calmodulin antagonist, on the growth of normal and malignant epidermal keratinocytes in culture. *Eur J Cancer Clin Oncol* 25, 19-26 (1989).
561. Karmakar, P., Natarajan, A. T., Poddar, R. K. & Dasgupta, U. B. Induction of apoptosis by Phenothiazine derivatives in V79 cells. *Toxicol Lett* 125, 19-28 (2001).
562. Borsa, J., Einspinner, M., Sargent, M. D. & Hickie, R. A. Selective cytotoxicity of calmidazolium and trifluoperazine for cycling versus noncycling C3H10T1/2 cells in vitro. *Cancer Res* 46, 133-6 (1986).
563. Perez, R. P., Handel, L. M. & Hamilton, T. C. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. *Gynecol Oncol* 46, 82-7 (1992).
564. Gangopadhyay, S., Karmakar, P., Dasgupta, U. & Chakraborty, A. Trifluoperazine stimulates ionizing radiation induced cell killing through inhibition of DNA repair. *Mutat Res* 633, 117-25 (2007).

565. Lazo, J. S., Chen, D. L., Gallicchio, V. S. & Hait, W. N. Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells. *Cancer Res* 46, 2236-40 (1986).
566. Yde, C. W. et al. The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. *Anticancer Drugs* 20, 723-35 (2009).
567. Frankfurt, O. S., Sugarbaker, E. V., Robb, J. A. & Villa, L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. *Cancer Lett* 97, 149-54 (1995).
568. Tzadok, S. et al. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. *Int J Oncol* 37, 1043-51.
569. Hwang, M. K., Min, Y. K. & Kim, S. H. Calmodulin inhibition contributes to sensitize TRAIL-induced apoptosis in human lung cancer H1299 cells. *Biochem Cell Biol* 87, 919-26 (2009).
570. Ahn, E. Y., Pan, G., Oh, J. H., Tytler, E. M. & McDonald, J. M. The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells. *Am J Pathol* 163, 2053-63 (2003).
571. Kennedy, K. A., Hait, W. N. & Lazo, J. S. Chemical modulation of bleomycin induced toxicity. *Int J Radiat Oncol Biol Phys* 12, 1367-70 (1986).
572. Lazo, J. S., Hait, W. N., Kennedy, K. A., Braun, I. D. & Meandzija, B. Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists. *Mol Pharmacol* 27, 387-93 (1985).
573. Karmakar, P., Dasgupta, U. B. & Poddar, R. K. Cytotoxic and genetic effects of X-irradiation of human cells in the presence of chlorpromazine. *Mutat Res* 321, 159-64 (1994).
574. Ishikawa, M., Ozaki, M., Takayanagi, Y. & Sasaki, K. Protection against cisplatin lethality and renal toxicity by chlorpromazine in mice. *Ren Fail* 16, 681-6 (1994).
575. Kramer, R. A. Protection against cisplatin nephrotoxicity by prochlorperazine. *Cancer Chemother Pharmacol* 25, 156-60 (1989).
576. Gailis, L. Protection against doxorubicin toxicity in mice by chlorpromazine hypothermia. *Res Commun Chem Pathol Pharmacol* 53, 319-30 (1986).
577. Nakashima, J. M., Hyde, D. M. & Giri, S. N. Effects of a calmodulin inhibitor on bleomycin-induced lung inflammation in hamsters. Biochemical, morphometric, and bronchoalveolar lavage data. *Am J Pathol* 124, 528-36 (1986).
578. Polliack, A. & Levij, I. S. Antineoplastic effect of chlorpromazine in chemical carcinogenesis in the hamster cheek pouch. *Cancer Res* 32, 1912-5 (1972).
579. Peak, M. J., Pfaff, M. & Peraino, C. Chlorpromazine reduces UV-induced squamous cell carcinogenesis in hairless mice and enhances UV-induced DNA damage in cultured cells. *Br J Cancer* 60, 220-2 (1989).
580. Tatsuta, M. et al. Inhibition by the calmodulin antagonist trifluoperazine of experimental hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. *Cancer Lett* 107, 179-85 (1996).
581. Dimova, S., Koleva, M., Rangelova, D. & Stoytchev, T. Effect of nifedipine, verapamil, diltiazem and trifluoperazine on acetaminophen toxicity in mice. *Arch Toxicol* 70, 112-8 (1995).
582. Yamamoto, H. Antagonism of acetaminophen-induced hepatocellular destruction by trifluoperazine in mice. *Pharmacol Toxicol* 67, 115-9 (1990).
583. Niewenhuis, R. J. & Prozialeck, W. C. Calmodulin inhibitors protect against cadmium-induced testicular damage in mice. *Biol Reprod* 37, 127-33 (1987).
584. Lee, Y. R. et al. A calcium-calmodulin antagonist blocks experimental *Vibrio vulnificus* cytolysin-induced lethality in an experimental mouse model. *Infect Immun* 72, 6157-9 (2004).
585. Hait, W. N., Lazo, J. S., Chen, D. L., Gallicchio, V. S. & Filderman, A. E. Antitumor and toxic effects of combination chemotherapy with bleomycin and a phenothiazine anticalmodulin agent. *J Natl Cancer Inst* 80, 246-50 (1988).
586. Onoda, J. M., Nelson, K. K., Taylor, J. D. & Honn, K. V. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). *Cancer Res* 49, 2844-50 (1989).
587. Gailis, L., Dumas, L. & Page, M. Ambiguous effect of chlorpromazine on doxorubicin activity against P388D1 tumours in mice. *Eur J Cancer Clin Oncol* 24, 169-73 (1988).
588. Hoshi, A., Kanzawa, F. & Kuretani, K. Antitumor activity of psychotropic drugs and their synergic action with cyclophosphamide. *Chem Pharm Bull (Tokyo)* 17, 848-50 (1969).
589. Cohen, M. H. Enhancement of the antitumor effect of 1,3-bis(2-chloroethyl)-1-nitrosourea by various psychotropic drugs in combination with caffeine. *J Pharmacol Exp Ther* 194, 475-9 (1975).

590. George, K. C. & Singh, B. B. Potentiation of radiation response of a mouse fibrosarcoma by phenothiazine drugs. *Indian J Exp Biol* 22, 305-7 (1984).
591. George, K. C., Srinivasan, V. T. & Singh, B. B. Cytotoxic effect of chlorpromazine and its interaction with radiation on a mouse fibrosarcoma. *Int J Radiat Biol Relat Stud Phys Chem Med* 38, 661-5 (1980).
592. Damsker, J. I., Macklis, R. & Brady, L. W. Radiosensitization of malignant melanoma--I. The effect of 7-hydroxy-chlorpromazine on the in vivo radiation response of Fortner's melanoma. *Int J Radiat Oncol Biol Phys* 4, 821-4 (1978).
593. Miller, R. L. et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. *J Clin Oncol* 6, 880-8 (1988).
594. Hait, W. N. et al. The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. *Cancer Res* 50, 6636-40 (1990).
595. Hait, W. N. et al. Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine. *Cancer Chemother Pharmacol* 23, 358-62 (1989).
596. McKelvey, E. M. et al. Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. *Cancer* 39, 5-10 (1977).
597. Cohen, M. H., Schoenfeld, D. & Wolter, J. Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. *Cancer Treat Rep* 64, 151-3 (1980).
598. Zakotnik, B. et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. *Int J Radiat Oncol Biol Phys* 41, 1121-7 (1998).
599. Moertel, C. G., Reitemeier, R. J. & Hahn, R. G. Effect of concomitant drug treatment on toxic and therapeutic activity of 5-fluorouracil (5-FU; NSC-19893). *Cancer Chemother Rep* 56, 245-7 (1972).
600. Bergh, J., Nilsson, K., Ekman, R. & Giovanella, B. Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung. *Acta Pathol Microbiol Immunol Scand A* 93, 133-47 (1985).
601. Umezawa, H., Maeda, K., Takeuchi, T. & Okami, Y. New antibiotics, bleomycin A and B. *J Antibiot (Tokyo)* 19, 200-9 (1966).
602. Elmroth, K., Nygren, J., Martensson, S., Ismail, I. H. & Hammarsten, O. Cleavage of cellular DNA by calicheamicin gamma1. *DNA Repair (Amst)* 2, 363-74 (2003).
603. Goodhead, D. T. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. *Int J Radiat Biol* 65, 7-17 (1994).
604. Chen, J. & Stubbe, J. Bleomycins: towards better therapeutics. *Nat Rev Cancer* 5, 102-12 (2005).
605. Dedon, P. C. & Goldberg, I. H. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. *Chem Res Toxicol* 5, 311-32 (1992).
606. Ward, J. F. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. *Prog Nucleic Acid Res Mol Biol* 35, 95-125 (1988).
607. Pastwa, E., Neumann, R. D. & Winters, T. A. In vitro repair of complex unligatable oxidatively induced DNA double-strand breaks by human cell extracts. *Nucleic Acids Res* 29, E78 (2001).
608. Frankenberg-Schwager, M. et al. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast *Saccharomyces cerevisiae*. *Toxicology* 212, 175-84 (2005).
609. Hanada, K. et al. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strand breaks. *EMBO J* 25, 4921-32 (2006).
610. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. *Nat Protoc* 1, 2315-9 (2006).
611. Endlich, B., Radford, I. R., Forrester, H. B. & Dewey, W. C. Computerized video time-lapse microscopy studies of ionizing radiation-induced rapid-interphase and mitosis-related apoptosis in lymphoid cells. *Radiat Res* 153, 36-48 (2000).
612. Herschleb, J., Ananiev, G. & Schwartz, D. C. Pulsed-field gel electrophoresis. *Nat Protoc* 2, 677-84 (2007).
613. Olive, P. L. & Banath, J. P. The comet assay: a method to measure DNA damage in individual cells. *Nat Protoc* 1, 23-9 (2006).
614. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. *J Biol Chem* 273, 5858-68 (1998).

615. An, J. et al. DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression. *BMC Mol Biol* 11, 18.
616. Burma, S., Chen, B. P., Murphy, M., Kurimasa, A. & Chen, D. J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. *J Biol Chem* 276, 42462-7 (2001).
617. Stiff, T. et al. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. *Cancer Res* 64, 2390-6 (2004).
618. Ward, I. M. & Chen, J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J Biol Chem* 276, 47759-62 (2001).
619. Tomimatsu, N., Mukherjee, B. & Burma, S. Distinct roles of ATR and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells. *EMBO Rep* 10, 629-35 (2009).
620. Wang, H., Wang, M., Wang, H., Bocker, W. & Iliakis, G. Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA-PK in human cells exposed to ionizing radiation and treated with kinase inhibitors. *J Cell Physiol* 202, 492-502 (2005).
621. Sedelnikova, O. A., Rogakou, E. P., Panyutin, I. G. & Bonner, W. M. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. *Radiat Res* 158, 486-92 (2002).
622. Ichijima, Y. et al. Phosphorylation of histone H2AX at M phase in human cells without DNA damage response. *Biochem Biophys Res Commun* 336, 807-12 (2005).
623. McManus, K. J. & Hendzel, M. J. ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells. *Mol Biol Cell* 16, 5013-25 (2005).
624. Ismail, I. H. & Hendzel, M. J. The gamma-H2A.X: is it just a surrogate marker of double-strand breaks or much more? *Environ Mol Mutagen* 49, 73-82 (2008).
625. Lu, C. et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. *Mol Cell* 23, 121-32 (2006).
626. Mukherjee, B. et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. *DNA Repair (Amst)* 5, 575-90 (2006).
627. Chan, D. W. et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. *Genes Dev* 16, 2333-8 (2002).
628. Bhatti, S. et al. ATM protein kinase: the linchpin of cellular defenses to stress. *Cell Mol Life Sci* 68, 2977-3006.
629. Ahn, J. Y., Schwarz, J. K., Piwnicka-Worms, H. & Canman, C. E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. *Cancer Res* 60, 5934-6 (2000).
630. Gatei, M. et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. *Nat Genet* 25, 115-9 (2000).
631. Lim, D. S. et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. *Nature* 404, 613-7 (2000).
632. Melchionna, R., Chen, X. B., Blasina, A. & McGowan, C. H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. *Nat Cell Biol* 2, 762-5 (2000).
633. Nusse, M., Beisker, W., Hoffmann, C. & Tarnok, A. Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. *Cytometry* 11, 813-21 (1990).
634. Marchion, D. C., Bicaku, E., Daud, A. I., Sullivan, D. M. & Munster, P. N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. *Cancer Res* 65, 3815-22 (2005).
635. Darzynkiewicz, Z. & Huang, X. Analysis of cellular DNA content by flow cytometry. *Curr Protoc Immunol Chapter 5, Unit 5 7* (2004).
636. Quah, B. J., Warren, H. S. & Parish, C. R. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. *Nat Protoc* 2, 2049-56 (2007).
637. Widlak, P. & Garrard, W. T. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. *J Cell Biochem* 94, 1078-87 (2005).
638. Gisselsson, D. Classification of chromosome segregation errors in cancer. *Chromosoma* 117, 511-9 (2008).
639. Fenech, M. et al. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. *Mutagenesis* 26, 125-32.
640. Hoffelder, D. R. et al. Resolution of anaphase bridges in cancer cells. *Chromosoma* 112, 389-97 (2004).

641. Henics, T. & Wheatley, D. N. Cytoplasmic vacuolation, adaptation and cell death: a view on new perspectives and features. *Biol Cell* 91, 485-98 (1999).
642. Sanchez-Alcazar, J. A., Ault, J. G., Khodjakov, A. & Schneider, E. Increased mitochondrial cytochrome c levels and mitochondrial hyperpolarization precede camptothecin-induced apoptosis in Jurkat cells. *Cell Death Differ* 7, 1090-100 (2000).
643. Ricci, J. E. et al. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. *Cell* 117, 773-86 (2004).
644. Schroder, B. A., Wrocklage, C., Hasilik, A. & Saftig, P. The proteome of lysosomes. *Proteomics* 10, 4053-76.
645. Zhao, M., Eaton, J. W. & Brunk, U. T. Bcl-2 phosphorylation is required for inhibition of oxidative stress-induced lysosomal leak and ensuing apoptosis. *FEBS Lett* 509, 405-12 (2001).
646. Hassane, D. C. et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. *Blood* 111, 5654-62 (2008).
647. Ishimatsu-Tsuji, Y., Soma, T. & Kishimoto, J. Identification of novel hair-growth inducers by means of connectivity mapping. *Faseb J* 24, 1489-96.
648. Li, J., Zhu, X. & Chen, J. Y. Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. *PLoS Comput Biol* 5, e1000450 (2009).
649. Lamb, J. The Connectivity Map: a new tool for biomedical research. *Nat Rev Cancer* 7, 54-60 (2007).
650. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102, 15545-50 (2005).
651. Belenkov, A. I., Paiement, J. P., Panasci, L. C., Monia, B. P. & Chow, T. Y. An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. *Cancer Res* 62, 5888-96 (2002).
652. Kim, S. H. et al. Ku autoantigen affects the susceptibility to anticancer drugs. *Cancer Res* 59, 4012-7 (1999).
653. Omori, S. et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. *DNA Repair (Amst)* 1, 299-310 (2002).
654. Eriksson, A., Yachnin, J., Lewensohn, R. & Nilsson, A. DNA-dependent protein kinase is inhibited by trifluoperazine. *Biochem Biophys Res Commun* 283, 726-31 (2001).
655. Banath, J. P. & Olive, P. L. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. *Cancer Res* 63, 4347-50 (2003).
656. Choi, K. H. et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. *BMC Psychiatry* 9, 57 (2009).
657. Ellis, L. et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. *Clin Cancer Res* 14, 4500-10 (2008).
658. Glaser, K. B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. *Mol Cancer Ther* 2, 151-63 (2003).
659. Haag, P. et al. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. *Exp Hematol* 37, 755-66 (2009).
660. Linenberger, M. L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. *Leukemia* 19, 176-82 (2005).
661. Chang, A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. *Lung Cancer* 71, 3-10.
662. Stronach, E. A. et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. *Neoplasia* 13, 1069-80.
663. Blazek, D. et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. *Genes Dev* 25, 2158-72.
664. Barlev, N. A. et al. Repression of GCN5 histone acetyltransferase activity via bromodomain-mediated binding and phosphorylation by the Ku-DNA-dependent protein kinase complex. *Mol Cell Biol* 18, 1349-58 (1998).
665. Wong, R. H. et al. A role of DNA-PK for the metabolic gene regulation in response to insulin. *Cell* 136, 1056-72 (2009).

666. Hait, W. N., Gesmonde, J. F. & Lazo, J. S. Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin. *Anticancer Res* 14, 1711-21 (1994).
667. Sullivan, G. F., Garcia-Welch, A., White, E., Lutzker, S. & Hait, W. N. Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. *J Exp Ther Oncol* 2, 19-26 (2002).
668. Mircheva, J., Smith, P. J. & Bleehen, N. M. Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity. *Br J Cancer* 53, 99-103 (1986).
669. Levesque, A. A., Fanous, A. A., Poh, A. & Eastman, A. Defective p53 signaling in p53 wild-type tumors attenuates p21 waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. *Mol Cancer Ther* 7, 252-62 (2008).
670. Grankvist, K., Bergstrom, P. & Henriksson, R. Different effects of chlorpromazine on bleomycin- and epirubicin induced cytotoxicity. *Biosci Rep* 10, 173-7 (1990).
671. Shin, S. Y., Choi, B. H., Kim, J. R., Kim, J. H. & Lee, Y. H. Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant L1210 mouse leukemia cells. *Eur J Pharm Sci* 28, 300-6 (2006).
672. Barbieri, F. et al. Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells. *Invest New Drugs* 21, 413-20 (2003).
673. Hultborn, R., Lundgren-Eriksson, L., Ottosson-Lonn, S., Ryd, W. & Weiss, L. Chlorpromazine-induced hypothermia in tumour-bearing mice, acute cytotoxic drug lethality and long-term survival. *Acta Oncol* 29, 941-4 (1990).
674. Shibata, H. et al. Potentiation of antitumor activity of pirarubicin by chlorpromazine in mice bearing doxorubicin-resistant P388 leukemia. *Res Commun Chem Pathol Pharmacol* 70, 359-62 (1990).
675. Ganapathi, R., Schmidt, H., Grabowski, D., Melia, M. & Ratliff, N. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance. *Br J Cancer* 58, 335-40 (1988).
676. Ford, J. M., Prozialeck, W. C. & Hait, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. *Mol Pharmacol* 35, 105-15 (1989).
677. Kawamura, K., Grabowski, D., Krivacic, K., Hidaka, H. & Ganapathi, R. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. *Biochem Pharmacol* 52, 1903-9 (1996).
678. Kamath, N. et al. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. *Cancer Commun* 3, 37-44 (1991).
679. Volm, M., Pommerenke, E. W., Efferth, T., Lohrke, H. & Mattern, J. Circumvention of multidrug resistance in human kidney and kidney carcinoma in vitro. *Cancer* 67, 2484-9 (1991).
680. Kamath, N., Grabowski, D., Ford, J. & Ganapathi, R. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype. *Br J Cancer* 67, 1203-8 (1993).
681. Yang, J. M. et al. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. *Biochem Biophys Res Commun* 266, 167-73 (1999).
682. Ishikawa, M., Takayanagi, Y. & Sasaki, K. Exacerbation of doxorubicin toxicity by chlorpromazine in male ddY mice. *Jpn J Pharmacol* 56, 221-4 (1991).
683. Garner, E. & Raj, K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. *Cell Cycle* 7, 277-82 (2008).
684. Gatz, S. A. & Wiesmuller, L. p53 in recombination and repair. *Cell Death Differ* 13, 1003-16 (2006).
685. Lindqvist, A. et al. Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. *EMBO J* 28, 3196-206 (2009).
686. Fairchild, R. G. et al. Chlorpromazine distribution in hamsters and mice bearing transplantable melanoma. *Cancer Res* 42, 556-62 (1982).
687. Blois, M. S., Jr. On chlorpromazine binding in vivo. *J Invest Dermatol* 45, 475-81 (1965).
688. Cooper, M. & Mishima, Y. Increased in vitro radio-sensitivity of malignant melanoma induced by the in vivo administration of chlorpromazine. *Br J Dermatol* 86, 491-4 (1972).

689. Gil-Ad, I. et al. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. *Oncol Rep* 15, 107-12 (2006).
690. Van Woert, M. H. & Palmer, S. H. Inhibition of the growth of mouse melanoma by chlorpromazine. *Cancer Res* 29, 1952-5 (1969).
691. Zbytniewski, Z. & Drewa, G. Inhibition of growth of transplantable melanotic melanoma in golden hamsters (*Mesocricetus auratus*, Waterhouse) by chlorpromazine. *Arch Immunol Ther Exp (Warsz)* 21, 871-5 (1973).
692. Osieka, R., Glatte, P., Pannenbacker, R. & Schmidt, C. G. Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft. *Cancer Treat Rep* 70, 1167-71 (1986).
693. Aubert, C. & Rouge, F. DTIC and CPZ cytotoxicities on established human melanocyte cell lines. *Med Oncol Tumor Pharmacother* 1, 195-9 (1984).
694. Rose, W. C., Trader, M. W., Dykes, D. J., Laster, W. R., Jr. & Schabel, F. M., Jr. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. *Cancer Treat Rep* 62, 2085-93 (1978).
695. Benjamin, C. L., Melnikova, V. O. & Ananthaswamy, H. N. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. *Adv Exp Med Biol* 624, 265-82 (2008).
696. Giglia-Mari, G. & Sarasin, A. TP53 mutations in human skin cancers. *Hum Mutat* 21, 217-28 (2003).
697. Lee, G. L. & Hait, W. N. Inhibition of growth of C6 astrocytoma cells by inhibitors of calmodulin. *Life Sci* 36, 347-54 (1985).
698. Aas, A. T., Brun, A., Pero, R. W. & Salford, L. G. Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth. *Br J Neurosurg* 8, 187-92 (1994).
699. Kwok, T. T. & Twentyman, P. R. The effect of pre- or post-treatment with a calmodulin inhibitor (trifluoperazine) on the response to cytotoxic agents of cells within small EMT6/Ca/VJAC spheroids. *Int J Radiat Oncol Biol Phys* 12, 1359-62 (1986).